10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended	July 29, 2022
☐	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________

Commission File Number 001-36820

®

Medtronic plc
(Exact name of registrant as specified in its charter)
Ireland	98-1183488
(State of incorporation)	(I.R.S. Employer Identification No.)

20 On Hatch, Lower Hatch Street

Dublin 2, Ireland

(Address of principal executive offices) (Zip Code)

+353 1 438-1700

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Ordinary shares, par value $0.0001 per share	MDT	New York Stock Exchange
0.00% Senior Notes due 2022	MDT/22B	New York Stock Exchange
0.375% Senior Notes due 2023	MDT/23B	New York Stock Exchange
0.000% Senior Notes due 2023	MDT/23C	New York Stock Exchange
0.25% Senior Notes due 2025	MDT/25	New York Stock Exchange
0.000% Senior Notes due 2025	MDT/25A	New York Stock Exchange
1.125% Senior Notes due 2027	MDT/27	New York Stock Exchange
0.375% Senior Notes due 2028	MDT/28	New York Stock Exchange
1.625% Senior Notes due 2031	MDT/31	New York Stock Exchange
1.00% Senior Notes due 2031	MDT/31A	New York Stock Exchange
0.750% Senior Notes due 2032	MDT/32	New York Stock Exchange
2.250% Senior Notes due 2039	MDT/39A	New York Stock Exchange
1.50% Senior Notes due 2039	MDT/39B	New York Stock Exchange
1.375% Senior Notes due 2040	MDT/40A	New York Stock Exchange
1.75% Senior Notes due 2049	MDT/49	New York Stock Exchange
1.625% Senior Notes due 2050	MDT/50	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐	Emerging growth company	☐
Non-accelerated filer	☐	Smaller Reporting Company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 1(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

As of August 29, 2022, 1,329,153,289 ordinary shares, par value $0.0001, of the registrant were outstanding.

TABLE OF CONTENTS

Item	Description	Page
	PART I
1.	Financial Statements (unaudited)	1
2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29
3.	Quantitative and Qualitative Disclosures About Market Risk	50
4.	Controls and Procedures	51
	PART II
1.	Legal Proceedings	51
2.	Unregistered Sales of Equity Securities and Use of Proceeds	51
5.	Other Information	51
6.	Exhibits	52
	Signature	53

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

Medtronic plc

Consolidated Statements of Income

(Unaudited)

	Three months ended
(in millions, except per share data)	July 29, 2022		July 30, 2021
Net sales	$	7,371	$	7,987
Costs and expenses:
Cost of products sold, excluding amortization of intangible assets	2,516		2,598
Research and development expense	692		750
Selling, general, and administrative expense	2,567		2,547
Amortization of intangible assets	423		436
Restructuring charges, net	14		11
Certain litigation charges, net	—		26
Other operating expense, net	35		760
Operating profit	1,125		859
Other non-operating income, net	(83)		(111)
Interest expense	164		137
Income before income taxes	1,044		833
Income tax provision	112		64
Net income	931		769
Net income attributable to noncontrolling interests	(2)		(6)
Net income attributable to Medtronic	$	929	$	763
Basic earnings per share	$	0.70	$	0.57
Diluted earnings per share	$	0.70	$	0.56
Basic weighted average shares outstanding	1,329.4		1,344.5
Diluted weighted average shares outstanding	1,334.5		1,356.4

The accompanying notes are an integral part of these consolidated financial statements.

1

Medtronic plc

Consolidated Statements of Comprehensive Income

(Unaudited)

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Net income	$	931	$	769
Other comprehensive income (loss), net of tax:
Unrealized (loss) gain on investment securities	(16)		12
Translation adjustment	(884)		(355)
Net investment hedge	1,002		424
Net change in retirement obligations	1		19
Unrealized gain on cash flow hedges	220		174
Other comprehensive income	324		274
Comprehensive income including noncontrolling interests	1,255		1,043
Comprehensive income attributable to noncontrolling interests	—		(4)
Comprehensive income attributable to Medtronic	$	1,255	$	1,039

The accompanying notes are an integral part of these consolidated financial statements.

2

Medtronic plc

Consolidated Balance Sheets

(Unaudited)

(in millions)	July 29, 2022		April 29, 2022
ASSETS
Current assets:
Cash and cash equivalents	$	2,140	$	3,714
Investments	6,733		6,859
Accounts receivable, less allowances and credit losses of $219 and $230, respectively	5,308		5,551
Inventories, net	4,809		4,616
Other current assets	3,145		2,318
Total current assets	22,135		23,059
Property, plant, and equipment	13,323		13,365
Accumulated depreciation	(8,043)		(7,952)
Property, plant, and equipment, net	5,281		5,413
Goodwill	40,324		40,502
Other intangible assets, net	15,775		15,595
Tax assets	3,311		3,403
Other assets	3,088		3,008
Total assets	$	89,914	$	90,981
LIABILITIES AND EQUITY
Current liabilities:
Current debt obligations	$	5,729	$	3,742
Accounts payable	2,180		2,276
Accrued compensation	1,773		2,121
Accrued income taxes	549		704
Other accrued expenses	3,816		3,551
Total current liabilities	14,049		12,394
Long-term debt	17,481		20,372
Accrued compensation and retirement benefits	1,102		1,113
Accrued income taxes	2,102		2,087
Deferred tax liabilities	899		884
Other liabilities	1,440		1,410
Total liabilities	37,071		38,260
Commitments and contingencies (Note 16)
Shareholders’ equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,329,276,973 and 1,330,743,395 shares issued and outstanding, respectively	—		—
Additional paid-in capital	24,335		24,566
Retained earnings	30,276		30,250
Accumulated other comprehensive loss	(1,939)		(2,265)
Total shareholders’ equity	52,672		52,551
Noncontrolling interests	170		171
Total equity	52,843		52,722
Total liabilities and equity	$	89,914	$	90,981

The accompanying notes are an integral part of these consolidated financial statements.

3

Medtronic plc

Consolidated Statements of Equity

(Unaudited)

	Ordinary Shares			Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Total  Shareholders’  Equity		Noncontrolling Interests		Total Equity
(in millions)	Number	Par Value
April 29, 2022	1,331	$	—	$	24,566	$	30,250	$	(2,265)	$	52,551	$	171	$	52,722
Net income	—	—		—		929		—		929		2		931
Other comprehensive income (loss)	—	—		—		—		326		326		(2)		324
Dividends to shareholders ($0.68 per ordinary share)	—	—		—		(903)		—		(903)		—		(903)
Issuance of shares under stock purchase and award plans	2	—		41		—		—		41		—		41
Repurchase of ordinary shares	(3)	—		(333)		—		—		(333)		—		(333)
Stock-based compensation	—	—		62		—		—		62		—		62
July 29, 2022	1,329	$	—	$	24,335	$	30,276	$	(1,939)	$	52,672	$	170	$	52,843

	Ordinary Shares			Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Total  Shareholders’  Equity		Noncontrolling Interests		Total Equity
(in millions)	Number	Par Value
April 29, 2021	1,345	$	—	$	26,319	$	28,594	$	(3,485)	$	51,428	$	174	$	51,602
Net income	—	—		—		763		—		763		6		769
Other comprehensive income (loss)	—	—		—		—		276		276		(2)		274
Dividends to shareholders ($0.63 per ordinary share)	—	—		—		(846)		—		(846)		—		(846)
Issuance of shares under stock purchase and award plans	2	—		107		—		—		107		—		107
Repurchase of ordinary shares	(2)	—		(311)		—		—		(311)		—		(311)
Stock-based compensation	—	—		69		—		—		69		—		69
July 30, 2021	1,345	$	—	$	26,184	$	28,511	$	(3,209)	$	51,486	$	178	$	51,664

The accompanying notes are an integral part of these consolidated financial statements.

4

Medtronic plc

Consolidated Statements of Cash Flows

(Unaudited)

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Operating Activities:
Net income	$	931	$	769
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	668		671
Provision for credit losses	15		15
Deferred income taxes	(18)		(11)
Stock-based compensation	62		69
Loss on debt extinguishment	53		—
MCS asset impairment and inventory write-down	—		515
Other, net	121		116
Change in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable, net	89		(40)
Inventories, net	(380)		(75)
Accounts payable and accrued liabilities	(147)		(416)
Other operating assets and liabilities	(311)		(321)
Net cash provided by operating activities	1,083		1,292
Investing Activities:
Acquisitions, net of cash acquired	(1,191)		—
Additions to property, plant, and equipment	(426)		(378)
Purchases of investments	(1,884)		(2,654)
Sales and maturities of investments	1,886		2,324
Other investing activities, net	30		(76)
Net cash used in investing activities	(1,585)		(784)
Financing Activities:
Proceeds from short-term borrowings (maturities greater than 90 days)	2,284		—
Payments on long-term debt	(2,311)		(1)
Dividends to shareholders	(903)		(846)
Issuance of ordinary shares	43		111
Repurchase of ordinary shares	(336)		(315)
Other financing activities	273		(4)
Net cash used in financing activities	(950)		(1,055)
Effect of exchange rate changes on cash and cash equivalents	(122)		(42)
Net change in cash and cash equivalents	(1,574)		(589)
Cash and cash equivalents at beginning of period	3,714		3,593
Cash and cash equivalents at end of period	$	2,140	$	3,004
Supplemental Cash Flow Information
Cash paid for:
Income taxes	$	260	$	249
Interest	68		63

The accompanying notes are an integral part of these consolidated financial statements.

5

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

1. Basis of Presentation

The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.

Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.

The COVID-19 pandemic ("COVID-19" or the "pandemic") has had, and may continue to have, an adverse effect on our business, results of operations, financial condition, and cash flows, and its future impacts remain uncertain and unpredictable. While there was not a material impact to the Company’s consolidated financial statements as of and for the three months ended July 29, 2022, changes in the Company’s assessment about the length and severity of the pandemic, as well as other factors, could result in actual results differing from estimates.

The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. Amounts reported in millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.

The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 29, 2022. The Company’s fiscal years 2023, 2022, and 2021 will end or ended on April 28, 2023, April 29, 2022, and April 30, 2021, respectively. Fiscal year 2021 was a 53-week year.

2. New Accounting Pronouncements

Recently Adopted

For the three months ended July 29, 2022, there were no newly adopted accounting pronouncements that had a material impact to our consolidated financial statements. As of July 29, 2022, there are no recently issued but not yet adopted accounting pronouncements that are expected to materially impact our consolidated financial statements.

3. Revenue

The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, renal disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations.

6

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The table below illustrates net sales by segment and division for the three months ended July 29, 2022 and July 30, 2021:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Cardiac Rhythm & Heart Failure	$	1,393	$	1,483
Structural Heart & Aortic	741		787
Coronary & Peripheral Vascular	579		620
Cardiovascular	2,713		2,890
Surgical Innovations	1,338		1,554
Respiratory, Gastrointestinal, & Renal	664		768
Medical Surgical	2,001		2,322
Cranial & Spinal Technologies	1,043		1,123
Specialty Therapies	667		641
Neuromodulation	405		440
Neuroscience	2,115		2,204
Diabetes	541		572
Total	$	7,371	$	7,987

The table below illustrates net sales by market geography for each segment for the three months ended July 29, 2022 and July 30, 2021:

	U.S.(1)				Non-U.S. Developed Markets(2)				Emerging Markets(3)
	Three months ended				Three months ended				Three months ended
(in millions)	July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021
Cardiovascular	$	1,298	$	1,420	$	892	$	1,003	$	523	$	467
Medical Surgical	843		990		767		869		392		463
Neuroscience	1,419		1,446		407		465		290		293
Diabetes	206		245		264		263		72		63
Total	$	3,766	$	4,101	$	2,328	$	2,601	$	1,276	$	1,286

(1)U.S. includes the United States and U.S. territories.

(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.

(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.

The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At July 29, 2022, $955 million of rebates were classified as other accrued expenses, and $576 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet. At April 29, 2022, $981 million of rebates were classified as other accrued expenses, and $548 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet.

Deferred Revenue and Remaining Performance Obligations

The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue at July 29, 2022 and April 29, 2022 was $391 million and $399 million, respectively. At July 29, 2022 and April 29, 2022, $302 million and $305 million was included in other accrued expenses, respectively, and $90 million and $94 million was included in other liabilities, respectively. During the three months ended July 29, 2022, the Company recognized $87 million of revenue that was included in deferred revenue as of April 29, 2022.

Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At July 29, 2022, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $801 million. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next three years.

7

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

4. Acquisitions and Assets and Liabilities Held for Sale

During the three months ended July 29, 2022, the Company had acquisitions that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future, yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the consolidated results of the Company for the three months ended July 29, 2022. The results of operations of acquired businesses have been included in the Company's consolidated statements of income since the date each business was acquired. For the three months ended July 29, 2022 and July 30, 2021, purchase price allocation adjustments were not significant.

Fiscal Year 2023

Intersect ENT

On May 13, 2022, the Company acquired Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader. The acquisition expands the Neuroscience segment portfolio of products used during ENT procedures, and combined with the Company's navigation, powered instruments, and existing tissue health products, will offer a broader suite of solutions to assist surgeons treating patients who suffer from chronic rhinosinusitis (CRS). Total consideration, net of cash acquired, for the transaction, in which the Company acquired all outstanding shares of Intersect ENT for $28.25 per share, was $1.2 billion consisting of $1.1 billion of cash and $98 million previously held investments in Intersect ENT. Based upon a preliminary acquisition valuation, the Company acquired $615 million of goodwill, $635 million of technology-based intangible assets, $35 million of customer-related intangible assets, and $13 million of tradenames with estimated useful lives of 20 years. The goodwill is not deductible for tax purposes.

Revenue and net loss attributable to Intersect ENT since the date of acquisition as well as costs incurred in connection with the acquisition included in the consolidated statements of income were not significant for the three months ended July 29, 2022.

The acquisition date fair values of the assets acquired and liabilities assumed were as follows:

(in millions)	Intersect ENT
Cash and cash equivalents	$	39
Inventory	32
Goodwill	615
Other intangible assets	683
Other assets	40
Total assets acquired	1,408
Current liabilities	63
Deferred tax liabilities	51
Other liabilities	18
Total liabilities assumed	131
Net assets acquired	$	1,277

8

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Other acquisitions

For acquisitions other than Intersect ENT, the acquisition date fair value of net assets acquired during the three months ended July 29, 2022 was $123 million. Based upon preliminary valuations, assets acquired were primarily comprised of $66 million of goodwill and $57 million of technology-based intangible assets with estimated useful lives of 16 years. The goodwill is deductible for tax purposes. The Company recognized $73 million of contingent consideration liabilities in connection with these acquisitions during the three months ended July 29, 2022, which are comprised of revenue and regulatory milestone-based payments.

Subsequent Acquisitions

Subsequent to July 29, 2022, on August 30, 2022 the Company acquired Affera, Inc. (Affera) a privately-held manufacturer of cardiac mapping and navigation systems and catheter-based cardiac ablation technologies. The acquisition expands the Cardiovascular segment portfolio of advanced cardiac ablation products and accessories to include its first cardiac mapping and navigation platform to meet physician needs within a growing patient population. Total consideration for the transaction is up to $1.0 billion, including up to $250 million of undiscounted contingent consideration related to certain technical and regulatory milestones. The transaction will be accounted for as a business combination using the acquisition method of accounting. This requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date.

Due to the limited amount of time since the acquisition date and the significant limitations on access to Affera information prior to the acquisition date, the preliminary acquisition valuation for the business combination is incomplete at this time. As a result, the Company is unable to provide the amounts recognized as of the acquisition date for the major classes of assets acquired and liabilities assumed, including the information required for valuation of intangible assets and goodwill. We will include such disclosures in our Form 10-Q for the quarter ending October 28, 2022.

Acquired In-Process Research & Development (IPR&D)

IPR&D with no alternative future use acquired outside of a business combination is expensed immediately. During the three months ended July 29, 2022, IPR&D acquired in connection with asset acquisitions of technology not yet approved by regulators was not significant. During the three months ended July 30, 2021, the Company acquired $90 million of IPR&D in connection with asset acquisitions of technology not yet approved by regulators, which was recognized in research and development expense in the consolidated statements of income.

Contingent Consideration

Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within other operating expense, net in the consolidated statements of income.

The fair value of contingent consideration at July 29, 2022 and April 29, 2022 was $193 million and $119 million, respectively. At July 29, 2022, $64 million was recorded in other accrued expenses, and $129 million was recorded in other liabilities in the consolidated balance sheet. At April 29, 2022, $35 million was recorded in other accrued expenses, and $84 million was recorded in other liabilities in the consolidated balance sheet.

The following table provides a reconciliation of the beginning and ending balances of contingent consideration:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Beginning balance	$	119	$	270
Purchase price contingent consideration	73		—
Purchase price allocation adjustments	—		25
Payments	—		(11)
Change in fair value	2		10
Ending balance	$	193	$	294

9

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:

	Fair Value at
(in millions)	July 29, 2022	Unobservable Input	Range	Weighted Average (1)
Revenue and other performance-based payments	$143	Discount rate	11.2% - 27.2%	15.0%
		Projected fiscal year of payment	2023 - 2027	2025
Product development and other milestone-based payments	$50	Discount rate	5.5%	5.5%
		Projected fiscal year of payment	2023 - 2024	2023

(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.

Assets and Liabilities Held for Sale

On May 25, 2022, the Company and DaVita Inc. (“DaVita”) entered into a definitive agreement for the Company to sell half of its Renal Care Solutions (RCS) business. This sale is part of an agreement between Medtronic and DaVita to form a new, independent kidney care-focused medical device company (“NewCo”) with equal equity ownership. As a result of entering into the definitive agreement, the RCS business met the criteria to be classified as held for sale on the date the agreement was entered into. The transaction is expected to close in calendar year 2023, subject to customary regulatory approvals and closing conditions. RCS is part of the Company’s Medical Surgical portfolio. The Company recorded a non-cash pre-tax impairment of $67 million, primarily related to goodwill, in the three months ending July 29, 2022 recognized in other operating expense, net in the consolidated statements of income. Refer to Note 10 to the consolidated financial statements for additional information on the goodwill impairment.

The following table presents information related to the assets and liabilities that were classified as held for sale in our consolidated balance sheet:

(in millions)	July 29, 2022
Inventories, net	$	119
Property, plant, and equipment, net	141
Goodwill	147
Other intangible assets, net	114
Other	48
Total assets held for sale (1)	$	568
Total liabilities held for sale (1)(2)	$	38

(1) Total assets held for sale and total liabilities held for sale are reported in other current assets and other accrued expenses, respectively in the consolidated balance sheets.

(2) No separate class of liability classified as held for sale was individually significant enough for separate disclosure.

There were no assets or liabilities classified as held for sale at April 29, 2022. The Company determined that the agreement to sell half of the RCS business does not meet the criteria to be classified as discontinued operations.

10

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

5. Restructuring and Other Costs

Enterprise Excellence

In the third quarter of fiscal year 2018, the Company announced its Enterprise Excellence restructuring program. Further program details are described in Note 4 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2022.

Since inception, the Company has incurred pre-tax exit and disposal costs and other costs, across all segments, of $1.6 billion in connection with the Enterprise Excellence program. In total, the Company estimates it will recognize approximately $1.8 billion of exit and disposal costs and other costs related to the program by the end of fiscal year 2023. The remaining charges are costs associated with the restructuring program, such as salaries and benefits for employees supporting the program, including program management and transition teams, and strategic and operational consulting services related to the three objectives of the program. These charges are recognized within restructuring charges, net, cost of products sold, and selling, general, and administrative expense in the consolidated statements of income.

For the three months ended July 29, 2022, the Company recognized net charges of $40 million, of which $19 million was recognized within cost of products sold and $28 million was recognized within selling, general, and administrative expense in the consolidated statements of income. For the three months ended July 30, 2021, the Company recognized net charges of $74 million, of which $33 million were recognized within cost of products sold and $30 million were recognized within selling, general, and administrative expense in the consolidated statements of income.

Simplification

In the first quarter of fiscal year 2021, the Company initiated the Simplification restructuring program. Further program details are described in Note 4 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2022.

Since inception, the Company has incurred pre-tax exit and disposal costs and other costs, across all segments, of $385 million in connection with the Simplification program. In total, the Company estimates it will recognize approximately $450 million of exit and disposal costs and other costs related to the Simplification program by the end of fiscal year 2023. The remaining charges are costs associated with the restructuring program, such as salaries for employees supporting the program and consulting expenses. These charges are recognized within restructuring charges, net, cost of products sold, and selling, general, and administrative expense in the consolidated statements of income.

For the three months ended July 29, 2022, the Company recognized net charges of $36 million of which $13 million were recognized within selling, general, and administrative expense in the consolidated statements of income. For the three months ended July 30, 2021, the Company recognized net charges of $7 million which were all recognized within selling, general, and administrative expense in the consolidated statements of income.

The following table summarizes the activity related to the restructuring programs above for the three months ended July 29, 2022:

(in millions)	Employee Termination Benefits		Associated Costs(1)		Other Costs		Total
April 29, 2022	$	81	$	27	$	1	$	110
Charges	23		61		1		85
Cash payments	(26)		(75)		(1)		(103)
Accrual adjustments(2)	(9)		—		—		(9)
July 29, 2022	$	69	$	13	$	1	$	83

(1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.

(2) Accrual adjustments relate to certain employees identified for termination finding other positions within the Company.

11

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Mechanical Circulatory Support (MCS)

In June 2021, the Company announced the decision to stop the distribution and sale of the Medtronic HVAD System in light of a growing body of observational clinical comparisons indicating a lower frequency of neurological adverse events and mortality with another circulatory support device available to patients compared to the HVAD system. In connection with this decision, the Company recorded charges of $726 million (MCS charges) within the Cardiovascular segment during the three months ended July 30, 2021, including $58 million recognized in costs of products sold and $668 million recognized within other operating expense, net in the consolidated statement of income. The charges included $515 million of non-cash impairments and write-downs primarily related to $409 million of intangible asset impairments and $58 million of inventory write-downs. The Company also recorded charges of $211 million for commitments and obligations associated with the decision, which included charges for patient support obligations, restructuring, and other associated costs. During the fourth quarter of fiscal year 2022, the Company recorded additional charges of $155 million within other operating expense, net primarily related to incremental commitments and obligations associated with the exit of the business. As of July 29, 2022, accruals were recorded in the consolidated balance sheet for these obligations, with $81 million reflected in other accrued expenses and $136 million recorded in other liabilities. Medtronic remains committed to serving the needs of the approximately 3,200 patients currently implanted with the HVAD system.

12

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

6. Financial Instruments

Debt Securities

The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at July 29, 2022 and April 29, 2022:

    

	July 29, 2022
	Valuation								Balance Sheet Classification
(in millions)	Cost		Unrealized Gains		Unrealized Losses		Fair Value		Investments		Other Assets
Level 1:
U.S. government and agency securities	$	532	$	1	$	(13)	$	520	$	520	$	—
Level 2:
Corporate debt securities	4,339		4		(156)		4,186		4,186		—
U.S. government and agency securities	928		—		(37)		891		891		—
Mortgage-backed securities	573		—		(38)		535		535		—
Non-U.S. government and agency securities	17		—		—		17		17		—
Certificates of deposit	10		—		—		10		10		—
Other asset-backed securities	595		—		(22)		574		574		—
Total Level 2	6,462		4		(253)		6,213		6,213		—
Level 3:
Auction rate securities	36		—		(3)		33		—		33
Total available-for-sale debt securities	$	7,030	$	5	$	(269)	$	6,767	$	6,733	$	33

	April 29, 2022
	Valuation								Balance Sheet Classification
(in millions)	Cost		Unrealized Gains		Unrealized Losses		Fair Value		Investments		Other Assets
Level 1:
U.S. government and agency securities	$	533	$	1	$	(15)	$	518	$	518	$	—
Level 2:
Corporate debt securities	4,457		4		(140)		4,321		4,321		—
U.S. government and agency securities	910		—		(41)		869		869		—
Mortgage-backed securities	592		—		(35)		558		558		—
Non-U.S. government and agency securities	17		—		—		17		17		—
Certificates of deposit	20		—		—		20		20		—
Other asset-backed securities	567		—		(11)		556		556		—
Total Level 2	6,563		4		(227)		6,341		6,341		—
Level 3:
Auction rate securities	36		—		(3)		33		—		33
Total available-for-sale debt securities	$	7,131	$	5	$	(245)	$	6,893	$	6,859	$	33

The amortized cost of debt securities excludes accrued interest, which is reported in other current assets in the consolidated balance sheets.

13

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at July 29, 2022 and April 29, 2022:

	July 29, 2022
	Less than 12 months				More than 12 months
(in millions)	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Corporate debt securities	$	243	$	(2)	$	3,044	$	(155)
U.S. government and agency securities	—		—		942		(50)
Mortgage-backed securities	—		—		521		(38)
Other asset-backed securities	—		—		532		(22)
Auction rate securities	—		—		33		(3)
Total	$	243	$	(2)	$	5,072	$	(267)

	April 29, 2022
	Less than 12 months				More than 12 months
(in millions)	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Corporate debt securities	$	222	$	(1)	$	2,993	$	(139)
U.S. government and agency securities	—		—		945		(56)
Mortgage-backed securities	—		—		507		(35)
Other asset-backed securities	—		—		526		(11)
Auction rate securities	—		—		33		(3)
Total	$	222	$	(1)	$	5,004	$	(244)

The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the three months ended July 29, 2022 and July 30, 2021. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement.

Activity related to the Company’s available-for-sale debt securities portfolio is as follows:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Proceeds from sales	$	1,864	$	2,272
Gross realized gains	1		4
Gross realized losses	(9)		(2)

The July 29, 2022 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

(in millions)	July 29, 2022
Due in one year or less	$	1,378
Due after one year through five years	3,597
Due after five years through ten years	1,102
Due after ten years	690
Total	$	6,767

14

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Equity Securities, Equity Method Investments, and Other Investments

The Company holds investments in equity securities with readily determinable fair values, equity investments without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments and investments without readily determinable fair values are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data.

The following table summarizes the Company's equity and other investments at July 29, 2022 and April 29, 2022, which are classified as other assets in the consolidated balance sheets:

(in millions)	July 29, 2022		April 29, 2022
Investments with readily determinable fair value (marketable equity securities)	$	26	$	64
Investments without readily determinable fair values	770		732
Equity method and other investments	84		85
Total equity and other investments	$	880	$	881

The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income.

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Proceeds from sales	$	21	$	52
Gross gains	15		58
Gross losses	(4)		(5)
Impairment losses recognized	(7)		(10)

During the three months ended July 29, 2022, there were $8 million of net unrealized gains on equity securities and other investments still held at July 29, 2022. During the three months ended July 30, 2021, there were $15 million of net unrealized gains on equity securities and other investments still held at July 30, 2021.

7. Financing Arrangements

Commercial Paper

The Company maintains commercial paper programs that allow the Company to issue U.S. dollar or Euro-denominated unsecured commercial paper notes. The aggregate amount outstanding at any time under the commercial paper programs may not exceed the equivalent of $3.5 billion. No commercial paper was outstanding at July 29, 2022 and April 29, 2022. The issuance of commercial paper reduces the amount of credit available under the Company’s existing Credit Facility, as defined below.

Line of Credit

The Company has a $3.5 billion five-year unsecured revolving credit facility (Credit Facility), which provides back-up funding for the commercial paper programs described above. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At July 29, 2022 and April 29, 2022, no amounts were outstanding under the Credit Facility.

Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with the covenants under the Credit Facility.

15

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Debt Obligations

The Company's debt obligations consisted of the following:

(in millions)	Maturity by Fiscal Year	July 29, 2022		April 29, 2022
Current debt obligations	2023 - 2024	$	5,729	$	3,742
Long-term debt
3.500 percent ten-year 2015 senior notes	2025	—		1,890
0.250 percent six-year 2019 senior notes	2026	1,012		1,064
0.000 percent five-year 2020 senior notes	2026	1,012		1,064
1.125 percent eight-year 2019 senior notes	2027	1,518		1,596
3.350 percent ten-year 2019 senior notes	2027	—		368
0.375 percent eight-year 2020 senior notes	2029	1,012		1,064
1.625 percent twelve-year 2019 senior notes	2031	1,012		1,064
1.000 percent twelve-year 2019 senior notes	2032	1,012		1,064
0.750 percent twelve-year 2020 senior notes	2033	1,012		1,064
4.375 percent twenty-year 2015 senior notes	2035	1,932		1,932
6.550 percent thirty-year 2007 CIFSA senior notes	2038	253		253
2.250 percent twenty-year 2019 senior notes	2039	1,012		1,064
6.500 percent thirty-year 2009 senior notes	2039	158		158
1.500 percent twenty-year 2019 senior notes	2040	1,012		1,064
5.550 percent thirty-year 2010 senior notes	2040	224		224
1.375 percent twenty-year 2020 senior notes	2041	1,012		1,064
4.500 percent thirty-year 2012 senior notes	2042	105		105
4.000 percent thirty-year 2013 senior notes	2043	305		305
4.625 percent thirty-year 2014 senior notes	2044	127		127
4.625 percent thirty-year 2015 senior notes	2045	1,813		1,813
1.750 percent thirty-year 2019 senior notes	2050	1,012		1,064
1.625 percent thirty-year 2020 senior notes	2051	1,012		1,064
Finance lease obligations	2023 - 2036	58		56
Deferred financing costs	2023 - 2051	(101)		(109)
Debt discount, net	2023 - 2051	(40)		(52)
Long-term debt		$	17,481	$	20,372

Senior Notes

The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.

Term Loan Agreements

On May 2, 2022, Medtronic Luxco entered into a term loan agreement (Fiscal 2023 Loan Agreement) by and among Medtronic Luxco, Medtronic plc, Medtronic, Inc., and Mizuho Bank, Ltd. as administrative agent and as lender. The Fiscal 2023 Loan Agreement provides an unsecured term loan in an aggregate principal amount of up to ¥300 billion with a term of 364 days. Borrowings under the Fiscal 2023 Loan Agreement bear interest at the TIBOR Rate (as defined in the Fiscal 2023 Loan Agreement) plus a margin of 0.40% per annum. Medtronic plc and Medtronic, Inc. have guaranteed the obligations of Medtronic Luxco under the Fiscal 2023 Loan Agreement. In May and June 2022, Medtronic Luxco borrowed an aggregate of ¥297 billion, or approximately $2.3 billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net proceeds of the borrowings to fund the early redemption of $1.9 billion of Medtronic Inc.'s 3.500% Senior Notes due 2025 for $1.9 billion of total consideration, and $368 million of Medtronic Luxco's 3.350% Senior Notes due 2027 for $376 million of total consideration. The Company recognized a total loss on debt extinguishment of $53 million in the quarter ended

16

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

July 29, 2022, which primarily includes cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss is recognized in interest expense in the consolidated statements of income.

Financial Instruments Not Measured at Fair Value

At July 29, 2022, the estimated fair value of the Company’s Senior Notes was $20.1 billion compared to a principal value of $21.1 billion. At April 29, 2022, the estimated fair value was $22.9 billion compared to a principal value of $24.2 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.

8. Derivatives and Currency Exchange Risk Management

The Company uses operational and economic hedges, including currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. Currencies of our derivative instruments include the Euro, Japanese Yen, Chinese Yuan, and others. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding was $17.7 billion and $13.8 billion at July 29, 2022 and April 29, 2022, respectively.

The Company also uses derivative and non-derivative instruments to manage the impact of currency exchange rate changes on net investments in foreign currency-denominated operations. The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets and statements of income.

Freestanding Derivative Contracts

Freestanding derivative contracts are primarily used to offset the Company’s exposure to the change in value of specific foreign-currency-denominated assets and liabilities, and to offset variability of cash flows associated with forecasted transactions denominated in foreign currencies. The gross notional amount of the Company's freestanding currency exchange rate contracts outstanding at July 29, 2022 and April 29, 2022 was $5.1 billion and $4.9 billion, respectively. The Company's freestanding currency exchange rate contracts are not designated as hedges, and therefore, changes in the value of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related change in value of foreign-currency-denominated assets, liabilities, and cash flows.

The Company also uses total return swaps to hedge the liability of a non-qualified deferred compensation plan. The gross notional amount of the Company's total return swaps outstanding at July 29, 2022 and April 29, 2022 was $212 million and $226 million, respectively. The Company's total return swaps are not designated as hedges, and therefore, changes in the value of these instruments are recognized in earnings. The cash flows related to the Company's freestanding derivative contracts are reported as operating or financing activities, depending on the nature of the underlying hedged item, in the consolidated statements of cash flows.

Cash Flow Hedges

Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. The gross notional amount of these contracts, designated as cash flow hedges, outstanding at July 29, 2022 and April 29, 2022 was $8.1 billion and $8.8 billion, respectively, and will mature within the subsequent three-year period. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss. The gain or loss on the derivative instrument is reclassified into earnings and is included in other operating expense, net or cost of products sold in the consolidated statements of income in the same period or periods during which the hedged transaction affects earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings in the current period. The cash flows related to all of the Company's derivative instruments designated as cash flow hedges are reported as operating activities in the consolidated statements of cash flows.

At July 29, 2022 and April 29, 2022, the Company had $694 million and $474 million in after-tax net unrealized gains, respectively, associated with cash flow hedging instruments recorded in accumulated other comprehensive loss. The Company expects that $510 million of after-tax net unrealized gains at July 29, 2022 will be recognized in the consolidated statements of income over the next 12 months.

17

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Net Investment Hedges

The Company has designated Euro-denominated and Yen-denominated debt as net investment hedges of certain of its European and Japanese operations to manage the exposure to currency and exchange rate movements for foreign currency-denominated net investments in foreign operations. At July 29, 2022, the Company had €16.0 billion, or $16.2 billion, of outstanding Euro-denominated debt designated as a hedge of its net investment in certain of its European operations, and ¥297 billion, or $2.2 billion, of outstanding Yen-denominated debt designated as a hedge of its net investment in certain of its Japanese operations. The Euro-denominated debt will mature in fiscal years 2023 through 2051, and the Yen-denominated debt will mature in fiscal year 2024.

The Company may also use derivative instruments to hedge the currency risk associated with its net investment in foreign operations. Foreign currency forward contracts may be used on a standalone basis or in combination with option collars. At July 29, 2022, the Company had foreign currency contracts with a notional value of €4.5 billion, or $4.6 billion, hedging a portion of its net investment in certain of its European operations. The foreign exchange contracts mature in fiscal years 2024 and 2025.

For instruments that are designated and qualify as net investment hedges, the gains or losses are reported as a component of accumulated other comprehensive loss. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in interest expense on a straight-line basis over the term of the hedge. During the three months ended July 29, 2022, the Company recognized $21 million in after-tax unrealized gains representing excluded components in interest expense. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows.

Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments

The amount of the gains and losses on our hedging instruments and the classification of those gains and losses within our consolidated financial statements for the three months ended July 29, 2022 and July 30, 2021 were as follows:

	(Gain) Loss Recognized in Accumulated Other Comprehensive Loss				(Gain) Loss Reclassified into Income
	Three months ended				Three months ended				Location of (Gain) Loss in Income Statement
(in millions)	July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021
Cash flow hedges
Currency exchange rate contracts	$	(342)	$	(164)	$	(137)	$	19	Other operating expense, net
Currency exchange rate contracts	(34)		4		18		11		Cost of products sold
Net investment hedges
Non-derivative instruments	(945)		(424)		—		—		N/A
Currency exchange rate contracts	(57)		—		—		—		N/A
Total	$	(1,378)	$	(584)	$	(120)	$	30

The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements during the three months ended July 29, 2022 and July 30, 2021 were as follows:

	(Gain) Loss Recognized in Income
	Three months ended				Location of (Gain) Loss in Income Statement
(in millions)	July 29, 2022		July 30, 2021
Derivatives not designated as hedging instruments
Currency exchange rate contracts	$	26	$	(17)	Other operating expense, net
Total return swaps	(1)		(13)		Other operating expense, net
Total	$	25	$	(30)

18

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Balance Sheet Presentation

The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at July 29, 2022 and April 29, 2022. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.

	Fair Value - Assets					Fair Value - Liabilities
(in millions)	July 29, 2022		April 29, 2022		Balance Sheet Classification	July 29, 2022		April 29, 2022		Balance Sheet Classification
Derivatives designated as hedging instruments
Currency exchange rate contracts	$	621	$	481	Other current assets	$	24	$	43	Other accrued expenses
Currency exchange rate contracts	268		168		Other assets	8		16		Other liabilities
Total derivatives designated as hedging instruments	889		649			33		60
Derivatives not designated as hedging instruments
Currency exchange rate contracts	18		46		Other current assets	20		49		Other accrued expenses
Total return swaps	—		—		Other current assets	9		20		Other accrued expenses
Total derivatives not designated as hedging instruments	18		46			29		69
Total derivatives	$	907	$	695		$	61	$	129

The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis.

	July 29, 2022				April 29, 2022
(in millions)	Derivative assets		Derivative Liabilities		Derivative assets		Derivative Liabilities
Level 1	$	907	$	53	$	695	$	109
Level 2	—		9		—		20
Total	$	907	$	61	$	695	$	129

The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.

The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.

	July 29, 2022
			Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recognized Assets (Liabilities)		Financial Instruments		Cash Collateral (Received) Posted		Net Amount
Derivative assets:
Currency exchange rate contracts	$	907	$	(42)	$	(531)	$	335
Derivative liabilities:
Currency exchange rate contracts	(53)		42		—		(11)
Total return swaps	(9)		—		—		(9)
	(61)		42		—		(20)
Total	$	845	$	—	$	(531)	$	315

19

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

	April 29, 2022
			Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recognized Assets (Liabilities)		Financial Instruments		Cash Collateral (Received) Posted		Net Amount
Derivative assets:
Currency exchange rate contracts	$	695	$	(109)	$	(254)	$	332
Derivative liabilities:
Currency exchange rate contracts	(109)		109		—		—
Total return swaps	(20)		—		—		(20)
	(129)		109		—		(20)
Total	$	566	$	—	$	(254)	$	312

9. Inventories

Inventory balances, net of reserves, were as follows:

(in millions)	July 29, 2022		April 29, 2022
Finished goods	$	3,145	$	3,070
Work in-process	739		682
Raw materials	926		864
Total	$	4,809	$	4,616

10. Goodwill and Other Intangible Assets

Goodwill

The following table presents the changes in the carrying amount of goodwill by segment:

(in millions)	Cardiovascular		Medical Surgical		Neuroscience		Diabetes		Total
April 29, 2022	$	7,160	$	19,957	$	11,132	$	2,254	$	40,502
Goodwill as a result of acquisitions	66		—		615		—		680
Purchase accounting adjustments	(10)		—		—		—		(10)
Transfer to held for sale	—		(208)		—		—		(208)
Currency translation and other	(49)		(507)		(83)		(1)		(640)
July 29, 2022	$	7,166	$	19,242	$	11,664	$	2,253	$	40,324

As a result of the agreement with DaVita, as disclosed in Note 4 to the consolidated financial statements, the Company allocated $208 million of goodwill to the RCS business that met the criteria to be classified as held for sale. Upon allocation, a goodwill impairment test was performed for the RCS business, and the Company recognized $61 million of goodwill impairment during the three months ended July 29, 2022. The goodwill impairment charges are recognized in other operating expense, net in the consolidated statements of income. The Company did not recognize any goodwill impairments during the three months ended July 30, 2021.

20

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Intangible Assets

The following table presents the gross carrying amount and accumulated amortization of intangible assets:

	July 29, 2022				April 29, 2022
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	16,927	$	(7,238)	$	16,953	$	(7,005)
Purchased technology and patents	11,311		(5,758)		10,802		(5,667)
Trademarks and tradenames	485		(268)		473		(266)
Other	97		(65)		80		(69)
Total	$	28,820	$	(13,328)	$	28,308	$	(13,006)
Indefinite-lived:
IPR&D	$	283	$	—	$	293	$	—

The Company did not recognize any definite-lived intangible asset charges during the three months ended July 29, 2022. During the three months ended July 30, 2021 the Company recognized $409 million of definite-lived intangible asset charges in connection with MCS within the Cardiovascular Portfolio. Refer to Note 5 to the consolidated financial statements for additional information on what led to the impairment. Intangible asset impairment charges are recognized in other operating expense, net in the consolidated statements of income.

The Company did not recognize any indefinite-lived intangible asset impairments during the three months ended July 29, 2022 and July 30, 2021. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future.

Amortization Expense

Intangible asset amortization expense for the three months ended July 29, 2022 and July 30, 2021 was $423 million and $436 million, respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at July 29, 2022, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:

(in millions)	Amortization Expense
Remaining 2023	$	1,261
2024	1,649
2025	1,627
2026	1,613
2027	1,589
2028	1,539

11. Income Taxes

The Company's effective tax rate for the three months ended July 29, 2022 was 10.7%, as compared to 7.7% for the three months ended July 30, 2021. The increase in our effective tax rate for the three months ended July 29, 2022, was primarily due to the tax impact of MCS charges in the three months ended July 30, 2021, partially offset by a $39 million charge in the three months ended July 30, 2021 related to a change in the Company's permanent reinvestment assertion on certain historical earnings. The increase was also partially offset by a $25 million benefit in the three months ended July 29, 2022 related to a valuation allowance release associated with certain carryover attributes due to the anticipated RCS transaction, as discussed in Note 4 to the consolidated financial statements.

At both July 29, 2022 and April 29, 2022, the Company's gross unrecognized tax benefits were $1.7 billion. In addition, the Company had accrued gross interest and penalties of $123 million at July 29, 2022. If all of the Company’s unrecognized tax benefits were recognized, approximately $1.6 billion would impact the Company’s effective tax rate. At July 29, 2022 and April 29, 2022, the amount of the Company's gross unrecognized tax benefits, net of cash advance, recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheets was $889 million and $802 million, respectively. The increase in the Company's gross unrecognized tax benefits, net of cash advance, was primarily due to the decrease in advance payments available to offset unrecognized tax benefits. The

21

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Company recognizes interest and penalties related to income tax matters within income tax provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheets.

Subsequent to the quarter close on July 29, 2022, on August 18, 2022 the U.S. Tax Court (Tax Court) issued its opinion on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006 (Opinion). While the Opinion rejected the IRS’s position and the Tax Court determined the methodology advanced by Medtronic was appropriate for purposes of determining the intercompany royalty rate between Puerto Rico and the U.S., it determined that the royalty rate should be higher, thereby increasing income allocated to the U.S. and consequently subject to U.S. tax. This case relates only to fiscal years 2005 and 2006. The Opinion remains subject to finalization by the Tax Court and to appeal by either or both parties. At this time, the Company is evaluating the impact of the Opinion and whether the Company will appeal. If the Opinion is finalized as is, without appeal by either party, the Company anticipates the findings will likely be applied for all years following fiscal year 2006. Under this potential scenario, the Company has currently estimated a potential income tax charge, including interest, of up to $2.0 billion.

Refer to Note 16 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

12. Earnings Per Share

Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.

The table below sets forth the computation of basic and diluted earnings per share:

	Three months ended
(in millions, except per share data)	July 29, 2022		July 30, 2021
Numerator:
Net income attributable to ordinary shareholders	$	929	$	763
Denominator:
Basic – weighted average shares outstanding	1,329.4		1,344.5
Effect of dilutive securities:
Employee stock options	2.7		8.5
Employee restricted stock units	1.3		2.3
Employee performance share units	1.1		1.0
Diluted – weighted average shares outstanding	1,334.5		1,356.4
Basic earnings per share	$	0.70	$	0.57
Diluted earnings per share	$	0.70	$	0.56

The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 14 million and 1 million ordinary shares for the three months ended July 29, 2022 and July 30, 2021, respectively, because their effect would have been anti-dilutive on the Company’s earnings per share.

22

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

13. Stock-Based Compensation

The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, performance share units, and employee stock purchase plan shares recognized for the three months ended July 29, 2022 and July 30, 2021:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Stock options	$	12	$	10
Restricted stock	27		41
Performance share units	12		6
Employee stock purchase plan	11		11
Total stock-based compensation expense	$	62	$	69
Cost of products sold	$	6	$	7
Research and development expense	7		8
Selling, general, and administrative expense	49		55
Total stock-based compensation expense	62		69
Income tax benefits	(11)		(11)
Total stock-based compensation expense, net of tax	$	51	$	58

14. Retirement Benefit Plans

The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three months ended July 29, 2022 and July 30, 2021:

	U.S.				Non-U.S.
	Three months ended				Three months ended
(in millions)	July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021
Service cost	$	19	$	25	$	12	$	16
Interest cost	36		26		10		7
Expected return on plan assets	(56)		(57)		(16)		(16)
Amortization of net actuarial loss	5		16		1		5
Net periodic benefit cost	$	4	$	10	$	7	$	12

Components of net periodic benefit cost other than the service component are recognized in other non-operating income, net in the consolidated statements of income.

23

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

15. Accumulated Other Comprehensive Loss

The following table provides changes in AOCI, net of tax, and by component:

(in millions)	Unrealized Gain (Loss) on Investment Securities		Cumulative Translation Adjustments		Net Investment Hedges		Net Change in Retirement Obligations		Unrealized Gain (Loss) on Cash Flow Hedges		Total Accumulated Other Comprehensive (Loss) Income
April 29, 2022	$	(209)	$	(2,599)	$	841	$	(773)	$	474	$	(2,265)
Other comprehensive income (loss) before reclassifications	(22)		(881)		1,002		3		312		414
Reclassifications	6		—		—		(2)		(91)		(87)
Other comprehensive income (loss)	(16)		(881)		1,002		1		220		326
July 29, 2022	$	(225)	$	(3,480)	$	1,843	$	(772)	$	694	$	(1,939)
(in millions)	Unrealized Gain (Loss) on Investment Securities		Cumulative Translation Adjustment		Net Investment Hedges		Net Change in Retirement Obligations		Unrealized Gain (Loss) on Cash Flow Hedges		Total Accumulated Other Comprehensive (Loss) Income
April 30, 2021	$	92	$	(519)	$	(1,458)	$	(1,347)	$	(253)	$	(3,485)
Other comprehensive income (loss) before reclassifications	14		(353)		424		1		144		230
Reclassifications	(2)		—		—		18		30		46
Other comprehensive income (loss)	12		(353)		424		19		174		276
July 30, 2021	$	104	$	(872)	$	(1,034)	$	(1,328)	$	(79)	$	(3,209)

The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during the three months ended July 29, 2022 and July 30, 2021 was a benefit of $9 million and an expense of $2 million, respectively. During the three months ended July 29, 2022, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $2 million. During the three months ended July 30, 2021, there was no income tax on realized gains and losses on investment securities reclassified from AOCI. When realized, gains and losses on investment securities reclassified from AOCI are recognized within other non-operating income, net. Refer to Note 6 to the consolidated financial statements for additional information.

For the three months ended July 29, 2022, the income tax on cumulative translation adjustment was a benefit of $3 million. During the three months ended July 30, 2021, there was no income tax on cumulative translation adjustment.

During the three months ended July 29, 2022 and July 30, 2021, there were no tax impacts on net investment hedges. Refer to Note 8 to the consolidated financial statements for additional information.

The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. During the three months ended July 29, 2022 and July 30, 2021, the net change in retirement obligations in other comprehensive income before reclassifications resulted in income tax expense of $1 million. During the three months ended July 29, 2022 and July 30, 2021, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of $6 million and $2 million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within other non-operating income, net. Refer to Note 14 to the consolidated financial statements for additional information.

The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during the three months ended July 29, 2022 and July 30, 2021 was an expense of $64 million and $16 million, respectively. During the three months ended July 29, 2022 and July 30, 2021, gains and losses on cash flow hedges reclassified from AOCI included income taxes of $22 million and were reduced by income taxes of $1 million, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within other operating expense, net or cost of products sold, and gains and losses on forward starting interest rate derivatives reclassified from AOCI are recognized within interest expense. Refer to Note 8 to the consolidated financial statements for additional information.

16. Commitments and Contingencies

Legal Matters

The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental

24

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.

The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income. The Company recognized no certain litigation charges during the three months ended July 29, 2022, whereas the Company recognized $26 million of certain litigation charges during the three months ended July 30, 2021. At July 29, 2022 and April 29, 2022, accrued litigation was approximately $0.3 billion. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.

Product Liability Matters

Pelvic Mesh Litigation

The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company $121 million towards the settlement of 11,000 of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional 5,000 claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 16,200 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of August 3, 2022, the Company had reached agreements to settle approximately 15,900 of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above.

Hernia Mesh Litigation

Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of August 10, 2022, subsidiaries of the Company have been named as defendants in lawsuits filed on behalf of approximately 6,050 individual plaintiffs, and certain plaintiffs’ law firms have advised the Company that they may file additional cases in the future. Approximately 5,600 plaintiffs have filed lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately 350 plaintiffs have filed lawsuits in a coordinated action in Minnesota state court, and there are approximately 90 actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.

25

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Environmental Proceedings

The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.

The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. The Company has proceeded with remediation in accordance with the MDEP order as modified by the Maine Board order.

Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary.

Following a trial in March 2002, the court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. In March 2021, the parties notified the court that they had agreed on a settlement in principle of all issues in this matter. Finalization of the proposed settlement remains subject to court approval.

The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above.

Income Taxes

In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion. Oral argument for the Appeal occurred in March 2018. The Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings, which it concluded in June 2021. The Tax Court issued its opinion on August 18, 2022, and it remains subject to appeal by either or both parties. At this time, the Company is evaluating the impact of the opinion and whether the Company will appeal.

The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006.

Medtronic, Inc.’s fiscal years 2017, 2018, and 2019 U.S. federal income tax returns are currently being audited by the IRS.

Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2018.

Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.

Refer to Note 11 for additional discussion of income taxes.

26

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Guarantees

In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.

The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, and/or cash flows.

17. Segment and Geographic Information

Segment disclosures are on a performance basis consistent with internal management reporting. Net sales of the Company's reportable segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. The Company’s management evaluates performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest expense, amortization of intangible assets, centralized distribution costs, non-operating income or expense items, certain corporate charges, and other items not allocated to the segments.

The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2022. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment.

There were no changes to the reportable segments during the quarter ended July 29, 2022. The Company's four principal operating and reportable segments are as follows: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.

27

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements:

Segment Operating Profit

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Cardiovascular	$	956	$	1,161
Medical Surgical	642		914
Neuroscience	815		962
Diabetes	77		133
Segment operating profit	2,490		3,170
Interest expense	(164)		(137)
Other non-operating income, net	83		111
Amortization of intangible assets	(423)		(436)
Corporate	(414)		(449)
Centralized distribution costs	(311)		(464)
Restructuring and associated costs	(76)		(81)
Acquisition-related items	(35)		(19)
Certain litigation charges, net	—		(26)
RCS impairments / costs	(74)		—
MCS impairments / costs	—		(726)
IPR&D charges	—		(90)
Medical device regulations	(32)		(21)
Income before income taxes	$	1,044	$	833

Geographic Information

Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. The following table presents net sales for the three months ended July 29, 2022 and July 30, 2021 for the Company's country of domicile, countries with significant concentrations, and all other countries:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Ireland	$	23	$	26
United States	3,766		4,101
Rest of world	3,582		3,860
Total other countries, excluding Ireland	7,348		7,961
Total	$	7,371	$	7,987

28

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

UNDERSTANDING OUR FINANCIAL INFORMATION

The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company, or we, us, or our). For a full understanding of financial condition and results of operations, you should read this discussion along with Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended April 29, 2022. In addition, you should read this discussion along with our consolidated financial statements and related notes thereto at and for the three months ended July 29, 2022. Amounts reported in millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.

Financial Trends

Throughout this Management’s Discussion and Analysis, we present certain financial measures that facilitate management's review of the operational performance of the Company and as a basis for strategic planning; however, such financial measures are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, financial measures presented in accordance with U.S. GAAP. We believe that non-GAAP financial measures provide information useful to investors in understanding the Company's underlying operational performance and trends and may facilitate comparisons with the performance of other companies in the medical technologies industry.

As presented in the GAAP to Non-GAAP Reconciliations section below, our non-GAAP financial measures exclude the impact of certain charges or benefits that contribute to or reduce earnings and that may affect financial trends and include certain charges or benefits that result from transactions or events that we believe may or may not recur with similar materiality or impact to our operations in future periods (Non-GAAP Adjustments).

In the event there is a Non-GAAP Adjustment recognized in our operating results, the tax cost or benefit attributable to that item is separately calculated and reported. Because the effective rate can be significantly impacted by the Non-GAAP Adjustments that take place during the period, we often refer to our tax rate using both the effective rate and the non-GAAP nominal tax rate (Non-GAAP Nominal Tax Rate). The Non-GAAP Nominal Tax Rate is calculated as the income tax provision, adjusted for the impact of Non-GAAP Adjustments, as a percentage of income before income taxes, excluding Non-GAAP Adjustments.

Free cash flow is a non-GAAP financial measure calculated by subtracting property, plant, and equipment additions from operating cash flows.

Refer to the “GAAP to Non-GAAP Reconciliations," "Income Taxes," and "Free Cash Flow" sections for reconciliations of the non-GAAP financial measures to their most directly comparable financial measures prepared in accordance with U.S. GAAP.

EXECUTIVE LEVEL OVERVIEW

Medtronic is the leading global healthcare technology company — alleviating pain, restoring health, and extending life for millions of people around the world. Our primary products include those for cardiac rhythm disorders, cardiovascular disease, advanced and general surgical care, respiratory and monitoring solutions, renal care, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat, and diabetes conditions.

The global healthcare system is continuing to respond to the challenge posed by the COVID-19 pandemic ("COVID-19" or the "pandemic"). Several of our businesses continued to be affected by the pandemic, including the most recent COVID-19 lockdowns in China which began in late March and continued through the end of May, and the impacts of healthcare system staffing shortages on procedural volumes. In addition to the impacts of the pandemic, certain businesses continue to be impacted by supply chain disruptions that began during the fourth quarter of fiscal year 2022. We cannot predict with confidence the duration and severity of the pandemic and its impact on global procedure volumes. We expect medical procedure rates may continue to vary by therapy and country and to be impacted by regional COVID-19 case volumes, vaccine and booster immunization rates, and new COVID-19 variants. Additionally, we cannot predict the impact further healthcare system staffing shortages will have on procedural volumes, and the continued impact supply chain disruptions will have on the business.

29

The following is a summary of revenue and diluted earnings per share for the three months ended July 29, 2022 and July 30, 2021, and operating cash flow for the three months ended July 29, 2022 and July 30, 2021:

30

GAAP to Non-GAAP Reconciliations

Starting with the quarter ended April 29, 2022, the Company no longer adjusts non-GAAP financial measures for certain license payments for, or acquisitions of, technology not approved by regulators due to recent industry guidance from the U.S. Securities and Exchange Commission. Historical non-GAAP financial measures presented in this quarterly report have been recast for comparability.

The tables below present our GAAP to Non-GAAP reconciliations for the three months ended July 29, 2022 and July 30, 2021:

	Three months ended July 29, 2022
(in millions, except per share data)	Income Before Income Taxes		Income Tax Provision (Benefit)		Net Income Attributable to Medtronic		Diluted EPS		Effective Tax Rate
GAAP	$	1,044	$	112	$	929	$	0.70	10.7	%
Non-GAAP Adjustments:
Restructuring and associated costs (1)	76		16		60		0.04		21.1
Acquisition-related items (2)	35		6		29		0.02		17.1
(Gain)/loss on minority investments (3)	(4)		—		(4)		—		—
Medical device regulations (4)	32		6		26		0.02		18.8
Amortization of intangible assets	423		65		359		0.27		15.4
RCS impairments / costs (5)	74		1		73		0.05		1.4
Debt redemption premium and other charges (6)	53		11		42		0.03		20.8
Certain tax adjustments, net (7)	—		13		(13)		(0.01)		—
Non-GAAP	$	1,734	$	230	$	1,502	$	1.13	13.3	%
	Three months ended July 30, 2021
(in millions, except per share data)	Income Before Income Taxes		Income Tax Provision (Benefit)		Net Income Attributable to Medtronic		Diluted EPS		Effective Tax Rate
GAAP	$	833	$	64	$	763	$	0.56	7.7	%
Non-GAAP Adjustments:
Restructuring and associated costs (1)	81		17		65		0.05		21.0
Acquisition-related items (2)	19		1		17		0.01		5.3
Certain litigation charges	26		5		21		0.02		19.2
(Gain)/loss on minority investments (3)	(31)		—		(29)		(0.02)		—
Medical device regulations (4)	21		4		17		0.01		19.0
Amortization of intangible assets	436		69		366		0.27		15.8
MCS impairment / costs (8)	726		162		564		0.42		22.3
Certain tax adjustments, net (9)	—		(53)		53		0.04		—
Non-GAAP	$	2,111	$	269	$	1,838	$	1.36	12.7	%

(1)Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.

(2)The charges primarily include business combination costs and changes in fair value of contingent consideration.

(3)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

(4)The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period.

(5)The charges predominantly include non-cash pre-tax impairments, primarily related to goodwill, as a result of the anticipated sale of half of the Company's Renal Care Solutions (RCS) business related to the May 25, 2022 agreement with DaVita Inc.

(6)The charges relate to the early redemption of approximately $2.3 billion of senior notes and were recorded within interest expense within the consolidated statements of income.

(7)The net benefit is due to a valuation allowance release associated with certain carryover attributes as a result of the anticipated RCS transaction listed above in (5) partially offset by the amortization of previously established deferred tax assets from intercompany intellectual property transactions.

31

(8)The charges relate to the Company’s June 2021 decision to stop the distribution and sale of the Medtronic HVAD System within the Mechanical Circulatory Support Operating Unit (MCS). The charges included $515 million of non-cash impairments, primarily related to $409 million of intangible asset impairments, as well as $211 million for commitments and obligations in connection with the decision, including customer support obligations, restructuring, and other associated costs. Medtronic is committed to serving the needs of the approximately 3,200 patients currently implanted with the HVAD System.

(9)The charges are associated with a change in the company’s permanently reinvestment assertion on certain historical earnings and the amortization on previously established deferred tax assets from intercompany intellectual property transactions.

Free Cash Flow

Free cash flow, a non-GAAP financial measure, is calculated by subtracting additions to property, plant, and equipment from net cash provided by operating activities. Management uses this non-GAAP financial measure, in addition to U.S. GAAP financial measures, to evaluate our operating results. Free cash flow should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. Reconciliations between net cash provided by operating activities (the most comparable U.S. GAAP measure) and free cash flow are as follows:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Net cash provided by operating activities	$	1,083	$	1,292
Additions to property, plant, and equipment	(426)		(378)
Free cash flow	$	657	$	914

Refer to the Summary of Cash Flows section for drivers of the change in cash provided by operating activities.

NET SALES

Segment and Division

The charts below illustrate the percent of net sales by segment for the three months ended July 29, 2022 and July 30, 2021:

32

The table below illustrates net sales by segment and division for the three months ended July 29, 2022 and July 30, 2021:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021		% Change
Cardiac Rhythm & Heart Failure	$	1,393	$	1,483	(6)	%
Structural Heart & Aortic	741		787		(6)
Coronary & Peripheral Vascular	579		620		(7)
Cardiovascular	2,713		2,890		(6)
Surgical Innovations	1,338		1,554		(14)
Respiratory, Gastrointestinal, & Renal	664		768		(14)
Medical Surgical	2,001		2,322		(14)
Cranial & Spinal Technologies	1,043		1,123		(7)
Specialty Therapies	667		641		4
Neuromodulation	405		440		(8)
Neuroscience	2,115		2,204		(4)
Diabetes	541		572		(5)
Total	$	7,371	$	7,987	(8)	%

Segment and Market Geography

The charts below illustrate the percent of net sales by market geography for the three months ended July 29, 2022 and July 30, 2021:

33

The table below includes net sales by market geography for each of our segments for the three months ended July 29, 2022 and July 30, 2021:

	U.S.(1)						Non-U.S. Developed Markets(2)						Emerging Markets(3)
	Three months ended						Three months ended						Three months ended
(in millions)	July 29, 2022		July 30, 2021		% Change		July 29, 2022		July 30, 2021		% Change		July 29, 2022		July 30, 2021		% Change
Cardiovascular	$	1,298	$	1,420	(9)	%	$	892	$	1,003	(11)	%	$	523	$	467	12	%
Medical Surgical	843		990		(15)		767		869		(12)		392		463		(15)
Neuroscience	1,419		1,446		(2)		407		465		(12)		290		293		(1)
Diabetes	206		245		(16)		264		263		—		72		63		14
Total	$	3,766	$	4,101	(8)	%	$	2,328	$	2,601	(10)	%	$	1,276	$	1,286	(1)	%

(1)U.S. includes the United States and U.S. territories.

(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.

(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.

The decline in net sales for three months ended July 29, 2022, as compared to the corresponding period in the prior fiscal year, was driven primarily by the impact of supply chain challenges in certain businesses. For the three months ended July 29, 2022, currency had an unfavorable impact on emerging markets and non-U.S. developed markets of $35 million and $315 million, respectively.

Looking ahead, a number of macro-economic and geopolitical factors could negatively impact our business, including without limitation:

•Competitive product launches and pricing pressure, geographic macro-economic risks including general price inflation, rising interest rates, reimbursement challenges, impacts from changes in the mix of our product offerings, delays in product registration approvals, replacement cycle challenges, and fluctuations in currency exchange rates;

•National and provincial tender pricing for certain products, particularly in China;

•The uncertain and uneven impact of COVID-19 on future procedural volumes, supply constraints including certain electronic components and semiconductors, healthcare staffing, worker absenteeism with our customers, suppliers, and in our own operations and field teams, and resulting impacts on demand for our products and therapies; and

•The potential impact that sanctions and other measures being imposed in response to the Russia-Ukraine conflict could have on revenue and supply chain. The financial impact of the conflict in the first quarter of fiscal year 2023, including on accounts receivable and inventory reserves, was not material and for the three months ended July 29, 2022, the business of the Company in these countries represented less than 1% of the Company's consolidated revenues and assets. Although the implications of this conflict are difficult to predict at this time, the ongoing conflict may increase pressure on the global economy and supply chains, resulting in increased future volatility risk for our business operations and performance.

Cardiovascular

Cardiovascular products include pacemakers, insertable cardiac monitors, cardiac resynchronization therapy devices, implantable cardioverter defibrillators (ICD), leads and delivery systems, electrophysiology catheters, products for the treatment of atrial fibrillation, information systems for the management of patients with Cardiac Rhythm & Heart Failure devices, products designed to reduce surgical site infections, coronary and peripheral stents and related delivery systems, balloons and related delivery systems, endovascular stent graft systems, heart valve replacement technologies, cardiac tissue ablation systems, and open heart and coronary bypass grafting surgical products. Cardiovascular also includes Care Management Services and Cath Lab Managed Services (CLMS) within the Cardiac Rhythm & Heart Failure division. Cardiovascular's net sales for the three months ended July 29, 2022 were $2.7 billion, which represents a decrease of 6 percent compared to the corresponding period in the prior fiscal year. Currency had an unfavorable impact of $138 million on net sales for the three months ended July 29, 2022. The net sales decrease for the three months ended July 29, 2022 was primarily due to supply chain challenges in certain businesses.

34

The graphs below illustrate the percent of Cardiovascular net sales by division for the three months ended July 29, 2022 and July 30, 2021:

Cardiac Rhythm & Heart Failure (CRHF) net sales for the three months ended July 29, 2022 decreased 6 percent as compared to the corresponding period in the prior fiscal year. The decrease was led by Cardiac Rhythm Management due to supply constraints within Defibrillation Solutions. The decrease was partially offset by increases in Cardiac Pacing Therapies and Procedure Innovations, due to continued adoption of Micra AV and TYRX antibacterial envelopes, respectively. Cardiac Ablation Solutions net sales for the three months ended July 29, 2022 also decreased due to COVID lockdowns as well as hospital staffing shortages in markets outside the U.S.

Structural Heart & Aortic (SHA) net sales for the three months ended July 29, 2022 decreased 6 percent as compared to the corresponding period in the prior fiscal year. The decrease was led by transcatheter aortic valve replacement (TAVR) performance as a result of strong sales in the comparative period, the impact from a FCA, and supply shortages of contrast. Aortic also contributed to the decrease caused by supply chain challenges and FCAs issued in prior fiscal years.

Coronary & Peripheral Vascular (CPV) net sales for the three months ended July 29, 2022 decreased 7 percent as compared to the corresponding period in the prior fiscal year. The decrease was led by Coronary and Renal Denervation with market procedural volumes remaining below pre-COVID levels in several major markets and headwinds related to U.S. hospital contrast shortages early in the quarter. Peripheral Vascular Health also experienced a decrease in net sales for the three months ended July 29, 2022 due to competitors re-entering the market and supply chain challenges.

In addition to the macro-economic and geopolitical factors described in the Executive Level Overview, looking ahead, we expect Cardiovascular could be affected by the following:

•Continued growth of our Micra transcatheter pacing system. The Micra AV launched in Japan in November 2021 and received approval in China in May 2022. Micra AV expands the Micra target population from 15 percent to 45 percent of pacemaker patients.

•Continued acceptance and growth from the Azure XT and S SureScan pacing systems. Azure pacemakers feature Medtronic-exclusive BlueSync technology, which enables automatic, secure wireless remote monitoring with increased device longevity.

•Growth of the Cobalt and Crome portfolio of ICDs and CRT-Ds.

•Continued acceptance and expansion of the Claria MRI CRT-D system with AdaptivCRT and compatibility with TriageHF technology.

•Continued acceptance and expansion of the LINQ II cardiac monitor. Supply for the LINQ II cardiac monitor is improving as we continue to ramp our wafer scale manufacturing. During the third quarter of fiscal year 2022, we

35

launched two AccuRhythm AI algorithms on the LINQ II platform to significantly reduce false positive alerts for Atrial Fibrillation and Pause while retaining sensitivity for true positive detection and reduce clinic workload and burden. AccuRhythm AI launched in Europe during the first quarter of fiscal year 2023.

•Growth of the CRT-P quadripolar pacing system.

•Continued growth, adoption, and utilization of the TYRX Envelope for implantable devices.

•Continued growth of Arctic Front cryoablation for treatment of atrial fibrillation.

•Continued acceptance and growth of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform into intermediate risk indication globally and for the treatment of patients determined to be at low risk with surgery.

•Continued expansion and training of field support to increase coverage in the U.S. centers performing TAVR procedures.

•Continued acceptance and growth from Evolut PRO, which provides industry-leading hemodynamics, reliable delivery, enhanced durability versus SAVR procedures at 5 years, and advanced sealing with an excellent safety profile. In August 2021, the U.S. FDA approved the Evolut FX TAVR, a system enhancement designed to improve the overall procedural experience through enhancements in deliverability, implant visibility and deployment stability. During the third quarter of fiscal year 2022, Evolut PRO received NMPA approval within China.

•Continued acceptance and growth from the VenaSeal Closure System in the U.S. The VenaSeal Closure System is a unique non-thermal solution to address superficial venous disease that provides improved patient comfort, reduces the recovery time, and eliminates the risk of thermal nerve injury.

•Pressure from competitors re-entering the market contributing to the decline in the Abre venous self-expanding stent system. Abre is designed for the unique challenges of venous disease. It offers easy deployment and delivers demonstrated endurance, to give patients freedom of movement.

•Our voluntary recall of the Valiant Navion Thoracic Stent Graft System and our ability to ramp production of our previous generation product, the Valiant Captivia Thoracic Stent Graft System. We are currently ramping production of the Valiant Captivia Thoracic Stent Graft System and plan to reach full production capacity in the second quarter of fiscal year 2023.

•Our ability to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, which include, but not limited to, the Symplicity Spyral Multi-Electrode Renal Denervation Catheter, Pulse Field Ablation, a novel energy source that is non-thermal and Aurora Extravascular ICD.

Medical Surgical

Medical Surgical’s products span the entire continuum of patient care from diagnosis to recovery, with a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications. The products include those for advanced and general surgical products, surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, advanced ablation, interventional lung, ventilators, airway products, renal care products, and sensors and monitors for pulse oximetry, capnography, level of consciousness and cerebral oximetry. Medical Surgical's net sales for the three months ended July 29, 2022 were $2.0 billion, a decrease of 14 percent as compared to the corresponding period in the prior fiscal year. Currency had an unfavorable impact of $115 million on net sales for the three months ended July 29, 2022. The net sales decrease for the three months ended July 29, 2022 was primarily driven by supply chain disruptions, the recent COVID-19 lockdowns and provincial volume-based procurement (VBP) stapling tenders in China, and a decline in ventilator sales due to the high COVID-19 demand in the corresponding period in the prior year.

36

The graphs below illustrate the percent of Medical Surgical net sales by division for the three months ended July 29, 2022 and July 30, 2021:

Surgical Innovations (SI) net sales for the three months ended July 29, 2022 decreased 14 percent, as compared to the corresponding period in the prior fiscal year. The decrease was led by Advanced Surgical instruments, driven by global supply chain challenges, including resins, semiconductors, and packaging trays, which impacted energy and stapling products, and recent COVID-19 lockdowns in China.

Respiratory, Gastrointestinal, & Renal (RGR) net sales for the three months ended July 29, 2022 decreased 14 percent as compared to the corresponding period in the prior fiscal year. The decrease was largely due to declines in ventilator demand when compared to the corresponding period in the prior year as demand dropped below pre-pandemic levels as expected.

In addition to the macro-economic and geopolitical factors described in the Executive Level Overview, looking ahead we expect Medical Surgical could be affected by the following:

•Acceptance and continued growth of Open-to-MIS (minimally invasive surgery) techniques and tools through our efforts to transition open surgery to MIS. Open-to-MIS initiative focuses on capturing the market opportunity that exists in transitioning open procedures to MIS, whether through traditional MIS, advanced instrumentation, or robotics. Through our approach, in parallel, we also expand our presence and optimize open surgery in current open surgery markets.

•Continued global acceptance and future growth of powered stapling and energy platform.

•Our ability to execute ongoing strategies addressing the competitive pressure of reprocessing vessel sealing disposables and growth of our surgical soft tissue robotics procedures in the U.S.

•Our ability to create markets and drive products and procedures into emerging markets with our high quality and cost-effective surgical products designed for customers in emerging markets. An example is our ValleyLab LS10 single channel vessel sealing generator, which is compatible with our line of LigaSure instruments and designed for simplified use and affordability.

•Continued elevation of the standard of care for respiratory compromise, leveraging our market leading MicroStream capnography technology.

•Continued acceptance and growth in patient monitoring, airway, and ventilation management. Key products in this area include the Puritan Bennett 980 ventilator, Microstream Capnography, Nellcor pulse oximetry system with OxiMax technology, Shiley tracheostomy and endotracheal tubes, McGRATH MAC video laryngoscopes, SonarMed Airway Monitoring System for the NICU, and the Nellcor Oxysoft pulse oximetry system for neonatal and adult critical care patients, which received U.S. FDA clearance during the fourth quarter of fiscal year 2022.

37

•Acceptance of less invasive standards of care in Gastrointestinal and Hepatology products, including GI Diagnostic and Therapeutic product lines. Recently launched products include the PillCam COLON capsule endoscopy, the Barrx platform through ablation with the Barrx 360 Express catheter, Endoflip imaging systems, Bravo Calibration-free reflux testing, and the Emprint ablation system with Thermosphere Technology.

•Continued and future acceptance of Interventional Lung Solutions. Products include our Illumisite navigation platform, combined with our portfolio of biopsy tools including the Arcpoint pulmonary needle, and to access lesions outside the airway, the CrossCountry transbronchial access tool. This comprehensive portfolio gives the power to display position and access lung nodules in the periphery of the lungs, in a minimally invasive approach to accessing difficult-to-reach areas of the lung, which may aid in the diagnosis of lung cancer.

•Expanding the use of less invasive treatments and furthering our commitment to improving options for women with abnormal uterine bleeding. Our expanded and strengthened surgical offerings complement our global gynecology business.

•Global adoption of robotic-assisted surgery and installations of Hugo robotic assisted surgery (RAS) system for urologic, bariatric, gynecologic, and general surgery procedures. This includes continued integration and adoption of Touch Surgery Enterprise with the first artificial intelligence powered surgical videos and analytics platform to make it easier to train and discover new techniques within the robotics platform. The Hugo RAS system, which received CE Mark in October 2021, as well as secured additional regulatory approvals outside the U.S., is designed to help reduce unwanted variability, improve patient outcomes, and, by extension, lower per procedure cost.

•The pending contribution of our Renal Care Solutions business as a result of the May 25, 2022 definitive agreement with DaVita Inc.

•Our ability to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, which include, but are not limited to, our Hugo RAS system in the U.S., our NextGen McGrath MAC video laryngoscopes, Signia power stapling devices, and our Ligasure and Sonicision vessel sealing devices.

Neuroscience

Neuroscience's products include various spinal implants, bone graft substitutes, biologic products, image-guided surgery and intra-operative imaging systems, robotic guidance systems used in the robot-assisted spine procedures, and systems that incorporate advanced energy surgical instruments. Neuroscience's products also focus on the treatment of overactive bladder, urinary retention, fecal incontinence, as well as products to treat ear, nose, and throat (ENT), and therapies to treat the diseases of the vasculature in and around the brain, including coils, neurovascular stents and flow diversion products. Neuroscience also manufactures products related to implantable neurostimulation therapies and drug delivery systems for the treatment of chronic pain, movement disorders, and epilepsy. Neuroscience’s net sales for the three months ended July 29, 2022 was $2.1 billion, a decrease of 4 percent, compared to the corresponding period in the prior fiscal year. Currency had an unfavorable impact of $64 million on net sales for the three months ended July 29, 2022. The net sales decrease for the three months ended July 29, 2022, was primarily due to supply chain challenges in certain businesses, prolonged purchasing timelines for large capital, and reduced Spinal sales in China in advance of potential national VBP tenders and COVID-19 lockdowns.

38

The graphs below illustrate the percent of Neuroscience net sales by division for the three months ended July 29, 2022 and July 30, 2021:

Cranial and Spinal Technologies (CST) net sales for the three months ended July 29, 2022 decreased 7 percent, as compared to the corresponding period in the prior fiscal year. Neurosurgery experienced decreases in large capital sales of StealthStation Navigation, and Spine and Cranial Robotics from prolonged customer purchasing timelines. Additionally, Biologics saw decreases in customer ordering patterns when compared to the corresponding period in the prior year.

Specialty Therapies (Specialty) net sales for the three months ended July 29, 2022 increased 4 percent, as compared to the corresponding period in the prior fiscal year. The increase was driven by growth in Neurovascular led by hemorrhagic and ischemic stroke, flow diversion and access delivery products. ENT growth for the three months ended July 29, 2022, including benefit from the recent May 2022 acquisition of Intersect ENT, partially offset by declines driven by supply chain disruptions in disposables. For the three months ended July 29, 2022, Pelvic Health experienced net sales declines due to recent competitive launches.

Neuromodulation (NM) net sales for the three months ended July 29, 2022 decreased 8 percent, as compared to the corresponding period in the prior fiscal year. For the three months ended July 29, 2022, declines were largely due to healthcare staffing challenges impacting spinal cord stimulation implant volumes, continued supply chain challenges in interventional, and difficult year-over-year comparisons in targeted drug delivery due to backlog recovery in the prior year comparative period.

In addition to the general impacts of COVID-19 on our Company as described in the Executive Level Overview, looking ahead we expect Neuroscience could be affected by the following:

•Continued growth from enabling technologies, including StealthStation and O-arm Imaging Systems, Midas, and ENT Navigation and Power Systems, as well as acceptance of the Stealth Autoguide cranial robotic guidance platform.

•Continued sales of Mazor robotic units and associated market adoption of robot-assisted spine procedures, including the Mazor X Stealth, our integrated robotics and navigation platform.

•Continued growth from spine titanium interbody implants.

•Continued adoption of our integrated solutions through the Surgical Synergy strategy which integrates our spinal implants with enabling technologies such as imaging, navigation, power instruments, nerve monitoring, and Mazor robotics, as well as AI-driven surgical planning, personalized spinal implants, and robot-assisted surgery due to the newly acquired Medicrea technologies.

•Market acceptance and continued global adoption of innovative new spine products and procedural solutions within our CST division, such as our Infinity OCT System and Prestige LP cervical disc system.

39

•Growth in the broader vertebral compression fracture (VCF) and adjacent markets as we continue to pursue the development of other therapies to treat more patients with VCF, including continued success of both the Kyphon V vertebroplasty system and the Osteocool RF Spinal Tumor ablation system.

•Continued acceptance and growth of our ENT and Pelvic Health therapies within our Specialty Therapies division, including our InterStim therapy with InterStim II, InterStim Micro and InterStim X neurostimulators for the treatment of the symptoms of overactive bladder, urinary retention, and bowel incontinence, and capital equipment sales of the Stealth Station ENT surgical navigation system and intraoperative NIM nerve monitoring system.

•Continued acceptance and growth of the Solitaire FR revascularization device for treatment of acute ischemic stroke and the Pipeline Embolization Devices, endovascular treatments for large or giant wide-necked brain aneurysms.

•Continued acceptance of our React Catheter and Riptide aspiration system, along with our next-generation Solitaire revascularization device.

•Market acceptance and continued global adoption of our Intellis spinal cord stimulator, DTM proprietary waveform, Evolve workflow algorithm, and Snapshot reporting to treat chronic pain in major markets around the world.

•Continued acceptance and growth of our Percept PC DBS device with BrainSense technology, including its treatment of Parkinson's Disease, epilepsy, and other movement disorders.

•Market acceptance and growth from SCS therapy for treating Diabetic Peripheral Neuropathy (DPN) on Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator which received U.S. FDA approval in January 2022.

•Ongoing obligations under the U.S. FDA consent decree entered in April 2015 relating to the SynchroMed drug infusion system and the Neuromodulation quality system. The U.S. FDA lifted its distribution requirements on our implantable drug pump in October 2017 and its warning letter in November 2017.

•Strengthening our position in the ear, nose and throat market as a result of the May 2022 acquisition of Intersect ENT, a global ear, nose and throat (ENT) medical technology leader. The acquisition expands Neuroscience's portfolio of products used during ENT procedures and, combined with the Company's navigation, powered instruments, and existing tissue health products, will offer a broader suite of solutions to assist surgeons treating patients who suffer from chronic rhinosinusitis (CRS).

•Our ability to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, which include our closed-loop Percept PC and RC devices with adaptive DBS (aDBS) within Neuromodulation, as well as our hemorrhagic stroke intravascular device within Specialty Therapies, and our next-generation spine enabling technologies within CST.

Diabetes

Diabetes' products include insulin pumps, continuous glucose monitoring (CGM) systems, consumables, and smart insulin pen systems. Diabetes' net sales for the three months ended July 29, 2022 were $541 million, a decrease of 5 percent as compared to the corresponding period in the prior fiscal year. Currency had an unfavorable impact of $33 million on net sales for the three months ended July 29, 2022. Diabetes' net sales were impacted by international growth in integrated CGM with offsetting declines in the durable pump business worldwide.

In addition to the macro-economic and geopolitical factors described in the Executive Level Overview, looking ahead we expect Diabetes could be affected by the following:

•Continued patient demand for the MiniMed 770G insulin pump system, which is powered by SmartGuard technology and features the added benefits of smartphone connectivity and an expanded age indication to children as young as age two.

•Continued acceptance and growth internationally for the MiniMed 780G insulin pump system. The global adoption of sensor-augmented insulin pump systems has resulted in strong sensor attachment rates.

•Continued acceptance and growth of the Guardian Connect CGM system, which displays glucose information directly to a smartphone to help ensure patients have access to their glucose levels seamlessly and discretely. The Guardian Connect CGM system is available on both Apple iOS and Android devices.

•Market acceptance and growth of our InPen smart pen system, which allows users to have their Medtronic CGM readings in real-time alongside insulin dose information, all in one view.

40

•Continued pump and CGM competition in an expanding global market.

•Changes in medical reimbursement policies and programs, along with additional payor coverage on insulin pumps.

•Resolution of findings contained in a December 2021 U.S. FDA warning letter relating to the MiniMed 600 series insulin pump and a remote controller device for MiniMed 508 and Paradigm pumps. We are currently working with the U.S. FDA to resolve the findings. The existence of the warning letter may limit our ability to launch certain new Diabetes products in the U.S. prior to resolution of the findings.

•Our ability to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, which include, but are not limited to, our MiniMed 780G insulin pump and the Guardian 4 sensor, which have been submitted to the U.S. FDA.

COSTS AND EXPENSES

The following is a summary of cost of products sold, research and development, and selling, general, and administrative expenses as a percent of net sales for the three months ended July 29, 2022 and July 30, 2021:

Cost of Products Sold We continue to focus on reducing our costs of production through supplier management, manufacturing improvements, and optimizing our manufacturing network. Cost of products sold for the three months ended July 29, 2022 was $2.5 billion, as compared to $2.6 billion for the corresponding period in the prior fiscal year. The increase in cost of products sold as a percentage of net sales was primarily attributable to increased freight, largely due to higher fuel costs and expedited shipments for backorders as a result of certain supply chain challenges, as well as increased labor and direct material manufacturing costs, predominantly due to inflationary pressures and supply chain challenges. The three months ended July 30, 2021 included $58 million of inventory write-downs associated with our June 2021 decision to stop the distribution and sale of Medtronic's HVAD System (MCS charges). Looking forward, our cost of products sold likely will be further negatively impacted by inflation, supply chain challenges, and higher labor and direct material costs.

Research and Development Expense We remain committed to deliver the best possible experiences for patients, physicians, and caregivers we serve; to create technologies that expand what’s possible across the entire human body to transform lives; to turn data and insights into real action to serve patient needs to improve care; and to expand healthcare access and deliver positive outcomes. Research and development expense for the three months ended July 29, 2022 was $692 million, as compared to $750 million for the corresponding period in the prior fiscal year. The three months ended July 30, 2021 included $90 million of acquisitions of, and license payments for, technology not yet approved by regulators, primarily in our Diabetes segment.

Selling, General, and Administrative Expense Our goal is to continue to leverage selling, general, and administrative expense initiatives. Selling, general, and administrative expense primarily consists of salaries and wages, other administrative costs, such as professional fees and marketing expenses, and certain acquisition and restructuring expenses. Selling, general, and administrative expense for the three months ended July 29, 2022 was $2.6 billion, as compared to $2.5 billion for the corresponding period in the prior fiscal year. The increase in selling, general, and administrative expense as a percentage of net sales was primarily driven by net sales declines and increased employee travel as compared to the corresponding period in the prior year when travel was limited.

41

The following is a summary of other costs and expenses (income):

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Amortization of intangible assets	$	423	$	436
Restructuring charges, net	14		11
Certain litigation charges, net	—		26
Other operating expense, net	35		760
Other non-operating income, net	(83)		(111)
Interest expense	164		137

Amortization of Intangible Assets Amortization of intangible assets includes the amortization expense of our definite-lived intangible assets, consisting of purchased patents, trademarks, tradenames, customer relationships, purchased technology, and other intangible assets.

Restructuring Charges, Net

Enterprise Excellence

In the third quarter of fiscal year 2018, we announced a multi-year global Enterprise Excellence Program designed to drive long-term business growth and sustainable efficiency. Further program details are described in Note 4 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2022.

Since inception, the Company has incurred pre-tax exit and disposal costs and other costs, across all segments, of $1.6 billion in connection with the Enterprise Excellence program. In total, the Company estimates it will recognize approximately $1.8 billion of exit and disposal costs and other costs related to the Enterprise Excellence program, the majority of which are expected to be incurred by the end of this fiscal year.

For the three months ended July 29, 2022, we recognized net charges of $40 million associated with our Enterprise Excellence Program. Net charges for the three months ended July 29, 2022 included costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses, including $19 million recognized within cost of products sold and $28 million recognized within selling, general, and administrative expense in the consolidated statements of income. Charges recognized within restructuring charges, net for the period were not significant.

For the three months ended July 30, 2021, we recognized net charges of $74 million associated with our Enterprise Excellence Program, including $11 million recognized within restructuring charges, net in the consolidated statements of income primarily comprised of employee termination benefits. Net charges for the three months ended July 30, 2021 also included costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses, including $33 million recognized within cost of products sold, and $30 million recognized within selling, general and administrative expense in the consolidated statements of income.

Simplification

In the first quarter of fiscal year 2021, we initiated our Simplification restructuring program, designed to make the Company a more nimble and competitive organization. Further program details are described in Note 4 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2022.

Since inception, the Company has incurred pre-tax exit and disposal costs and other costs, across all segments, of $385 million in connection with the Simplification program. In total, the Company estimates it will recognize approximately $450 million of exit and disposal costs and other costs related to the Simplification program, the majority of which are expected to be incurred by the end of this fiscal year.

For the three months ended July 29, 2022, we recognized net charges of $36 million including $21 million recognized within restructuring charges, net in the consolidated statements of income primarily comprised of employee termination benefits. Net charges for the three months ended July 29, 2022 also included costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses, including $13 million recognized within selling, general and administrative expense in the consolidated statements of income.

42

For the three months ended July 30, 2021, we recognized net charges of $7 million which included costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses. These charges were recognized within selling, general and administrative expense in the consolidated statements of income.

For additional information about our restructuring programs, refer to Note 5 to the current period's consolidated financial statements.

Certain Litigation Charges, Net We classify specified certain litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income. For additional information, refer to Note 16 in the current period's consolidated financial statements.

Other Operating Expense, Net Other operating expense, net primarily includes royalty income and expense, currency remeasurement and derivative gains and losses, Puerto Rico excise taxes, changes in the fair value of contingent consideration, MCS charges, impairment charges, and income from funded research and development arrangements.

For the three months ended July 29, 2022, the change in other operating expense, net was primarily driven by MCS charges recorded during three months ended July 30, 2021. The charges of $668 million primarily included $409 million of intangible asset impairments and $211 million for commitments and obligations, including customer support obligations, restructuring, and other associated costs. Additionally, the change is driven by the net currency impact of remeasurement expense and our hedging programs, which resulted in a net gain of $81 million combined for the three months ended July 29, 2022 as compared to a net loss of $33 million for the corresponding period in the prior year. During the three months ended July 29, 2022, the Company also recorded non-cash pre-tax impairments of $67 million, primarily related to goodwill, as a result of the anticipated sale of half of the Company's RCS business, related to the May 25, 2022 agreement with DaVita Inc.

Other Non-Operating Income, Net Other non-operating income, net includes the non-service component of net periodic pension and postretirement benefit cost, investment gains and losses, and interest income.

For the three months ended July 29, 2022, the decrease in other non-operating income, net is primarily attributable to reduced gains on our equity method and minority investment portfolios partially offset by an increase in interest income. Gains on equity method and minority investments were $4 million and $43 million for the three months ended July 29, 2022 and July 30, 2021, respectively. Interest income was $55 million and $43 million for the three months ended July 29, 2022 and July 30, 2021, respectively.

Interest Expense Interest expense includes interest incurred on our outstanding borrowings, amortization of debt issuance costs and debt premiums or discounts, amortization of amounts excluded from the effectiveness assessment of certain net investment hedges, and charges recognized in connection with the early redemption of senior notes. The increase in interest expense was primarily due to the $53 million charge incurred as a result of the early redemption of approximately $2.3 billion of senior notes during the three months ended July 29, 2022.

INCOME TAXES

	Three months ended
(in millions)	July 29, 2022			July 30, 2021
Income tax provision	$	112		$	64
Income before income taxes	1,044			833
Effective tax rate	10.7		%	7.7		%
Non-GAAP income tax provision	$	230		$	269
Non-GAAP income before income taxes	1,734			2,111
Non-GAAP Nominal Tax Rate	13.3		%	12.7		%
Difference between the effective tax rate and Non-GAAP Nominal Tax Rate	2.6		%	5.0		%

Our effective tax rate for the three months ended July 29, 2022 was 10.7%, as compared to 7.7% for the three months ended July 30, 2021. The increase in our effective tax rate was primarily due to the tax impact of MCS charges in the three months ended July 30, 2021, partially offset by a $39 million charge in the three months ended July 30, 2021 related to a change in the Company’s permanent reinvestment assertion on certain historical earnings. The increase was also partially offset by a $25 million benefit in the three months ended July 29, 2022 related to a valuation allowance release associated with certain carryover attributes due to the anticipated RCS transaction, as discussed in Note 4 to the current period's consolidated financial statements.

43

Our Non-GAAP Nominal Tax Rate for the three months ended July 29, 2022 was 13.3%, as compared to 12.7% for the three months ended July 30, 2021. The increase in our Non-GAAP Nominal Tax Rate was primarily due to the decrease in the stock-based compensation benefit and the impact of year-over-year changes in operational results by jurisdiction. An increase in our Non-GAAP Nominal Tax Rate of 1 percent would result in an additional income tax provision for the three months ended July 29, 2022 of approximately $17 million.

Subsequent to the quarter close on July 29, 2022, on August 18, 2022 the U.S. Tax Court (Tax Court) issued its opinion on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006 (Opinion). While the Opinion rejected the IRS’s position and the Tax Court determined the methodology advanced by Medtronic was appropriate for purposes of determining the intercompany royalty rate between Puerto Rico and the U.S., it determined that the royalty rate should be higher, thereby increasing income allocated to the U.S. and consequently subject to U.S. tax. This case relates only to fiscal years 2005 and 2006. The Opinion remains subject to finalization by the Tax Court and to appeal by either or both parties. At this time, the Company is evaluating the impact of the Opinion and whether the Company will appeal. If the Opinion is finalized as is, without appeal by either party, the Company anticipates the findings will likely be applied for all years following fiscal year 2006. Under this potential scenario, the Company has currently estimated a potential income tax charge, including interest, of up to $2.0 billion, which would result in a future cash payment of up to $2.5 billion and no material impact to the Company’s tax rate going forward. The impact of this potential scenario was contemplated in the Company's fiscal year 2023 adjusted earnings per share guidance reiterated on August 23, 2022.

LIQUIDITY AND CAPITAL RESOURCES

We are currently in a strong financial position, and we believe our balance sheet and liquidity as of July 29, 2022 provide us with flexibility, and our cash, cash equivalents, and current investments, along with our credit facility and related commercial paper programs will satisfy our foreseeable operating needs.

Our liquidity and capital structure are evaluated regularly within the context of our annual operating and strategic planning processes. We consider the liquidity necessary to fund our operations, which includes working capital needs, investments in research and development, property, plant, and equipment, and other operating costs. We also consider capital allocation alternatives that balance returning value to shareholders through dividends and share repurchases, satisfying maturing debt, and acquiring businesses and technology.

Summary of Cash Flows

The following is a summary of cash provided by (used in) operating, investing, and financing activities, the effect of exchange rate changes on cash and cash equivalents, and the net change in cash and cash equivalents:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Cash provided by (used in):
Operating activities	$	1,083	$	1,292
Investing activities	(1,585)		(784)
Financing activities	(950)		(1,055)
Effect of exchange rate changes on cash and cash equivalents	(122)		(42)
Net change in cash and cash equivalents	$	(1,574)	$	(589)

Operating Activities The $209 million decrease in net cash provided was primarily driven by a decrease in cash collected from customers, partially offset by a decrease in cash paid to employees. The decrease in cash collected from customers was primarily related to supply chain challenges, which caused lower net sales as compared to the corresponding period in the prior fiscal year. Cash paid to employees decreased due to lower annual incentive plan payouts for prior year performance compared to the corresponding period in the prior fiscal year.

Investing Activities The $801 million increase in cash used was primarily attributable to cash paid for acquisitions of $1.2 billion, partially offset by a decrease in net purchases of investments of $332 million, as compared to the corresponding period in the prior fiscal year. For more information on the aforementioned acquisitions, refer to Note 4 to the current's period's consolidated financial statements.

Financing Activities There was a $105 million decrease in net cash used during the three months ended July 29, 2022, as compared to the corresponding period in the prior fiscal year. In the current period, the Company issued short-term borrowings of approximately $2.3 billion under the Fiscal 2023 Loan Agreement and used the proceeds to fund the early redemption of senior notes for total consideration of $2.3 billion. Also contributing to the total change was the decrease in share issuances of $68 million and increase in dividends paid of $57 million. For more information on the issuance of the Term Loan and redemptions of senior notes, refer to the Debt and Capital section.

44

Debt and Capital

Our capital structure consists of equity and interest-bearing debt. We primarily utilize unsecured senior debt obligations to meet our financing needs and, to a lesser extent, bank borrowings. From time to time, we may repurchase our outstanding debt obligations in the open market or through privately negotiated transactions.

Total debt at July 29, 2022 was $23.2 billion as compared to $24.1 billion at April 29, 2022. The decrease in total debt was driven by fluctuations in exchange rates as it pertains to our Euro-denominated senior notes.

On May 2, 2022, we entered into a term loan agreement (Fiscal 2023 Loan Agreement) with Mizuho Bank, Ltd. for an aggregate principal amount of up to ¥300 billion with a term of 364 days. In May and June 2022, Medtronic Luxco borrowed an aggregate of ¥297 billion, or approximately $2.3 billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net proceeds of the borrowings to fund the early redemption of $1.9 billion of Medtronic Inc. Senior Notes for $1.9 billion of total consideration, and $368 million of Medtronic Luxco Senior Notes for $376 million of total consideration. The Company recognized a total loss on debt extinguishment of $53 million in the quarter ended July 29, 2022, which primarily includes cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss was recognized in interest expense in the consolidated statements of income.

We repurchase our ordinary shares on occasion as part of our focus on returning value to our shareholders. In March 2019, the Company's Board of Directors authorized the repurchase of $6.0 billion of the Company's ordinary shares. There is no specific time period associated with these repurchase authorizations. During the three months ended July 29, 2022, the Company repurchased a total of 3 million shares under this program at an average price of $96.48. At July 29, 2022, we had approximately $2.6 billion remaining under the share repurchase program authorized by our Board of Directors.

For more information on credit arrangements, refer to Note 7 to the current period's consolidated financial statements and Note 6 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended April 29, 2022.

Liquidity

Our liquidity sources at July 29, 2022 included $2.1 billion of cash and cash equivalents and $6.7 billion of current investments. Additionally, we maintain commercial paper programs and a Credit Facility.

Our investments primarily include available-for-sale debt securities, including U.S. and non-U.S. government and agency securities, corporate debt securities, mortgage-backed securities, certificates of deposits, and other asset-backed securities. Refer to Note 6 to the current period's consolidated financial statements for additional information regarding fair value measurements.

We maintain multicurrency commercial paper programs for short-term financing, which allow us to issue unsecured commercial paper notes on a private placement basis up to a maximum aggregate amount outstanding at any time of $3.5 billion. At both July 29, 2022 and April 29, 2022, we had no commercial paper outstanding. The issuance of commercial paper reduces the amount of credit available under our existing line of credit, as explained below.

We also have a $3.5 billion five-year syndicated credit facility (Credit Facility), which expires in December 2026. At each anniversary date of the Credit Facility we can request a one-year extension of the maturity date. The Credit Facility provides backup funding for the commercial paper programs and may also be used for general corporate purposes. The Credit Facility provides us with the ability to increase our borrowing capacity by an additional $1.0 billion at any time during the term of the agreement. At July 29, 2022 and April 29, 2022, no amounts were outstanding under the Credit Facility.

Interest rates on advances of our Credit Facility are determined by a pricing matrix based on our long-term debt ratings assigned by Standard & Poor's Ratings Services (S&P) and Moody's Investors Service (Moody’s). Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. We are in compliance with all covenants related to the Credit Facility.

45

The following table is a summary of our S&P and Moody's long-term debt ratings and short-term debt ratings:

	Agency Rating(1)
	July 29, 2022	April 29, 2022
Standard & Poor's Ratings Services
Long-term debt	A	A
Short-term debt	A-1	A-1
Moody's Investors Service
Long-term debt	A3	A3
Short-term debt	P-2	P-2

(1) Agency ratings are subject to change, and there may be no assurance that an agency will continue to provide ratings and/or maintain its current ratings. A security rating is not a recommendation to buy, sell or hold securities, and may be subject to revision or withdrawal at any time by the rating agency, and each rating should be evaluated independently of any other rating.

S&P and Moody's long-term debt ratings and short-term debt ratings at July 29, 2022 were unchanged as compared to the ratings at April 29, 2022. We do not expect the S&P and Moody's ratings to have a significant impact on our liquidity or future flexibility to access additional liquidity given our balance sheet, Credit Facility, and related commercial paper programs.

We have future contractual obligations and other minimum commercial commitments that are entered into in the normal course of business. We believe our off-balance sheet arrangements do not have a material current or anticipated future effect on our consolidated earnings, financial position, and/or cash flows. There have been no material changes to our long-term contractual obligations as reported in our most recent Annual Report filed on Form 10-K for the fiscal year ended April 29, 2022.

ACQUISITIONS

Information regarding acquisitions is included in Note 4 to the current period's consolidated financial statements.

CRITICAL ACCOUNTING ESTIMATES

We have used various accounting policies to prepare the consolidated financial statements in accordance with U.S. GAAP. Our significant accounting policies are disclosed in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended April 29, 2022.

The preparation of the consolidated financial statements, in conformity with U.S. GAAP, requires us to use judgment in making estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates reflect our best judgment about economic and market conditions and the potential effects on the valuation and/or carrying value of assets and liabilities based upon relevant information available. We base our estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

As of July 29, 2022, there were no material changes to our critical accounting estimates.

NEW ACCOUNTING PRONOUNCEMENTS

Information regarding new accounting pronouncements is included in Note 2 to the current period's consolidated financial statements.

46

SUPPLEMENTAL GUARANTOR FINANCIAL INFORMATION

Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc., a wholly-owned subsidiary issuer, under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA), a wholly-owned subsidiary issuer, under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd., both of which are wholly-owned subsidiary guarantors of the CIFSA Senior Notes. Medtronic plc and Medtronic, Inc. each have provided a full and unconditional guarantee of the obligations of Medtronic Luxco under the Senior Notes (Medtronic Luxco Senior Notes). The following is a summary of these guarantees:

Guarantees of Medtronic Senior Notes

•Parent Company Guarantor – Medtronic plc

•Subsidiary Issuer – Medtronic, Inc.

•Subsidiary Guarantor – Medtronic Luxco

Guarantees of Medtronic Luxco Senior Notes

•Parent Company Guarantor – Medtronic plc

•Subsidiary Issuer – Medtronic Luxco

•Subsidiary Guarantor – Medtronic, Inc.

Guarantees of CIFSA Senior Notes

•Parent Company Guarantor – Medtronic plc

•Subsidiary Issuer – CIFSA

•Subsidiary Guarantors – Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. (CIFSA Subsidiary Guarantors)

The following tables present summarized results of operations for the three months ended July 29, 2022 and summarized balance sheet information at July 29, 2022 and April 29, 2022 for the obligor groups of Medtronic and Medtronic Luxco Senior Notes, and CIFSA Senior Notes. The obligor group consists of the parent company guarantor, subsidiary issuer, and subsidiary guarantors for the applicable senior notes. The summarized financial information is presented after elimination of (i) intercompany transactions and balances among the guarantors and issuers and (ii) equity in earnings from and investments in any subsidiary that is a non-guarantor or issuer.

47

The summarized results of operations information for the three months ended July 29, 2022 was as follows:

(in millions)	Medtronic & Medtronic Luxco Senior Notes (1)		CIFSA Senior Notes (2)
Net sales	$	589	$	—
Operating profit (loss)	(141)		(15)
Loss before income taxes	(423)		(253)
Net loss attributable to Medtronic	(328)		(251)

The summarized balance sheet information at July 29, 2022 was as follows:

(in millions)	Medtronic & Medtronic Luxco Senior Notes (1)		CIFSA Senior Notes (2)
Total current assets(3)	$	17,225	$	7,393
Total noncurrent assets(4)	12,135		8,394
Total current liabilities(5)	35,386		26,478
Total noncurrent liabilities(6)	46,315		59,163
Noncontrolling interests	170		170

(1)The Medtronic Senior Notes and Medtronic Luxco Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, and Medtronic, Inc. Refer to the guarantee summary above for further details.

(2)The CIFSA Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, CIFSA, and CIFSA Subsidiary Guarantors. Refer to the guarantee summary above for further details.

(3)Includes receivables due from non-guarantor subsidiaries of $16.4 billion and $7.1 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.

(4)Includes loans receivable due from non-guarantor subsidiaries of $6.5 billion and $8.4 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.

(5)Includes payables due to non-guarantor subsidiaries of $27.0 billion and $20.1 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.

(6)Includes loans payable due to non-guarantor subsidiaries of $27.6 billion and $46.3 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.

The summarized balance sheet information at April 29, 2022 was as follows:

(in millions)	Medtronic & Medtronic Luxco Senior Notes (1)		CIFSA Senior Notes (2)
Total current assets(3)	$	20,767	$	6,881
Total noncurrent assets(4)	12,099		8,293
Total current liabilities(5)	32,647		24,302
Total noncurrent liabilities(6)	50,542		60,292
Noncontrolling interests	171		171

(1)The Medtronic Senior Notes and Medtronic Luxco Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, and Medtronic, Inc. Refer to the guarantee summary above for further details.

(2)The CIFSA Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, CIFSA, and CIFSA Subsidiary Guarantors. Refer to the guarantee summary above for further details.

(3)Includes receivables due from non-guarantor subsidiaries of $20.2 billion and $6.9 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.

(4)Includes loans receivable due from non-guarantor subsidiaries of $6.5 billion and $8.3 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.

(5)Includes payables due to non-guarantor subsidiaries of $26.4 billion and $20.2 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.

(6)Includes loans payable due to non-guarantor subsidiaries of $29.0 billion and $46.4 billion for Medtronic & Medtronic Luxco Senior Notes, and CIFSA Senior Notes, respectively.

48

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, and other written reports and oral statements made by or with the approval of one of the Company’s executive officers from time to time, may include “forward-looking” statements. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy and plans, objectives of management for future operations and current expectations or forecasts of future results, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Our forward-looking statements may include statements related to our growth and growth strategies, developments in the markets for our products, therapies and services, financial results, product development launches and effectiveness, research and development strategy, regulatory approvals, competitive strengths, the potential or anticipated direct or indirect impact of COVID-19 on our business, results of operations, and/or financial condition, restructuring and cost-saving initiatives, intellectual property rights, litigation and tax matters, governmental proceedings and investigations, mergers and acquisitions, divestitures, market acceptance of our products, therapies and services, accounting estimates, financing activities, ongoing contractual obligations, working capital adequacy, value of our investments, our effective tax rate, our expected returns to shareholders, and sales efforts. In some cases, such statements may be identified by the use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “will,” and similar words or expressions. Forward-looking statements in this Quarterly Report include, but are not limited to, statements regarding our ability to drive long-term shareholder value, development and future launches of products and continued or future acceptance of products, therapies and services in our segments; expected timing for completion of research studies relating to our products; market positioning and performance of our products, including stabilization of certain product markets; divestitures and the potential benefits thereof; the costs and benefits of integrating previous acquisitions; anticipated timing for United States (U.S.) Food and Drug Administration (U.S. FDA) and non-U.S. regulatory approval of new products; increased presence in new markets, including markets outside the U.S.; changes in the market and our market share; acquisitions and investment initiatives, including the timing of regulatory approvals as well as integration of acquired companies into our operations; the resolution of tax matters; the effectiveness of our development activities in reducing patient care costs and hospital stay lengths; our approach towards cost containment; our expectations regarding healthcare costs, including potential changes to reimbursement policies and pricing pressures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and governmental proceedings and investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment of dividends and redemption of shares; the continued strength of our balance sheet and liquidity; our accounts receivable exposure; and the potential impact of our compliance with governmental regulations and accounting guidance.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations, financial condition, and/or cash flows. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the “Risk Factors” section and elsewhere in our Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. One must carefully consider forward-looking statements and understand that such forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and involve a variety of risks and uncertainties, known and unknown, including, among others, those discussed in the sections entitled “Government Regulation” within “Item 1. Business” and “Item 1A. Risk Factors” in our Annual Report on Form 10-K, as well as those related to:

•competition in the medical device industry;

•delays in regulatory approvals;

•the global COVID-19 pandemic, including new COVID-19 variants that may emerge, as well as impacts of the pandemic on healthcare staffing levels;

•reduction or interruption in our supply;

•failure to complete or achieve the intended benefits of acquisitions or divestitures;

•adverse regulatory action;

•laws and governmental regulations;

•litigation results;

•quality problems;

•healthcare policy changes;

•cybersecurity incidents;

49

•international operations, including the impact of armed conflicts;

•self-insurance;

•commercial insurance;

•changes in applicable tax rates;

•positions taken by taxing authorities;

•decreasing selling prices and pricing pressure;

•liquidity shortfalls;

•fluctuations in currency exchange rates;

•inflation; or

•disruption of our current plans and operations.

Consequently, no forward-looking statement may be guaranteed, and actual results may vary materially from those projected in the forward-looking statements. We intend to take advantage of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our forward-looking statements and are including this sentence for the express purpose of enabling us to use the protections of the safe harbor with respect to all forward-looking statements. While we may elect to update these forward-looking statements at some point in the future, whether as a result of any new information, future events, or otherwise, we have no current intention of doing so except to the extent required by applicable law.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

CURRENCY EXCHANGE RATE RISK

Due to the global nature of our operations, we are exposed to currency exchange rate changes, which may cause fluctuations in earnings and cash flows. Fluctuations in the currency exchange rates of currency exposures that are unhedged, such as in certain emerging markets, may result in future earnings and cash flow volatility. The gross notional amount of all currency exchange rate derivative instruments outstanding at July 29, 2022 and April 29, 2022 was $17.7 billion and $13.8 billion, respectively. At July 29, 2022, these contracts were in a net unrealized gain position of $854 million. Additional information regarding our currency exchange rate derivative instruments is included in Note 8 to the current period's consolidated financial statements.

A sensitivity analysis of changes in the fair value of all currency exchange rate derivative contracts at July 29, 2022 indicates that, if the U.S. dollar uniformly strengthened/weakened by 10 percent against all currencies, it would have the following impact on the fair value of these contracts:

	Increase (decrease)
(in millions)	July 29, 2022
10% appreciation in the U.S. dollar	$	391
10% depreciation in the U.S. dollar	(391)

Any gains and losses on the fair value of derivative contracts would generally be offset by gains and losses on the underlying transactions. These offsetting gains and losses are not reflected in the above analysis.

INTEREST RATE RISK

We are subject to interest rate risk on our short-term investments and our borrowings. We manage interest rate risk in the aggregate, while focusing on our immediate and intermediate liquidity needs. Our debt portfolio at July 29, 2022 was comprised of debt predominantly denominated in U.S. dollars, Euros, and Yen, of which substantially all is fixed rate debt. We are also exposed to interest rate changes affecting our investments in interest rate sensitive instruments, which include our marketable debt securities.

A sensitivity analysis of the impact on our interest rate-sensitive financial instruments of a hypothetical 10 basis point change in interest rates, as compared to interest rates at July 29, 2022, would have the following impact on the fair value of these instruments:

	Increase (decrease)
(in millions)	July 29, 2022
10 basis point increase in interest rates	$	55
10 basis point decrease in interest rates	(55)

50

For a discussion of current market conditions and the impact on our financial condition and results of operations, please see the “Liquidity” section of the current period's Management's Discussion and Analysis. For additional discussion of market risk, refer to Notes 6 and 8 to the current period's consolidated financial statements.

Item 4. Controls and Procedures

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) and changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) are effective.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act) during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

In accordance with Item 103 of Regulation S-K, we have adopted a $1 million disclosure threshold for proceedings under environmental laws to which a governmental authority is a party, as we believe matters under this threshold are not material to the Company. A discussion of the Company’s legal proceedings and other loss contingencies are described in Note 16 to the current period's consolidated financial statements.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

The following table provides information about the shares repurchased by the Company during the first quarter of fiscal year 2023:

Fiscal Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as a Part of Publicly Announced Program	Maximum Approximate Dollar Value of Shares that may yet be Purchased Under the Program
4/30/2022-5/27/2022	1,617,917	$	102.71	1,617,917	$	2,784,039,915
5/28/2022-7/1/2022	1,055,222	92.00		1,055,222	2,686,962,132
7/2/2022-7/29/2022	781,989	89.64		781,989	2,616,862,313
Total	3,455,128	$	96.48	3,455,128	$	2,616,862,313

In March 2019, the Company's Board of Directors authorized the repurchase of $6.0 billion of the Company's ordinary shares. There is no specific time-period associated with these repurchase authorizations.

Item 5. Other Information

Not applicable.

51

Item 6. Exhibits

(a)	Exhibits
	10.1	Letter Agreement by and between Medtronic, Inc. and Ivan K. Fong dated November 19, 2021
	31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
	31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
	32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	101.SCH	Inline XBRL Schema Document.
	101.CAL	Inline XBRL Calculation Linkbase Document.
	101.DEF	Inline XBRL Definition Linkbase Document.
	101.LAB	Inline XBRL Label Linkbase Document.
	101.PRE	Inline XBRL Presentation Linkbase Document.
	104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

52

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned authorized officer.

		Medtronic plc
		(Registrant)
Date:	September 1, 2022	/s/ Jennifer M. Kirk
		Jennifer M. Kirk
		Senior Vice President, Global Controller and Chief Accounting Officer (Principal Accounting Officer)

53

EX-10.1

Office of Chairman and Chief Executive Officer

Medtronic, Inc.

710 Medtronic Parkway, LC210 Minneapolis, MN 55432-5604 USA

Tel: 1.763.514.4000

www.medtronic.com

November 19, 2021

Dear Ivan,

I am pleased to provide you with this offer of employment at Medtronic (the Company). Your valuable experience and expertise will help shape our business and improve the lives of patients. Building the right team of talented people plus our market-leading position is a powerful combination – one that presents opportunity for tremendous growth and success.

By accepting our offer, you will be eligible to receive the following salary and benefits:

Title

Executive Vice President, General Counsel and Secretary

In this role, you will report to me and serve as a member of the Executive Committee. In this position, you shall have the responsibilities and duties commensurate with the General Counsel and Secretary role at Medtronic, and such other duties and responsibilities that are assigned by me.

Employment Location

Your assignment with Medtronic will be based out of Operational Headquarters in Fridley, MN.

Employment Date

To Be Mutually Agreed Upon but in no event later than April 1, 2022.

Base Salary

Your base salary will be $835,000 annually ($32,115.38 Biweekly), less applicable withholdings and deductions, commencing upon employment and paid in accordance with Medtronic’s standard payroll practices.

Business Allowance

In order to defray the cost of an automobile, tax preparation and financial planning, or other related expenses, you will be provided with an annual allowance of $24,000 (paid bi-weekly).

Medtronic Incentive Plan (“MIP”)

You are eligible to participate in the MIP with a target payout of 100% of your annual base salary on the last date of the MIP Period. Your actual payout will be determined by the achievement of MIP measures and is subject to applicable tax withholdings and deductions. Your MIP payment

for FY2022 will be based on a full year’s base salary and will be prorated to reflect your employment date. Please note that the actual terms of the Medtronic Incentive Plan govern eligibility and payout.

Annual Long-Term Incentive (“LTI”) Program

You will be eligible to participate in the regular annual LTI program beginning FY22. The annual target value for your participation in the LTI program is $3,230,000. Regular annual LTI awards are comprised of Performance Share Units, Non-Qualified Stock Options, and Time-Based Restricted Stock Units. Annual LTI awards are typically granted in Q2 of each fiscal year. Your FY22 LTI Award will be granted with a target value of $3,230,000 on your employment date.

The table below provides key highlights of your FY22 award.

Default Weight(1)	Vehicle	Vesting
50%	Performance Share Units (PSU)	August 2, 2024.
30%	Non-Qualified Stock Options (NQSO) (2)	25% per year beginning August 2, 2022.
20%	Time-Based Restricted Stock Units (TB-RSU)	100% August 2, 2024.

(1) Annual LTI Award vehicle splits may differ from above table in countries where local regulations prohibit PSUs, Stock Options, or RSUs.

(2) Number of stock options issued based on the Black-Scholes value at the time of grant.

Medtronic reserves the right to modify targets for any performance-based awards in line with plan terms and provisions. All LTI awards are subject to standard plan terms and provisions as described in the applicable award agreement(s) and approval by the appropriate Committee.

Total Target Direct Compensation

Your Total Target Direct Compensation (which consists of base salary + target MIP + target long-term incentives) will be $4,900,000 annually.

New Hire Cash Bonus

You will receive a one-time cash bonus in the amount of $650,000 (less standard federal and state withholding and authorized deductions) to be paid no later than 30 days after your employment date. Payment will be made on the first regularly scheduled pay date following date referenced above.

One-Time Restricted Stock Unit Grant

Additionally, you will be nominated to receive a one-time Restricted Stock Unit (RSU) award with a total target value of $2,500,000. This award vests over three years:

(1) 50% ($1.25M) vests December 2022

(2) 25% ($625K) vests December 2023

(3) 25% ($625K) vests December 2024

One-Time Stock Option Grant

Additionally, you will be nominated to receive a one-time, stock option award with a grant date value of $2,800,000 and an exercise price based on the closing price of the Company’s stock on the date of grant. The stock option grant will have a 10-year term and will vest over four years at 25% per year, beginning on the first anniversary of the date of the grant.

All terms and conditions of the stock option grant award will be described in the stock option award agreement provided following the grant date.

One-Time Performance Share Unit Grant

You will be nominated to receive a one-time Performance Share Unit (PSU) award for the Performance period FY2022-FY2024 with a target value of $2,200,000. PSUs have a three-fiscal year performance period after which the number of shares is increased or decreased from the grant date shares based on Medtronic’s performance against long-term performance goals. The award will vest August 2, 2024.

All terms and conditions of PSU awards will be described in the PSU award agreements and delivered to you following the PSU grant date. PSU awards are subject to approval by the Compensation Committee of the Board of Directors.

The One-Time Restricted Stock Unit Grant, Stock Option Grant, and Performance Share Unit Grant shall be granted to you on the employment date.

Paid Time Off (PTO)

You will be able to take time off when it works for you. As a reference point, please note the following guideline provided to other U.S. Medtronic employees: 10 fixed holidays and 4-5 weeks of paid time off.

Benefits

You will be offered a competitive benefits package upon meeting eligibility requirements as provided for in the Plan documents. For 2021 Medtronic benefits information on-line, visit benefits.medtronic.com, which provides details about all of our benefit offerings, as well as FAQs, recorded learning modules and links to plan documents and policy information.

Deferred Compensation Plan

You will be eligible to participate in Medtronic's Capital Accumulation Plan ("CAP"), a nonqualified deferred compensation plan, within 60 days after your date of hire. You will be eligible to defer a portion of your base salary for calendar year 2022.

Change in Control

You will participate in Medtronic’s Section 16 Officer Change in Control Policy.

Stock Ownership Policy

Medtronic’s policy requires Section 16 Officers to maintain Medtronic stock equal to three (3) times annual salary. Unless noted otherwise by an equity grant agreement, Section 16 Officers must retain 50% of the after-tax shares following settlement of equity compensation awards, including stock option exercises and restricted stock vesting, until the stock ownership requirement is met.

Employee Agreement

The compensation and benefits provided in this Offer are contingent on you signing the Medtronic Employee Agreement, which specifies certain employment terms and conditions. That agreement is provided to you with this Offer Letter.

Outside Activities

The Company agrees that you may continue to serve as a director of Cboe Global Markets, Inc.In addition, the Company will reimburse you (or pay directly for you) the reasonable costs you incur to participate in bar and other professional associations, and to keep your law license active (including registration fees and continuing legal education).

Termination

Your employment with Medtronic is “at will” and may be terminated at any time by Medtronic or by you.  If your employment is terminated by the Company without Cause, as defined in the 2021 Medtronic plc Long-Term Incentive Plan, or you resign for Good Reason (as defined below) on or prior to the third anniversary of the employment date, and contingent upon your signing and complying with a severance and release agreement, the Company shall pay or provide you with:

I.The amount of cash severance equal to (A) two times of (B) the sum of (1) your base salary in effect at the time of employment termination and (2) your annual MIP Incentive, payable in a lump sum on the date sixty (60) days after the date of termination. The MIP incentive is based on the lesser of target or actual or, as of your termination date, forecasted actual performance for the fiscal year in which termination occurs.

II.An amount equal to the product of (A) 24 and (B) the monthly premium for COBRA continuation coverage under the Company’s medical, dental and vision plans, payable in a lump sum on the date sixty (60) days after the date of termination.  

III.Continued vesting of the one-time new hire Restricted Stock Unit Grant specified in the section titled “One-Time Restricted Stock Unit Grant”, the one-time Stock Option Grant specified in the section titled “One-Time Stock Option Grant”, and the one-time new hire FY2022-FY2024 Performance Share Unit Grant specified in the section titled “One-Time Special Performance Share Unit Grant,” as if you had remained employed, and the vested options pursuant to the Stock Option Grant will remain exercisable until the 5th anniversary of your termination date (but not beyond the original expiration date). Except as otherwise provided herein, these awards are subject to the terms and conditions of the grant agreement and the vesting provisions contained within.

These severance benefits are aligned with Medtronic’s published severance practice for Section 16 Officers.

In addition, for all terminations of employment, you will receive: (1) your base salary and benefits due through the date of termination, (2) reimbursement of any unreimbursed business expenses, (3) payment of any amounts due under the MIP for the year prior to the year in which your date of termination occurs (payable when bonuses for such year are paid to employed senior executives) and (4) your rights pursuant to any Company plan, policy, benefit or other agreement, including without limitation, with respect to your LTI awards.

For purposes of this letter agreement and consistent with Medtronic’s standard practice, Good Reason shall mean any of the following without your prior written consent: (i) there is a material diminution in your positions, authorities or duties, including you no longer report directly and solely to the CEO, you are no longer the Company’s General Counsel, Secretary or an Executive Vice President or you fail to be on the Executive Committee, (ii) your Base Salary, annual MIP target or annual LTI target value is reduced or you are not awarded the LTIs in the same proportion of PSUs, stock options and RSUs and on the same terms and conditions as other senior executives, (iii) you fail to be covered by the Company’s Section 16 Officer Change in Control Policy on the same basis as any other senior executive, or (iv) a successor to all or substantially all of the Company’s business or assets fails to assume this letter agreement either contractually or as a matter of law as of the date of the closing of such transaction. Notwithstanding the foregoing, you shall not be permitted to resign for Good Reason, unless you provide written notice to the Company setting forth the acts or omissions giving rise to your right to resign for Good Reason within sixty (60) days of the later of your first learning of such act or omission or its occurrence, the Company fails to cure such act or omission within thirty (30) days of receipt of your notice and, if the Company fails to cure such act or omission within its 30-day cure period, you actually resign your employment within sixty (60) days following the end of the Company’s cure period.

Indemnification/D&O Liability Insurance

During your employment and thereafter, the Company shall indemnify you (and advance you expenses) to the fullest extent permitted by its bylaws, other corporate documents and/or Company policy or, if greater, applicable law and also agrees that you shall be covered under its directors’ and officers’ liability insurance policies on a basis no less favorable to you than any other senior executive of the Company is so covered.

Offer Acceptance

Ivan, join us to collaborate boldly with others to tackle healthcare’s greatest challenges and to help us achieve our Mission to alleviate pain, restore health and extend life for patients everywhere. Please review and direct any questions to either myself or Carol Surface, Chief Human Resources Officer. This offer will remain outstanding and irrevocable by the Company unless you fail to return an executed copy of this letter agreement to Carol Surface by 11:59 pm CT on November 26, 2021.

Sincerely,

Geoff Martha

Chairman and Chief Executive Officer

cc: Carol Surface

I, Ivan Fong, accept this offer of employment and agree to the terms and conditions outlined in this letter. I understand that the attached terms and conditions of employment apply and that I must also sign the attached Employee Agreement.

Ivan Fong

Date

EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer

Pursuant to Section 302 of the

Sarbanes-Oxley Act of 2002

I, Geoffrey S. Martha, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Medtronic plc;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

September 1, 2022	/s/ Geoffrey S. Martha
	Geoffrey S. Martha
	Chief Executive Officer

EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer

Pursuant to Section 302 of the

Sarbanes-Oxley Act of 2002

I, Karen L. Parkhill, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Medtronic plc;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

September 1, 2022	/s/ Karen L. Parkhill
	Karen L. Parkhill
	Executive Vice President and
	Chief Financial Officer

EX-32.1

Exhibit 32.1

Certification of Chief Executive Officer

Pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with this quarterly report on Form 10-Q of Medtronic plc for the quarter ended July 29, 2022, the undersigned hereby certifies, in his capacity as Chief Executive Officer of Medtronic plc, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)The information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Medtronic plc.

September 1, 2022	/s/ Geoffrey S. Martha
	Geoffrey S. Martha
	Chief Executive Officer

EX-32.2

Exhibit 32.2

Certification of Chief Financial Officer

Pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with this quarterly report on Form 10-Q of Medtronic plc for the quarter ended July 29, 2022, the undersigned hereby certifies, in her capacity as Chief Financial Officer of Medtronic plc, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)The information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Medtronic plc.

September 1, 2022	/s/ Karen L. Parkhill
	Karen L. Parkhill
	Executive Vice President and
	Chief Financial Officer

XML

Cover - shares	3 Months Ended
	Jul. 29, 2022	Aug. 29, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 29, 2022
Document Transition Report	false
Entity File Number	001-36820
Entity Registrant Name	Medtronic plc
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1183488
Entity Address, Address Line One	20 On Hatch, Lower Hatch Street
Entity Address, City or Town	Dublin 2
Entity Address, Country	IE
Country Region	353
City Area Code	1
Local Phone Number	438-1700
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Ordinary Shares Outstanding		1,329,153,289
Entity Central Index Key	0001613103
Current Fiscal Year End Date	--04-28
Amendment Flag	false
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Entity Address, Postal Zip Code	D02 XH02
Ordinary shares, par value $0.0001 per share
Entity Information [Line Items]
Title of 12(b) Security	Ordinary shares, par value $0.0001 per share
Trading Symbol	MDT
Security Exchange Name	NYSE
0.00% Senior Notes due 2022
Entity Information [Line Items]
Title of 12(b) Security	0.00% Senior Notes due 2022
Trading Symbol	MDT/22B
Security Exchange Name	NYSE
0.375% Senior Notes due 2023
Entity Information [Line Items]
Title of 12(b) Security	0.375% Senior Notes due 2023
Trading Symbol	MDT/23B
Security Exchange Name	NYSE
0.000% Senior Notes due 2023
Entity Information [Line Items]
Title of 12(b) Security	0.000% Senior Notes due 2023
Trading Symbol	MDT/23C
Security Exchange Name	NYSE
0.25% Senior Notes due 2025
Entity Information [Line Items]
Title of 12(b) Security	0.25% Senior Notes due 2025
Trading Symbol	MDT/25
Security Exchange Name	NYSE
0.000% Senior Notes due 2025
Entity Information [Line Items]
Title of 12(b) Security	0.000% Senior Notes due 2025
Trading Symbol	MDT/25A
Security Exchange Name	NYSE
1.125% Senior Notes due 2027
Entity Information [Line Items]
Title of 12(b) Security	1.125% Senior Notes due 2027
Trading Symbol	MDT/27
Security Exchange Name	NYSE
0.375% Senior Notes due 2028
Entity Information [Line Items]
Title of 12(b) Security	0.375% Senior Notes due 2028
Trading Symbol	MDT/28
Security Exchange Name	NYSE
1.625% Senior Notes due 2031
Entity Information [Line Items]
Title of 12(b) Security	1.625% Senior Notes due 2031
Trading Symbol	MDT/31
Security Exchange Name	NYSE
1.00% Senior Notes due 2031
Entity Information [Line Items]
Title of 12(b) Security	1.00% Senior Notes due 2031
Trading Symbol	MDT/31A
Security Exchange Name	NYSE
0.750% Senior Notes due 2032
Entity Information [Line Items]
Title of 12(b) Security	0.750% Senior Notes due 2032
Trading Symbol	MDT/32
Security Exchange Name	NYSE
2.250% Senior Notes due 2039
Entity Information [Line Items]
Title of 12(b) Security	2.250% Senior Notes due 2039
Trading Symbol	MDT/39A
Security Exchange Name	NYSE
1.50% Senior Notes due 2039
Entity Information [Line Items]
Title of 12(b) Security	1.50% Senior Notes due 2039
Trading Symbol	MDT/39B
Security Exchange Name	NYSE
1.375% Senior Notes due 2040
Entity Information [Line Items]
Title of 12(b) Security	1.375% Senior Notes due 2040
Trading Symbol	MDT/40A
Security Exchange Name	NYSE
1.75% Senior Notes due 2049
Entity Information [Line Items]
Title of 12(b) Security	1.75% Senior Notes due 2049
Trading Symbol	MDT/49
Security Exchange Name	NYSE
1.625% Senior Notes due 2050
Entity Information [Line Items]
Title of 12(b) Security	1.625% Senior Notes due 2050
Trading Symbol	MDT/50
Security Exchange Name	NYSE

XML

Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Income Statement [Abstract]
Net sales	$ 7,371,000,000	$ 7,987,000,000
Costs and expenses:
Cost of products sold, excluding amortization of intangible assets	2,516,000,000	2,598,000,000
Research and development expense	692,000,000	750,000,000
Selling, general, and administrative expense	2,567,000,000	2,547,000,000
Amortization of intangible assets	423,000,000	436,000,000
Restructuring charges, net	14,000,000	11,000,000
Certain litigation charges, net	0	26,000,000
Other operating expense, net	35,000,000	760,000,000
Operating profit	1,125,000,000	859,000,000
Other non-operating income, net	(83,000,000)	(111,000,000)
Interest expense	164,000,000	137,000,000
Income before income taxes	1,044,000,000	833,000,000
Income tax provision	112,000,000	64,000,000
Net income	931,000,000	769,000,000
Net income attributable to noncontrolling interests	(2,000,000)	(6,000,000)
Net income attributable to Medtronic	$ 929,000,000	$ 763,000,000
Basic earnings per share (usd per share)	$ 0.70	$ 0.57
Diluted earnings per share (usd per share)	$ 0.70	$ 0.56
Basic weighted average shares outstanding (shares)	1,329.4	1,344.5
Diluted weighted average shares outstanding (shares)	1,334.5	1,356.4

XML

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 931	$ 769
Other comprehensive income (loss), net of tax:
Unrealized (loss) gain on investment securities	(16)	12
Translation adjustment	(884)	(355)
Net investment hedge	1,002	424
Net change in retirement obligations	1	19
Unrealized gain on cash flow hedges	220	174
Other comprehensive income	324	274
Comprehensive income including noncontrolling interests	1,255	1,043
Comprehensive income attributable to noncontrolling interests	0	(4)
Comprehensive income attributable to Medtronic	$ 1,255	$ 1,039

XML

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jul. 29, 2022	Apr. 29, 2022
Current assets:
Cash and cash equivalents	$ 2,140	$ 3,714
Investments	6,733	6,859
Accounts receivable, less allowances and credit losses of $219 and $230, respectively	5,308	5,551
Inventories, net	4,809	4,616
Other current assets	3,145	2,318
Total current assets	22,135	23,059
Property, plant, and equipment	13,323	13,365
Accumulated depreciation	(8,043)	(7,952)
Property, plant, and equipment, net	5,281	5,413
Goodwill	40,324	40,502
Other intangible assets, net	15,775	15,595
Tax assets	3,311	3,403
Other assets	3,088	3,008
Total assets	89,914	90,981
Current liabilities:
Current debt obligations	5,729	3,742
Accounts payable	2,180	2,276
Accrued compensation	1,773	2,121
Accrued income taxes	549	704
Other accrued expenses	3,816	3,551
Total current liabilities	14,049	12,394
Long-term debt	17,481	20,372
Accrued compensation and retirement benefits	1,102	1,113
Accrued income taxes	2,102	2,087
Deferred tax liabilities	899	884
Other liabilities	1,440	1,410
Total liabilities	37,071	38,260
Commitments and contingencies (Note 16)
Shareholders’ equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,329,276,973 and 1,330,743,395 shares issued and outstanding, respectively	0	0
Additional paid-in capital	24,335	24,566
Retained earnings	30,276	30,250
Accumulated other comprehensive loss	(1,939)	(2,265)
Total shareholders’ equity	52,672	52,551
Noncontrolling interests	170	171
Total equity	52,843	52,722
Total liabilities and equity	$ 89,914	$ 90,981

XML

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Jul. 29, 2022	Apr. 29, 2022
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 219	$ 230
Ordinary shares, par value (usd per share)	$ 0.0001	$ 0.0001
Ordinary shares authorized (shares)	2,600,000,000	2,600,000,000
Ordinary shares issued (shares)	1,329,276,973	1,330,743,395
Ordinary shares outstanding (shares)	1,329,276,973	1,330,743,395

XML

Consolidated Statements of Equity (Unaudited) - USD ($) $ in Millions	Total	Total Shareholders’ Equity	Ordinary Shares	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interests
Beginning balance (shares) at Apr. 30, 2021			1,345,000,000
Beginning balance at Apr. 30, 2021	$ 51,602	$ 51,428	$ 0	$ 26,319	$ 28,594	$ (3,485)	$ 174
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	769	763			763		6
Other comprehensive income (loss)	274	276				276	(2)
Dividends to shareholders	(846)	(846)			(846)
Issuance of shares under stock purchase and award plans (shares)			2,000,000
Issuance of shares under stock purchase and award plans	107	107		107
Repurchase of ordinary shares (shares)			(2,000,000)
Repurchase of ordinary shares	(311)	(311)		(311)
Stock-based compensation	69	69		69
Ending balance (shares) at Jul. 30, 2021			1,345,000,000
Ending balance at Jul. 30, 2021	$ 51,664	51,486	$ 0	26,184	28,511	(3,209)	178
Beginning balance (shares) at Apr. 29, 2022	1,330,743,395		1,331,000,000
Beginning balance at Apr. 29, 2022	$ 52,722	52,551	$ 0	24,566	30,250	(2,265)	171
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	931	929			929		2
Other comprehensive income (loss)	324	326				326	(2)
Dividends to shareholders	(903)	(903)			(903)
Issuance of shares under stock purchase and award plans (shares)			2,000,000
Issuance of shares under stock purchase and award plans	41	41		41
Repurchase of ordinary shares (shares)			(3,000,000)
Repurchase of ordinary shares	(333)	(333)		(333)
Stock-based compensation	$ 62	62		62
Ending balance (shares) at Jul. 29, 2022	1,329,276,973		1,329,000,000
Ending balance at Jul. 29, 2022	$ 52,843	$ 52,672	$ 0	$ 24,335	$ 30,276	$ (1,939)	$ 170

XML

Consolidated Statements of Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Statement of Stockholders' Equity [Abstract]
Dividends to shareholders (usd per share)	$ 0.68	$ 0.63

XML

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Operating Activities:
Net income	$ 931	$ 769
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	668	671
Provision for credit losses	15	15
Deferred income taxes	(18)	(11)
Stock-based compensation	62	69
Loss on debt extinguishment	53	0
MCS asset impairment and inventory write-down	0	515
Other, net	121	116
Change in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable, net	89	(40)
Inventories, net	(380)	(75)
Accounts payable and accrued liabilities	(147)	(416)
Other operating assets and liabilities	(311)	(321)
Net cash provided by operating activities	1,083	1,292
Investing Activities:
Acquisitions, net of cash acquired	(1,191)	0
Additions to property, plant, and equipment	(426)	(378)
Purchases of investments	(1,884)	(2,654)
Sales and maturities of investments	1,886	2,324
Other investing activities, net	30	(76)
Net cash used in investing activities	(1,585)	(784)
Financing Activities:
Proceeds from short-term borrowings (maturities greater than 90 days)	2,284	0
Payments on long-term debt	(2,311)	(1)
Dividends to shareholders	(903)	(846)
Issuance of ordinary shares	43	111
Repurchase of ordinary shares	(336)	(315)
Other financing activities	273	(4)
Net cash used in financing activities	(950)	(1,055)
Effect of exchange rate changes on cash and cash equivalents	(122)	(42)
Net change in cash and cash equivalents	(1,574)	(589)
Cash and cash equivalents at beginning of period	3,714	3,593
Cash and cash equivalents at end of period	2,140	3,004
Cash paid for:
Income taxes	260	249
Interest	$ 68	$ 63

XML

Basis of Presentation

3 Months Ended

Jul. 29, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.

Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.

The COVID-19 pandemic ("COVID-19" or the "pandemic") has had, and may continue to have, an adverse effect on our business, results of operations, financial condition, and cash flows, and its future impacts remain uncertain and unpredictable. While there was not a material impact to the Company’s consolidated financial statements as of and for the three months ended July 29, 2022, changes in the Company’s assessment about the length and severity of the pandemic, as well as other factors, could result in actual results differing from estimates.

The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. Amounts reported in millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.

The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 29, 2022. The Company’s fiscal years 2023, 2022, and 2021 will end or ended on April 28, 2023, April 29, 2022, and April 30, 2021, respectively. Fiscal year 2021 was a 53-week year.

XML

New Accounting Pronouncements

3 Months Ended

Jul. 29, 2022

Accounting Standards Update and Change in Accounting Principle [Abstract]

New Accounting Pronouncements

New Accounting Pronouncements

Recently Adopted

For the three months ended July 29, 2022, there were no newly adopted accounting pronouncements that had a material impact to our consolidated financial statements. As of July 29, 2022, there are no recently issued but not yet adopted accounting pronouncements that are expected to materially impact our consolidated financial statements.

XML

Revenue

3 Months Ended

Jul. 29, 2022

Revenue from Contract with Customer [Abstract]

Revenue

Revenue The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, renal disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations.

The table below illustrates net sales by segment and division for the three months ended July 29, 2022 and July 30, 2021:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Cardiac Rhythm & Heart Failure	$	1,393	$	1,483
Structural Heart & Aortic	741		787
Coronary & Peripheral Vascular	579		620
Cardiovascular	2,713		2,890
Surgical Innovations	1,338		1,554
Respiratory, Gastrointestinal, & Renal	664		768
Medical Surgical	2,001		2,322
Cranial & Spinal Technologies	1,043		1,123
Specialty Therapies	667		641
Neuromodulation	405		440
Neuroscience	2,115		2,204
Diabetes	541		572
Total	$	7,371	$	7,987

The table below illustrates net sales by market geography for each segment for the three months ended July 29, 2022 and July 30, 2021:

	U.S.(1)				Non-U.S. Developed Markets(2)				Emerging Markets(3)
	Three months ended				Three months ended				Three months ended
(in millions)	July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021
Cardiovascular	$	1,298	$	1,420	$	892	$	1,003	$	523	$	467
Medical Surgical	843		990		767		869		392		463
Neuroscience	1,419		1,446		407		465		290		293
Diabetes	206		245		264		263		72		63
Total	$	3,766	$	4,101	$	2,328	$	2,601	$	1,276	$	1,286

(1)U.S. includes the United States and U.S. territories.

(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.

(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.

The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At July 29, 2022, $955 million of rebates were classified as other accrued expenses, and $576 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet. At April 29, 2022, $981 million of rebates were classified as other accrued expenses, and $548 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet.

Deferred Revenue and Remaining Performance Obligations

The Company records a deferred revenue liability if a customer pays consideration, or the Company has the right to invoice, before the Company transfers a good or service to the customer. Deferred revenue at July 29, 2022 and April 29, 2022 was $391 million and $399 million, respectively. At July 29, 2022 and April 29, 2022, $302 million and $305 million was included in other accrued expenses, respectively, and $90 million and $94 million was included in other liabilities, respectively. During the three months ended July 29, 2022, the Company recognized $87 million of revenue that was included in deferred revenue as of April 29, 2022.

Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At July 29, 2022, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $801 million. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next three years.

XML

Acquisitions and Assets and Liabilities Held for Sale

3 Months Ended

Jul. 29, 2022

Business Combination and Asset Acquisition [Abstract]

Acquisitions and Assets and Liabilities Held for Sale

Acquisitions and Assets and Liabilities Held for Sale

During the three months ended July 29, 2022, the Company had acquisitions that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future, yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the consolidated results of the Company for the three months ended July 29, 2022. The results of operations of acquired businesses have been included in the Company's consolidated statements of income since the date each business was acquired. For the three months ended July 29, 2022 and July 30, 2021, purchase price allocation adjustments were not significant.

Fiscal Year 2023

Intersect ENT

On May 13, 2022, the Company acquired Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader. The acquisition expands the Neuroscience segment portfolio of products used during ENT procedures, and combined with the Company's navigation, powered instruments, and existing tissue health products, will offer a broader suite of solutions to assist surgeons treating patients who suffer from chronic rhinosinusitis (CRS). Total consideration, net of cash acquired, for the transaction, in which the Company acquired all outstanding shares of Intersect ENT for $28.25 per share, was $1.2 billion consisting of $1.1 billion of cash and $98 million previously held investments in Intersect ENT. Based upon a preliminary acquisition valuation, the Company acquired $615 million of goodwill, $635 million of technology-based intangible assets, $35 million of customer-related intangible assets, and $13 million of tradenames with estimated useful lives of 20 years. The goodwill is not deductible for tax purposes.

Revenue and net loss attributable to Intersect ENT since the date of acquisition as well as costs incurred in connection with the acquisition included in the consolidated statements of income were not significant for the three months ended July 29, 2022.

The acquisition date fair values of the assets acquired and liabilities assumed were as follows:

(in millions)	Intersect ENT
Cash and cash equivalents	$	39
Inventory	32
Goodwill	615
Other intangible assets	683
Other assets	40
Total assets acquired	1,408
Current liabilities	63
Deferred tax liabilities	51
Other liabilities	18
Total liabilities assumed	131
Net assets acquired	$	1,277

Other acquisitions

For acquisitions other than Intersect ENT, the acquisition date fair value of net assets acquired during the three months ended July 29, 2022 was $123 million. Based upon preliminary valuations, assets acquired were primarily comprised of $66 million of goodwill and $57 million of technology-based intangible assets with estimated useful lives of 16 years. The goodwill is deductible for tax purposes. The Company recognized $73 million of contingent consideration liabilities in connection with these acquisitions during the three months ended July 29, 2022, which are comprised of revenue and regulatory milestone-based payments.

Subsequent Acquisitions

Subsequent to July 29, 2022, on August 30, 2022 the Company acquired Affera, Inc. (Affera) a privately-held manufacturer of cardiac mapping and navigation systems and catheter-based cardiac ablation technologies. The acquisition expands the Cardiovascular segment portfolio of advanced cardiac ablation products and accessories to include its first cardiac mapping and navigation platform to meet physician needs within a growing patient population. Total consideration for the transaction is up to $1.0 billion, including up to $250 million of undiscounted contingent consideration related to certain technical and regulatory milestones. The transaction will be accounted for as a business combination using the acquisition method of accounting. This requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date.

Due to the limited amount of time since the acquisition date and the significant limitations on access to Affera information prior to the acquisition date, the preliminary acquisition valuation for the business combination is incomplete at this time. As a result, the Company is unable to provide the amounts recognized as of the acquisition date for the major classes of assets acquired and liabilities assumed, including the information required for valuation of intangible assets and goodwill. We will include such disclosures in our Form 10-Q for the quarter ending October 28, 2022.

Acquired In-Process Research & Development (IPR&D)

IPR&D with no alternative future use acquired outside of a business combination is expensed immediately. During the three months ended July 29, 2022, IPR&D acquired in connection with asset acquisitions of technology not yet approved by regulators was not significant. During the three months ended July 30, 2021, the Company acquired $90 million of IPR&D in connection with asset acquisitions of technology not yet approved by regulators, which was recognized in research and development expense in the consolidated statements of income.

Contingent Consideration

Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within other operating expense, net in the consolidated statements of income.

The fair value of contingent consideration at July 29, 2022 and April 29, 2022 was $193 million and $119 million, respectively. At July 29, 2022, $64 million was recorded in other accrued expenses, and $129 million was recorded in other liabilities in the consolidated balance sheet. At April 29, 2022, $35 million was recorded in other accrued expenses, and $84 million was recorded in other liabilities in the consolidated balance sheet.

The following table provides a reconciliation of the beginning and ending balances of contingent consideration:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Beginning balance	$	119	$	270
Purchase price contingent consideration	73		—
Purchase price allocation adjustments	—		25
Payments	—		(11)
Change in fair value	2		10
Ending balance	$	193	$	294

The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:

	Fair Value at
(in millions)	July 29, 2022	Unobservable Input	Range	Weighted Average (1)
Revenue and other performance-based payments	$143	Discount rate	11.2% - 27.2%	15.0%
		Projected fiscal year of payment	2023 - 2027	2025
Product development and other milestone-based payments	$50	Discount rate	5.5%	5.5%
		Projected fiscal year of payment	2023 - 2024	2023

(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.

Assets and Liabilities Held for Sale

On May 25, 2022, the Company and DaVita Inc. (“DaVita”) entered into a definitive agreement for the Company to sell half of its Renal Care Solutions (RCS) business. This sale is part of an agreement between Medtronic and DaVita to form a new, independent kidney care-focused medical device company (“NewCo”) with equal equity ownership. As a result of entering into the definitive agreement, the RCS business met the criteria to be classified as held for sale on the date the agreement was entered into. The transaction is expected to close in calendar year 2023, subject to customary regulatory approvals and closing conditions. RCS is part of the Company’s Medical Surgical portfolio. The Company recorded a non-cash pre-tax impairment of $67 million, primarily related to goodwill, in the three months ending July 29, 2022 recognized in other operating expense, net in the consolidated statements of income. Refer to Note 10 to the consolidated financial statements for additional information on the goodwill impairment.

The following table presents information related to the assets and liabilities that were classified as held for sale in our consolidated balance sheet:

(in millions)	July 29, 2022
Inventories, net	$	119
Property, plant, and equipment, net	141
Goodwill	147
Other intangible assets, net	114
Other	48
Total assets held for sale (1)	$	568
Total liabilities held for sale (1)(2)	$	38

(1) Total assets held for sale and total liabilities held for sale are reported in other current assets and other accrued expenses, respectively in the consolidated balance sheets.

(2) No separate class of liability classified as held for sale was individually significant enough for separate disclosure.

There were no assets or liabilities classified as held for sale at April 29, 2022. The Company determined that the agreement to sell half of the RCS business does not meet the criteria to be classified as discontinued operations.

XML

Restructuring and Other Costs

3 Months Ended

Jul. 29, 2022

Restructuring and Related Activities [Abstract]

Restructuring and Other Costs

Restructuring and Other Costs

Enterprise Excellence

In the third quarter of fiscal year 2018, the Company announced its Enterprise Excellence restructuring program. Further program details are described in Note 4 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2022.

Since inception, the Company has incurred pre-tax exit and disposal costs and other costs, across all segments, of $1.6 billion in connection with the Enterprise Excellence program. In total, the Company estimates it will recognize approximately $1.8 billion of exit and disposal costs and other costs related to the program by the end of fiscal year 2023. The remaining charges are costs associated with the restructuring program, such as salaries and benefits for employees supporting the program, including program management and transition teams, and strategic and operational consulting services related to the three objectives of the program. These charges are recognized within restructuring charges, net, cost of products sold, and selling, general, and administrative expense in the consolidated statements of income.

For the three months ended July 29, 2022, the Company recognized net charges of $40 million, of which $19 million was recognized within cost of products sold and $28 million was recognized within selling, general, and administrative expense in the consolidated statements of income. For the three months ended July 30, 2021, the Company recognized net charges of $74 million, of which $33 million were recognized within cost of products sold and $30 million were recognized within selling, general, and administrative expense in the consolidated statements of income.

Simplification

In the first quarter of fiscal year 2021, the Company initiated the Simplification restructuring program. Further program details are described in Note 4 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2022.

Since inception, the Company has incurred pre-tax exit and disposal costs and other costs, across all segments, of $385 million in connection with the Simplification program. In total, the Company estimates it will recognize approximately $450 million of exit and disposal costs and other costs related to the Simplification program by the end of fiscal year 2023. The remaining charges are costs associated with the restructuring program, such as salaries for employees supporting the program and consulting expenses. These charges are recognized within restructuring charges, net, cost of products sold, and selling, general, and administrative expense in the consolidated statements of income.

For the three months ended July 29, 2022, the Company recognized net charges of $36 million of which $13 million were recognized within selling, general, and administrative expense in the consolidated statements of income. For the three months ended July 30, 2021, the Company recognized net charges of $7 million which were all recognized within selling, general, and administrative expense in the consolidated statements of income.

The following table summarizes the activity related to the restructuring programs above for the three months ended July 29, 2022:

(in millions)	Employee Termination Benefits		Associated Costs(1)		Other Costs		Total
April 29, 2022	$	81	$	27	$	1	$	110
Charges	23		61		1		85
Cash payments	(26)		(75)		(1)		(103)
Accrual adjustments(2)	(9)		—		—		(9)
July 29, 2022	$	69	$	13	$	1	$	83

(1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.

(2) Accrual adjustments relate to certain employees identified for termination finding other positions within the Company.

Mechanical Circulatory Support (MCS)

In June 2021, the Company announced the decision to stop the distribution and sale of the Medtronic HVAD System in light of a growing body of observational clinical comparisons indicating a lower frequency of neurological adverse events and mortality with another circulatory support device available to patients compared to the HVAD system. In connection with this decision, the Company recorded charges of $726 million (MCS charges) within the Cardiovascular segment during the three months ended July 30, 2021, including $58 million recognized in costs of products sold and $668 million recognized within other operating expense, net in the consolidated statement of income. The charges included $515 million of non-cash impairments and write-downs primarily related to $409 million of intangible asset impairments and $58 million of inventory write-downs. The Company also recorded charges of $211 million for commitments and obligations associated with the decision, which included charges for patient support obligations, restructuring, and other associated costs. During the fourth quarter of fiscal year 2022, the Company recorded additional charges of $155 million within other operating expense, net primarily related to incremental commitments and obligations associated with the exit of the business. As of July 29, 2022, accruals were recorded in the consolidated balance sheet for these obligations, with $81 million reflected in other accrued expenses and $136 million recorded in other liabilities. Medtronic remains committed to serving the needs of the approximately 3,200 patients currently implanted with the HVAD system.

XML

Financial Instruments

3 Months Ended

Jul. 29, 2022

Investments [Abstract]

Financial Instruments

Financial Instruments

Debt Securities

The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at July 29, 2022 and April 29, 2022:

    

	July 29, 2022
	Valuation								Balance Sheet Classification
(in millions)	Cost		Unrealized Gains		Unrealized Losses		Fair Value		Investments		Other Assets
Level 1:
U.S. government and agency securities	$	532	$	1	$	(13)	$	520	$	520	$	—
Level 2:
Corporate debt securities	4,339		4		(156)		4,186		4,186		—
U.S. government and agency securities	928		—		(37)		891		891		—
Mortgage-backed securities	573		—		(38)		535		535		—
Non-U.S. government and agency securities	17		—		—		17		17		—
Certificates of deposit	10		—		—		10		10		—
Other asset-backed securities	595		—		(22)		574		574		—
Total Level 2	6,462		4		(253)		6,213		6,213		—
Level 3:
Auction rate securities	36		—		(3)		33		—		33
Total available-for-sale debt securities	$	7,030	$	5	$	(269)	$	6,767	$	6,733	$	33

	April 29, 2022
	Valuation								Balance Sheet Classification
(in millions)	Cost		Unrealized Gains		Unrealized Losses		Fair Value		Investments		Other Assets
Level 1:
U.S. government and agency securities	$	533	$	1	$	(15)	$	518	$	518	$	—
Level 2:
Corporate debt securities	4,457		4		(140)		4,321		4,321		—
U.S. government and agency securities	910		—		(41)		869		869		—
Mortgage-backed securities	592		—		(35)		558		558		—
Non-U.S. government and agency securities	17		—		—		17		17		—
Certificates of deposit	20		—		—		20		20		—
Other asset-backed securities	567		—		(11)		556		556		—
Total Level 2	6,563		4		(227)		6,341		6,341		—
Level 3:
Auction rate securities	36		—		(3)		33		—		33
Total available-for-sale debt securities	$	7,131	$	5	$	(245)	$	6,893	$	6,859	$	33

The amortized cost of debt securities excludes accrued interest, which is reported in other current assets in the consolidated balance sheets.

The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at July 29, 2022 and April 29, 2022:

	July 29, 2022
	Less than 12 months				More than 12 months
(in millions)	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Corporate debt securities	$	243	$	(2)	$	3,044	$	(155)
U.S. government and agency securities	—		—		942		(50)
Mortgage-backed securities	—		—		521		(38)
Other asset-backed securities	—		—		532		(22)
Auction rate securities	—		—		33		(3)
Total	$	243	$	(2)	$	5,072	$	(267)

	April 29, 2022
	Less than 12 months				More than 12 months
(in millions)	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Corporate debt securities	$	222	$	(1)	$	2,993	$	(139)
U.S. government and agency securities	—		—		945		(56)
Mortgage-backed securities	—		—		507		(35)
Other asset-backed securities	—		—		526		(11)
Auction rate securities	—		—		33		(3)
Total	$	222	$	(1)	$	5,004	$	(244)

The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the three months ended July 29, 2022 and July 30, 2021. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement.

Activity related to the Company’s available-for-sale debt securities portfolio is as follows:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Proceeds from sales	$	1,864	$	2,272
Gross realized gains	1		4
Gross realized losses	(9)		(2)

The July 29, 2022 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

(in millions)	July 29, 2022
Due in one year or less	$	1,378
Due after one year through five years	3,597
Due after five years through ten years	1,102
Due after ten years	690
Total	$	6,767

Equity Securities, Equity Method Investments, and Other Investments

The Company holds investments in equity securities with readily determinable fair values, equity investments without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments and investments without readily determinable fair values are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data.

The following table summarizes the Company's equity and other investments at July 29, 2022 and April 29, 2022, which are classified as other assets in the consolidated balance sheets:

(in millions)	July 29, 2022		April 29, 2022
Investments with readily determinable fair value (marketable equity securities)	$	26	$	64
Investments without readily determinable fair values	770		732
Equity method and other investments	84		85
Total equity and other investments	$	880	$	881

The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income.

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Proceeds from sales	$	21	$	52
Gross gains	15		58
Gross losses	(4)		(5)
Impairment losses recognized	(7)		(10)

During the three months ended July 29, 2022, there were $8 million of net unrealized gains on equity securities and other investments still held at July 29, 2022. During the three months ended July 30, 2021, there were $15 million of net unrealized gains on equity securities and other investments still held at July 30, 2021.

XML

Financing Arrangements

3 Months Ended

Jul. 29, 2022

Debt Disclosure [Abstract]

Financing Arrangements

Financing Arrangements

Commercial Paper

The Company maintains commercial paper programs that allow the Company to issue U.S. dollar or Euro-denominated unsecured commercial paper notes. The aggregate amount outstanding at any time under the commercial paper programs may not exceed the equivalent of $3.5 billion. No commercial paper was outstanding at July 29, 2022 and April 29, 2022. The issuance of commercial paper reduces the amount of credit available under the Company’s existing Credit Facility, as defined below.

Line of Credit

The Company has a $3.5 billion five-year unsecured revolving credit facility (Credit Facility), which provides back-up funding for the commercial paper programs described above. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At July 29, 2022 and April 29, 2022, no amounts were outstanding under the Credit Facility.

Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with the covenants under the Credit Facility.

Debt Obligations

The Company's debt obligations consisted of the following:

(in millions)	Maturity by Fiscal Year	July 29, 2022		April 29, 2022
Current debt obligations	2023 - 2024	$	5,729	$	3,742
Long-term debt
3.500 percent ten-year 2015 senior notes	2025	—		1,890
0.250 percent six-year 2019 senior notes	2026	1,012		1,064
0.000 percent five-year 2020 senior notes	2026	1,012		1,064
1.125 percent eight-year 2019 senior notes	2027	1,518		1,596
3.350 percent ten-year 2019 senior notes	2027	—		368
0.375 percent eight-year 2020 senior notes	2029	1,012		1,064
1.625 percent twelve-year 2019 senior notes	2031	1,012		1,064
1.000 percent twelve-year 2019 senior notes	2032	1,012		1,064
0.750 percent twelve-year 2020 senior notes	2033	1,012		1,064
4.375 percent twenty-year 2015 senior notes	2035	1,932		1,932
6.550 percent thirty-year 2007 CIFSA senior notes	2038	253		253
2.250 percent twenty-year 2019 senior notes	2039	1,012		1,064
6.500 percent thirty-year 2009 senior notes	2039	158		158
1.500 percent twenty-year 2019 senior notes	2040	1,012		1,064
5.550 percent thirty-year 2010 senior notes	2040	224		224
1.375 percent twenty-year 2020 senior notes	2041	1,012		1,064
4.500 percent thirty-year 2012 senior notes	2042	105		105
4.000 percent thirty-year 2013 senior notes	2043	305		305
4.625 percent thirty-year 2014 senior notes	2044	127		127
4.625 percent thirty-year 2015 senior notes	2045	1,813		1,813
1.750 percent thirty-year 2019 senior notes	2050	1,012		1,064
1.625 percent thirty-year 2020 senior notes	2051	1,012		1,064
Finance lease obligations	2023 - 2036	58		56
Deferred financing costs	2023 - 2051	(101)		(109)
Debt discount, net	2023 - 2051	(40)		(52)
Long-term debt		$	17,481	$	20,372

Senior Notes

The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.

Term Loan Agreements

On May 2, 2022, Medtronic Luxco entered into a term loan agreement (Fiscal 2023 Loan Agreement) by and among Medtronic Luxco, Medtronic plc, Medtronic, Inc., and Mizuho Bank, Ltd. as administrative agent and as lender. The Fiscal 2023 Loan Agreement provides an unsecured term loan in an aggregate principal amount of up to ¥300 billion with a term of 364 days. Borrowings under the Fiscal 2023 Loan Agreement bear interest at the TIBOR Rate (as defined in the Fiscal 2023 Loan Agreement) plus a margin of 0.40% per annum. Medtronic plc and Medtronic, Inc. have guaranteed the obligations of Medtronic Luxco under the Fiscal 2023 Loan Agreement. In May and June 2022, Medtronic Luxco borrowed an aggregate of ¥297 billion, or approximately $2.3 billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net proceeds of the borrowings to fund the early redemption of $1.9 billion of Medtronic Inc.'s 3.500% Senior Notes due 2025 for $1.9 billion of total consideration, and $368 million of Medtronic Luxco's 3.350% Senior Notes due 2027 for $376 million of total consideration. The Company recognized a total loss on debt extinguishment of $53 million in the quarter ended

July 29, 2022, which primarily includes cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss is recognized in interest expense in the consolidated statements of income.

Financial Instruments Not Measured at Fair Value

At July 29, 2022, the estimated fair value of the Company’s Senior Notes was $20.1 billion compared to a principal value of $21.1 billion. At April 29, 2022, the estimated fair value was $22.9 billion compared to a principal value of $24.2 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.

XML

Derivatives and Currency Exchange Risk Management

3 Months Ended

Jul. 29, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivatives and Currency Exchange Risk Management

Derivatives and Currency Exchange Risk Management

The Company uses operational and economic hedges, including currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. Currencies of our derivative instruments include the Euro, Japanese Yen, Chinese Yuan, and others. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding was $17.7 billion and $13.8 billion at July 29, 2022 and April 29, 2022, respectively.

The Company also uses derivative and non-derivative instruments to manage the impact of currency exchange rate changes on net investments in foreign currency-denominated operations. The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets and statements of income.

Freestanding Derivative Contracts

Freestanding derivative contracts are primarily used to offset the Company’s exposure to the change in value of specific foreign-currency-denominated assets and liabilities, and to offset variability of cash flows associated with forecasted transactions denominated in foreign currencies. The gross notional amount of the Company's freestanding currency exchange rate contracts outstanding at July 29, 2022 and April 29, 2022 was $5.1 billion and $4.9 billion, respectively. The Company's freestanding currency exchange rate contracts are not designated as hedges, and therefore, changes in the value of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related change in value of foreign-currency-denominated assets, liabilities, and cash flows.

The Company also uses total return swaps to hedge the liability of a non-qualified deferred compensation plan. The gross notional amount of the Company's total return swaps outstanding at July 29, 2022 and April 29, 2022 was $212 million and $226 million, respectively. The Company's total return swaps are not designated as hedges, and therefore, changes in the value of these instruments are recognized in earnings. The cash flows related to the Company's freestanding derivative contracts are reported as operating or financing activities, depending on the nature of the underlying hedged item, in the consolidated statements of cash flows.

Cash Flow Hedges

Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. The gross notional amount of these contracts, designated as cash flow hedges, outstanding at July 29, 2022 and April 29, 2022 was $8.1 billion and $8.8 billion, respectively, and will mature within the subsequent three-year period. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss. The gain or loss on the derivative instrument is reclassified into earnings and is included in other operating expense, net or cost of products sold in the consolidated statements of income in the same period or periods during which the hedged transaction affects earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings in the current period. The cash flows related to all of the Company's derivative instruments designated as cash flow hedges are reported as operating activities in the consolidated statements of cash flows.

At July 29, 2022 and April 29, 2022, the Company had $694 million and $474 million in after-tax net unrealized gains, respectively, associated with cash flow hedging instruments recorded in accumulated other comprehensive loss. The Company expects that $510 million of after-tax net unrealized gains at July 29, 2022 will be recognized in the consolidated statements of income over the next 12 months.

Net Investment Hedges

The Company has designated Euro-denominated and Yen-denominated debt as net investment hedges of certain of its European and Japanese operations to manage the exposure to currency and exchange rate movements for foreign currency-denominated net investments in foreign operations. At July 29, 2022, the Company had €16.0 billion, or $16.2 billion, of outstanding Euro-denominated debt designated as a hedge of its net investment in certain of its European operations, and ¥297 billion, or $2.2 billion, of outstanding Yen-denominated debt designated as a hedge of its net investment in certain of its Japanese operations. The Euro-denominated debt will mature in fiscal years 2023 through 2051, and the Yen-denominated debt will mature in fiscal year 2024.

The Company may also use derivative instruments to hedge the currency risk associated with its net investment in foreign operations. Foreign currency forward contracts may be used on a standalone basis or in combination with option collars. At July 29, 2022, the Company had foreign currency contracts with a notional value of €4.5 billion, or $4.6 billion, hedging a portion of its net investment in certain of its European operations. The foreign exchange contracts mature in fiscal years 2024 and 2025.

For instruments that are designated and qualify as net investment hedges, the gains or losses are reported as a component of accumulated other comprehensive loss. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in interest expense on a straight-line basis over the term of the hedge. During the three months ended July 29, 2022, the Company recognized $21 million in after-tax unrealized gains representing excluded components in interest expense. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows.

Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments

The amount of the gains and losses on our hedging instruments and the classification of those gains and losses within our consolidated financial statements for the three months ended July 29, 2022 and July 30, 2021 were as follows:

	(Gain) Loss Recognized in Accumulated Other Comprehensive Loss				(Gain) Loss Reclassified into Income
	Three months ended				Three months ended				Location of (Gain) Loss in Income Statement
(in millions)	July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021
Cash flow hedges
Currency exchange rate contracts	$	(342)	$	(164)	$	(137)	$	19	Other operating expense, net
Currency exchange rate contracts	(34)		4		18		11		Cost of products sold
Net investment hedges
Non-derivative instruments	(945)		(424)		—		—		N/A
Currency exchange rate contracts	(57)		—		—		—		N/A
Total	$	(1,378)	$	(584)	$	(120)	$	30

The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements during the three months ended July 29, 2022 and July 30, 2021 were as follows:

	(Gain) Loss Recognized in Income
	Three months ended				Location of (Gain) Loss in Income Statement
(in millions)	July 29, 2022		July 30, 2021
Derivatives not designated as hedging instruments
Currency exchange rate contracts	$	26	$	(17)	Other operating expense, net
Total return swaps	(1)		(13)		Other operating expense, net
Total	$	25	$	(30)

Balance Sheet Presentation

The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at July 29, 2022 and April 29, 2022. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.

	Fair Value - Assets					Fair Value - Liabilities
(in millions)	July 29, 2022		April 29, 2022		Balance Sheet Classification	July 29, 2022		April 29, 2022		Balance Sheet Classification
Derivatives designated as hedging instruments
Currency exchange rate contracts	$	621	$	481	Other current assets	$	24	$	43	Other accrued expenses
Currency exchange rate contracts	268		168		Other assets	8		16		Other liabilities
Total derivatives designated as hedging instruments	889		649			33		60
Derivatives not designated as hedging instruments
Currency exchange rate contracts	18		46		Other current assets	20		49		Other accrued expenses
Total return swaps	—		—		Other current assets	9		20		Other accrued expenses
Total derivatives not designated as hedging instruments	18		46			29		69
Total derivatives	$	907	$	695		$	61	$	129

The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis.

	July 29, 2022				April 29, 2022
(in millions)	Derivative assets		Derivative Liabilities		Derivative assets		Derivative Liabilities
Level 1	$	907	$	53	$	695	$	109
Level 2	—		9		—		20
Total	$	907	$	61	$	695	$	129

The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.

The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.

	July 29, 2022
			Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recognized Assets (Liabilities)		Financial Instruments		Cash Collateral (Received) Posted		Net Amount
Derivative assets:
Currency exchange rate contracts	$	907	$	(42)	$	(531)	$	335
Derivative liabilities:
Currency exchange rate contracts	(53)		42		—		(11)
Total return swaps	(9)		—		—		(9)
	(61)		42		—		(20)
Total	$	845	$	—	$	(531)	$	315

	April 29, 2022
			Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recognized Assets (Liabilities)		Financial Instruments		Cash Collateral (Received) Posted		Net Amount
Derivative assets:
Currency exchange rate contracts	$	695	$	(109)	$	(254)	$	332
Derivative liabilities:
Currency exchange rate contracts	(109)		109		—		—
Total return swaps	(20)		—		—		(20)
	(129)		109		—		(20)
Total	$	566	$	—	$	(254)	$	312

XML

Inventories

3 Months Ended

Jul. 29, 2022

Inventory Disclosure [Abstract]

Inventories

Inventories

Inventory balances, net of reserves, were as follows:

(in millions)	July 29, 2022		April 29, 2022
Finished goods	$	3,145	$	3,070
Work in-process	739		682
Raw materials	926		864
Total	$	4,809	$	4,616

XML

Goodwill and Other Intangible Assets

3 Months Ended

Jul. 29, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

Goodwill and Other Intangible Assets

Goodwill

The following table presents the changes in the carrying amount of goodwill by segment:

(in millions)	Cardiovascular		Medical Surgical		Neuroscience		Diabetes		Total
April 29, 2022	$	7,160	$	19,957	$	11,132	$	2,254	$	40,502
Goodwill as a result of acquisitions	66		—		615		—		680
Purchase accounting adjustments	(10)		—		—		—		(10)
Transfer to held for sale	—		(208)		—		—		(208)
Currency translation and other	(49)		(507)		(83)		(1)		(640)
July 29, 2022	$	7,166	$	19,242	$	11,664	$	2,253	$	40,324

As a result of the agreement with DaVita, as disclosed in Note 4 to the consolidated financial statements, the Company allocated $208 million of goodwill to the RCS business that met the criteria to be classified as held for sale. Upon allocation, a goodwill impairment test was performed for the RCS business, and the Company recognized $61 million of goodwill impairment during the three months ended July 29, 2022. The goodwill impairment charges are recognized in other operating expense, net in the consolidated statements of income. The Company did not recognize any goodwill impairments during the three months ended July 30, 2021.

Intangible Assets

The following table presents the gross carrying amount and accumulated amortization of intangible assets:

	July 29, 2022				April 29, 2022
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	16,927	$	(7,238)	$	16,953	$	(7,005)
Purchased technology and patents	11,311		(5,758)		10,802		(5,667)
Trademarks and tradenames	485		(268)		473		(266)
Other	97		(65)		80		(69)
Total	$	28,820	$	(13,328)	$	28,308	$	(13,006)
Indefinite-lived:
IPR&D	$	283	$	—	$	293	$	—

The Company did not recognize any definite-lived intangible asset charges during the three months ended July 29, 2022. During the three months ended July 30, 2021 the Company recognized $409 million of definite-lived intangible asset charges in connection with MCS within the Cardiovascular Portfolio. Refer to Note 5 to the consolidated financial statements for additional information on what led to the impairment. Intangible asset impairment charges are recognized in other operating expense, net in the consolidated statements of income.

The Company did not recognize any indefinite-lived intangible asset impairments during the three months ended July 29, 2022 and July 30, 2021. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future.

Amortization Expense

Intangible asset amortization expense for the three months ended July 29, 2022 and July 30, 2021 was $423 million and $436 million, respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at July 29, 2022, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:

(in millions)	Amortization Expense
Remaining 2023	$	1,261
2024	1,649
2025	1,627
2026	1,613
2027	1,589
2028	1,539

XML

Income Taxes

3 Months Ended

Jul. 29, 2022

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

The Company's effective tax rate for the three months ended July 29, 2022 was 10.7%, as compared to 7.7% for the three months ended July 30, 2021. The increase in our effective tax rate for the three months ended July 29, 2022, was primarily due to the tax impact of MCS charges in the three months ended July 30, 2021, partially offset by a $39 million charge in the three months ended July 30, 2021 related to a change in the Company's permanent reinvestment assertion on certain historical earnings. The increase was also partially offset by a $25 million benefit in the three months ended July 29, 2022 related to a valuation allowance release associated with certain carryover attributes due to the anticipated RCS transaction, as discussed in Note 4 to the consolidated financial statements.

At both July 29, 2022 and April 29, 2022, the Company's gross unrecognized tax benefits were $1.7 billion. In addition, the Company had accrued gross interest and penalties of $123 million at July 29, 2022. If all of the Company’s unrecognized tax benefits were recognized, approximately $1.6 billion would impact the Company’s effective tax rate. At July 29, 2022 and April 29, 2022, the amount of the Company's gross unrecognized tax benefits, net of cash advance, recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheets was $889 million and $802 million, respectively. The increase in the Company's gross unrecognized tax benefits, net of cash advance, was primarily due to the decrease in advance payments available to offset unrecognized tax benefits. The

Company recognizes interest and penalties related to income tax matters within income tax provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheets.

Subsequent to the quarter close on July 29, 2022, on August 18, 2022 the U.S. Tax Court (Tax Court) issued its opinion on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006 (Opinion). While the Opinion rejected the IRS’s position and the Tax Court determined the methodology advanced by Medtronic was appropriate for purposes of determining the intercompany royalty rate between Puerto Rico and the U.S., it determined that the royalty rate should be higher, thereby increasing income allocated to the U.S. and consequently subject to U.S. tax. This case relates only to fiscal years 2005 and 2006. The Opinion remains subject to finalization by the Tax Court and to appeal by either or both parties. At this time, the Company is evaluating the impact of the Opinion and whether the Company will appeal. If the Opinion is finalized as is, without appeal by either party, the Company anticipates the findings will likely be applied for all years following fiscal year 2006. Under this potential scenario, the Company has currently estimated a potential income tax charge, including interest, of up to $2.0 billion.

Refer to Note 16 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

XML

Earnings Per Share

3 Months Ended

Jul. 29, 2022

Earnings Per Share [Abstract]

Earnings Per Share

Earnings Per Share

Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.

The table below sets forth the computation of basic and diluted earnings per share:

	Three months ended
(in millions, except per share data)	July 29, 2022		July 30, 2021
Numerator:
Net income attributable to ordinary shareholders	$	929	$	763
Denominator:
Basic – weighted average shares outstanding	1,329.4		1,344.5
Effect of dilutive securities:
Employee stock options	2.7		8.5
Employee restricted stock units	1.3		2.3
Employee performance share units	1.1		1.0
Diluted – weighted average shares outstanding	1,334.5		1,356.4
Basic earnings per share	$	0.70	$	0.57
Diluted earnings per share	$	0.70	$	0.56

The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 14 million and 1 million ordinary shares for the three months ended July 29, 2022 and July 30, 2021, respectively, because their effect would have been anti-dilutive on the Company’s earnings per share.

XML

Stock-Based Compensation

3 Months Ended

Jul. 29, 2022

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

Stock-Based Compensation

The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, performance share units, and employee stock purchase plan shares recognized for the three months ended July 29, 2022 and July 30, 2021:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Stock options	$	12	$	10
Restricted stock	27		41
Performance share units	12		6
Employee stock purchase plan	11		11
Total stock-based compensation expense	$	62	$	69
Cost of products sold	$	6	$	7
Research and development expense	7		8
Selling, general, and administrative expense	49		55
Total stock-based compensation expense	62		69
Income tax benefits	(11)		(11)
Total stock-based compensation expense, net of tax	$	51	$	58

XML

Retirement Benefit Plans

3 Months Ended

Jul. 29, 2022

Retirement Benefits [Abstract]

Retirement Benefit Plans

Retirement Benefit Plans

The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three months ended July 29, 2022 and July 30, 2021:

	U.S.				Non-U.S.
	Three months ended				Three months ended
(in millions)	July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021
Service cost	$	19	$	25	$	12	$	16
Interest cost	36		26		10		7
Expected return on plan assets	(56)		(57)		(16)		(16)
Amortization of net actuarial loss	5		16		1		5
Net periodic benefit cost	$	4	$	10	$	7	$	12

Components of net periodic benefit cost other than the service component are recognized in other non-operating income, net in the consolidated statements of income.

XML

Accumulated Other Comprehensive Loss

3 Months Ended

Jul. 29, 2022

Equity [Abstract]

Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss

The following table provides changes in AOCI, net of tax, and by component:

(in millions)	Unrealized Gain (Loss) on Investment Securities		Cumulative Translation Adjustments		Net Investment Hedges		Net Change in Retirement Obligations		Unrealized Gain (Loss) on Cash Flow Hedges		Total Accumulated Other Comprehensive (Loss) Income
April 29, 2022	$	(209)	$	(2,599)	$	841	$	(773)	$	474	$	(2,265)
Other comprehensive income (loss) before reclassifications	(22)		(881)		1,002		3		312		414
Reclassifications	6		—		—		(2)		(91)		(87)
Other comprehensive income (loss)	(16)		(881)		1,002		1		220		326
July 29, 2022	$	(225)	$	(3,480)	$	1,843	$	(772)	$	694	$	(1,939)
(in millions)	Unrealized Gain (Loss) on Investment Securities		Cumulative Translation Adjustment		Net Investment Hedges		Net Change in Retirement Obligations		Unrealized Gain (Loss) on Cash Flow Hedges		Total Accumulated Other Comprehensive (Loss) Income
April 30, 2021	$	92	$	(519)	$	(1,458)	$	(1,347)	$	(253)	$	(3,485)
Other comprehensive income (loss) before reclassifications	14		(353)		424		1		144		230
Reclassifications	(2)		—		—		18		30		46
Other comprehensive income (loss)	12		(353)		424		19		174		276
July 30, 2021	$	104	$	(872)	$	(1,034)	$	(1,328)	$	(79)	$	(3,209)

The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during the three months ended July 29, 2022 and July 30, 2021 was a benefit of $9 million and an expense of $2 million, respectively. During the three months ended July 29, 2022, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $2 million. During the three months ended July 30, 2021, there was no income tax on realized gains and losses on investment securities reclassified from AOCI. When realized, gains and losses on investment securities reclassified from AOCI are recognized within other non-operating income, net. Refer to Note 6 to the consolidated financial statements for additional information.

For the three months ended July 29, 2022, the income tax on cumulative translation adjustment was a benefit of $3 million. During the three months ended July 30, 2021, there was no income tax on cumulative translation adjustment.

During the three months ended July 29, 2022 and July 30, 2021, there were no tax impacts on net investment hedges. Refer to Note 8 to the consolidated financial statements for additional information.

The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. During the three months ended July 29, 2022 and July 30, 2021, the net change in retirement obligations in other comprehensive income before reclassifications resulted in income tax expense of $1 million. During the three months ended July 29, 2022 and July 30, 2021, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of $6 million and $2 million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within other non-operating income, net. Refer to Note 14 to the consolidated financial statements for additional information.

The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during the three months ended July 29, 2022 and July 30, 2021 was an expense of $64 million and $16 million, respectively. During the three months ended July 29, 2022 and July 30, 2021, gains and losses on cash flow hedges reclassified from AOCI included income taxes of $22 million and were reduced by income taxes of $1 million, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within other operating expense, net or cost of products sold, and gains and losses on forward starting interest rate derivatives reclassified from AOCI are recognized within interest expense. Refer to Note 8 to the consolidated financial statements for additional information.

XML

Commitments and Contingencies

3 Months Ended

Jul. 29, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Legal Matters

The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental

proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.

The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income. The Company recognized no certain litigation charges during the three months ended July 29, 2022, whereas the Company recognized $26 million of certain litigation charges during the three months ended July 30, 2021. At July 29, 2022 and April 29, 2022, accrued litigation was approximately $0.3 billion. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.

Product Liability Matters

Pelvic Mesh Litigation

The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company $121 million towards the settlement of 11,000 of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional 5,000 claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 16,200 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of August 3, 2022, the Company had reached agreements to settle approximately 15,900 of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above.

Hernia Mesh Litigation

Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of August 10, 2022, subsidiaries of the Company have been named as defendants in lawsuits filed on behalf of approximately 6,050 individual plaintiffs, and certain plaintiffs’ law firms have advised the Company that they may file additional cases in the future. Approximately 5,600 plaintiffs have filed lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately 350 plaintiffs have filed lawsuits in a coordinated action in Minnesota state court, and there are approximately 90 actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.

Environmental Proceedings

The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.

The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. The Company has proceeded with remediation in accordance with the MDEP order as modified by the Maine Board order.

Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary.

Following a trial in March 2002, the court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. In March 2021, the parties notified the court that they had agreed on a settlement in principle of all issues in this matter. Finalization of the proposed settlement remains subject to court approval.

The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above.

Income Taxes

In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion. Oral argument for the Appeal occurred in March 2018. The Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings, which it concluded in June 2021. The Tax Court issued its opinion on August 18, 2022, and it remains subject to appeal by either or both parties. At this time, the Company is evaluating the impact of the opinion and whether the Company will appeal.

The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006.

Medtronic, Inc.’s fiscal years 2017, 2018, and 2019 U.S. federal income tax returns are currently being audited by the IRS.

Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2018.

Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.

Refer to Note 11 for additional discussion of income taxes.

Guarantees

In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.

The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, and/or cash flows.

XML

Segment and Geographic Information

3 Months Ended

Jul. 29, 2022

Segment Reporting [Abstract]

Segment and Geographic Information

Segment and Geographic Information

Segment disclosures are on a performance basis consistent with internal management reporting. Net sales of the Company's reportable segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. The Company’s management evaluates performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest expense, amortization of intangible assets, centralized distribution costs, non-operating income or expense items, certain corporate charges, and other items not allocated to the segments.

The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2022. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment.

There were no changes to the reportable segments during the quarter ended July 29, 2022. The Company's four principal operating and reportable segments are as follows: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.

The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements:

Segment Operating Profit

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Cardiovascular	$	956	$	1,161
Medical Surgical	642		914
Neuroscience	815		962
Diabetes	77		133
Segment operating profit	2,490		3,170
Interest expense	(164)		(137)
Other non-operating income, net	83		111
Amortization of intangible assets	(423)		(436)
Corporate	(414)		(449)
Centralized distribution costs	(311)		(464)
Restructuring and associated costs	(76)		(81)
Acquisition-related items	(35)		(19)
Certain litigation charges, net	—		(26)
RCS impairments / costs	(74)		—
MCS impairments / costs	—		(726)
IPR&D charges	—		(90)
Medical device regulations	(32)		(21)
Income before income taxes	$	1,044	$	833

Geographic Information

Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. The following table presents net sales for the three months ended July 29, 2022 and July 30, 2021 for the Company's country of domicile, countries with significant concentrations, and all other countries:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Ireland	$	23	$	26
United States	3,766		4,101
Rest of world	3,582		3,860
Total other countries, excluding Ireland	7,348		7,961
Total	$	7,371	$	7,987

XML

Basis of Presentation (Policies)

3 Months Ended

Jul. 29, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.

Consolidation

The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. Amounts reported in millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.

Fiscal Period

The Company’s fiscal years 2023, 2022, and 2021 will end or ended on April 28, 2023, April 29, 2022, and April 30, 2021, respectively. Fiscal year 2021 was a 53-week year.

Recently Adopted

Recently Adopted

For the three months ended July 29, 2022, there were no newly adopted accounting pronouncements that had a material impact to our consolidated financial statements. As of July 29, 2022, there are no recently issued but not yet adopted accounting pronouncements that are expected to materially impact our consolidated financial statements.

XML

Revenue (Tables)

3 Months Ended

Jul. 29, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The table below illustrates net sales by segment and division for the three months ended July 29, 2022 and July 30, 2021:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Cardiac Rhythm & Heart Failure	$	1,393	$	1,483
Structural Heart & Aortic	741		787
Coronary & Peripheral Vascular	579		620
Cardiovascular	2,713		2,890
Surgical Innovations	1,338		1,554
Respiratory, Gastrointestinal, & Renal	664		768
Medical Surgical	2,001		2,322
Cranial & Spinal Technologies	1,043		1,123
Specialty Therapies	667		641
Neuromodulation	405		440
Neuroscience	2,115		2,204
Diabetes	541		572
Total	$	7,371	$	7,987

The table below illustrates net sales by market geography for each segment for the three months ended July 29, 2022 and July 30, 2021:

	U.S.(1)				Non-U.S. Developed Markets(2)				Emerging Markets(3)
	Three months ended				Three months ended				Three months ended
(in millions)	July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021
Cardiovascular	$	1,298	$	1,420	$	892	$	1,003	$	523	$	467
Medical Surgical	843		990		767		869		392		463
Neuroscience	1,419		1,446		407		465		290		293
Diabetes	206		245		264		263		72		63
Total	$	3,766	$	4,101	$	2,328	$	2,601	$	1,276	$	1,286

(1)U.S. includes the United States and U.S. territories.

(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.

(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.

XML

Acquisitions and Assets and Liabilities Held for Sale (Tables)

3 Months Ended

Jul. 29, 2022

Business Combination and Asset Acquisition [Abstract]

Schedule of Fair Value of the Assets Acquired and Liabilities Assumed

The acquisition date fair values of the assets acquired and liabilities assumed were as follows:

(in millions)	Intersect ENT
Cash and cash equivalents	$	39
Inventory	32
Goodwill	615
Other intangible assets	683
Other assets	40
Total assets acquired	1,408
Current liabilities	63
Deferred tax liabilities	51
Other liabilities	18
Total liabilities assumed	131
Net assets acquired	$	1,277

Reconciliation of Beginning and Ending Balances of Contingent Consideration

The following table provides a reconciliation of the beginning and ending balances of contingent consideration:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Beginning balance	$	119	$	270
Purchase price contingent consideration	73		—
Purchase price allocation adjustments	—		25
Payments	—		(11)
Change in fair value	2		10
Ending balance	$	193	$	294

Fair Value Measurements, Contingent Consideration, Significant Unobservable Inputs

The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:

	Fair Value at
(in millions)	July 29, 2022	Unobservable Input	Range	Weighted Average (1)
Revenue and other performance-based payments	$143	Discount rate	11.2% - 27.2%	15.0%
		Projected fiscal year of payment	2023 - 2027	2025
Product development and other milestone-based payments	$50	Discount rate	5.5%	5.5%
		Projected fiscal year of payment	2023 - 2024	2023

(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.

Assets and Liabilities Classified as Held for Sale

The following table presents information related to the assets and liabilities that were classified as held for sale in our consolidated balance sheet:

(in millions)	July 29, 2022
Inventories, net	$	119
Property, plant, and equipment, net	141
Goodwill	147
Other intangible assets, net	114
Other	48
Total assets held for sale (1)	$	568
Total liabilities held for sale (1)(2)	$	38

(1) Total assets held for sale and total liabilities held for sale are reported in other current assets and other accrued expenses, respectively in the consolidated balance sheets.

(2) No separate class of liability classified as held for sale was individually significant enough for separate disclosure.

XML

Restructuring and Other Costs (Tables)

3 Months Ended

Jul. 29, 2022

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs

The following table summarizes the activity related to the restructuring programs above for the three months ended July 29, 2022:

(in millions)	Employee Termination Benefits		Associated Costs(1)		Other Costs		Total
April 29, 2022	$	81	$	27	$	1	$	110
Charges	23		61		1		85
Cash payments	(26)		(75)		(1)		(103)
Accrual adjustments(2)	(9)		—		—		(9)
July 29, 2022	$	69	$	13	$	1	$	83

(1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.

(2) Accrual adjustments relate to certain employees identified for termination finding other positions within the Company.

XML

Financial Instruments (Tables)

3 Months Ended

Jul. 29, 2022

Investments [Abstract]

Investments by Category and Related Balance Sheet Presentation

The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at July 29, 2022 and April 29, 2022:

    

	July 29, 2022
	Valuation								Balance Sheet Classification
(in millions)	Cost		Unrealized Gains		Unrealized Losses		Fair Value		Investments		Other Assets
Level 1:
U.S. government and agency securities	$	532	$	1	$	(13)	$	520	$	520	$	—
Level 2:
Corporate debt securities	4,339		4		(156)		4,186		4,186		—
U.S. government and agency securities	928		—		(37)		891		891		—
Mortgage-backed securities	573		—		(38)		535		535		—
Non-U.S. government and agency securities	17		—		—		17		17		—
Certificates of deposit	10		—		—		10		10		—
Other asset-backed securities	595		—		(22)		574		574		—
Total Level 2	6,462		4		(253)		6,213		6,213		—
Level 3:
Auction rate securities	36		—		(3)		33		—		33
Total available-for-sale debt securities	$	7,030	$	5	$	(269)	$	6,767	$	6,733	$	33

	April 29, 2022
	Valuation								Balance Sheet Classification
(in millions)	Cost		Unrealized Gains		Unrealized Losses		Fair Value		Investments		Other Assets
Level 1:
U.S. government and agency securities	$	533	$	1	$	(15)	$	518	$	518	$	—
Level 2:
Corporate debt securities	4,457		4		(140)		4,321		4,321		—
U.S. government and agency securities	910		—		(41)		869		869		—
Mortgage-backed securities	592		—		(35)		558		558		—
Non-U.S. government and agency securities	17		—		—		17		17		—
Certificates of deposit	20		—		—		20		20		—
Other asset-backed securities	567		—		(11)		556		556		—
Total Level 2	6,563		4		(227)		6,341		6,341		—
Level 3:
Auction rate securities	36		—		(3)		33		—		33
Total available-for-sale debt securities	$	7,131	$	5	$	(245)	$	6,893	$	6,859	$	33

Gross Unrealized Losses and Fair Values of Available-for-sale Securities that Have Been in a Continuous Unrealized Loss Position Deemed to be Temporary, Aggregated by Investment Category

The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at July 29, 2022 and April 29, 2022:

	July 29, 2022
	Less than 12 months				More than 12 months
(in millions)	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Corporate debt securities	$	243	$	(2)	$	3,044	$	(155)
U.S. government and agency securities	—		—		942		(50)
Mortgage-backed securities	—		—		521		(38)
Other asset-backed securities	—		—		532		(22)
Auction rate securities	—		—		33		(3)
Total	$	243	$	(2)	$	5,072	$	(267)

	April 29, 2022
	Less than 12 months				More than 12 months
(in millions)	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Corporate debt securities	$	222	$	(1)	$	2,993	$	(139)
U.S. government and agency securities	—		—		945		(56)
Mortgage-backed securities	—		—		507		(35)
Other asset-backed securities	—		—		526		(11)
Auction rate securities	—		—		33		(3)
Total	$	222	$	(1)	$	5,004	$	(244)

Activity Related to the Company's Available-for-Sale Securities Portfolio

Activity related to the Company’s available-for-sale debt securities portfolio is as follows:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Proceeds from sales	$	1,864	$	2,272
Gross realized gains	1		4
Gross realized losses	(9)		(2)

Available-For-Sale Debt Securities, Contractual Maturities

The July 29, 2022 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

(in millions)	July 29, 2022
Due in one year or less	$	1,378
Due after one year through five years	3,597
Due after five years through ten years	1,102
Due after ten years	690
Total	$	6,767

Summary of Equity and Other Investments

The following table summarizes the Company's equity and other investments at July 29, 2022 and April 29, 2022, which are classified as other assets in the consolidated balance sheets:

(in millions)	July 29, 2022		April 29, 2022
Investments with readily determinable fair value (marketable equity securities)	$	26	$	64
Investments without readily determinable fair values	770		732
Equity method and other investments	84		85
Total equity and other investments	$	880	$	881

Activity Related to the Company's Equity and Other Investments Portfolio

The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income.

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Proceeds from sales	$	21	$	52
Gross gains	15		58
Gross losses	(4)		(5)
Impairment losses recognized	(7)		(10)

XML

Financing Arrangements (Tables)

3 Months Ended

Jul. 29, 2022

Debt Disclosure [Abstract]

Long-term Debt

The Company's debt obligations consisted of the following:

(in millions)	Maturity by Fiscal Year	July 29, 2022		April 29, 2022
Current debt obligations	2023 - 2024	$	5,729	$	3,742
Long-term debt
3.500 percent ten-year 2015 senior notes	2025	—		1,890
0.250 percent six-year 2019 senior notes	2026	1,012		1,064
0.000 percent five-year 2020 senior notes	2026	1,012		1,064
1.125 percent eight-year 2019 senior notes	2027	1,518		1,596
3.350 percent ten-year 2019 senior notes	2027	—		368
0.375 percent eight-year 2020 senior notes	2029	1,012		1,064
1.625 percent twelve-year 2019 senior notes	2031	1,012		1,064
1.000 percent twelve-year 2019 senior notes	2032	1,012		1,064
0.750 percent twelve-year 2020 senior notes	2033	1,012		1,064
4.375 percent twenty-year 2015 senior notes	2035	1,932		1,932
6.550 percent thirty-year 2007 CIFSA senior notes	2038	253		253
2.250 percent twenty-year 2019 senior notes	2039	1,012		1,064
6.500 percent thirty-year 2009 senior notes	2039	158		158
1.500 percent twenty-year 2019 senior notes	2040	1,012		1,064
5.550 percent thirty-year 2010 senior notes	2040	224		224
1.375 percent twenty-year 2020 senior notes	2041	1,012		1,064
4.500 percent thirty-year 2012 senior notes	2042	105		105
4.000 percent thirty-year 2013 senior notes	2043	305		305
4.625 percent thirty-year 2014 senior notes	2044	127		127
4.625 percent thirty-year 2015 senior notes	2045	1,813		1,813
1.750 percent thirty-year 2019 senior notes	2050	1,012		1,064
1.625 percent thirty-year 2020 senior notes	2051	1,012		1,064
Finance lease obligations	2023 - 2036	58		56
Deferred financing costs	2023 - 2051	(101)		(109)
Debt discount, net	2023 - 2051	(40)		(52)
Long-term debt		$	17,481	$	20,372

XML

Derivatives and Currency Exchange Risk Management (Tables)

3 Months Ended

Jul. 29, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Gains and Losses on Derivative Instruments

The amount of the gains and losses on our hedging instruments and the classification of those gains and losses within our consolidated financial statements for the three months ended July 29, 2022 and July 30, 2021 were as follows:

	(Gain) Loss Recognized in Accumulated Other Comprehensive Loss				(Gain) Loss Reclassified into Income
	Three months ended				Three months ended				Location of (Gain) Loss in Income Statement
(in millions)	July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021
Cash flow hedges
Currency exchange rate contracts	$	(342)	$	(164)	$	(137)	$	19	Other operating expense, net
Currency exchange rate contracts	(34)		4		18		11		Cost of products sold
Net investment hedges
Non-derivative instruments	(945)		(424)		—		—		N/A
Currency exchange rate contracts	(57)		—		—		—		N/A
Total	$	(1,378)	$	(584)	$	(120)	$	30

The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements during the three months ended July 29, 2022 and July 30, 2021 were as follows:

	(Gain) Loss Recognized in Income
	Three months ended				Location of (Gain) Loss in Income Statement
(in millions)	July 29, 2022		July 30, 2021
Derivatives not designated as hedging instruments
Currency exchange rate contracts	$	26	$	(17)	Other operating expense, net
Total return swaps	(1)		(13)		Other operating expense, net
Total	$	25	$	(30)

Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets

The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at July 29, 2022 and April 29, 2022. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.

	Fair Value - Assets					Fair Value - Liabilities
(in millions)	July 29, 2022		April 29, 2022		Balance Sheet Classification	July 29, 2022		April 29, 2022		Balance Sheet Classification
Derivatives designated as hedging instruments
Currency exchange rate contracts	$	621	$	481	Other current assets	$	24	$	43	Other accrued expenses
Currency exchange rate contracts	268		168		Other assets	8		16		Other liabilities
Total derivatives designated as hedging instruments	889		649			33		60
Derivatives not designated as hedging instruments
Currency exchange rate contracts	18		46		Other current assets	20		49		Other accrued expenses
Total return swaps	—		—		Other current assets	9		20		Other accrued expenses
Total derivatives not designated as hedging instruments	18		46			29		69
Total derivatives	$	907	$	695		$	61	$	129

Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis.

	July 29, 2022				April 29, 2022
(in millions)	Derivative assets		Derivative Liabilities		Derivative assets		Derivative Liabilities
Level 1	$	907	$	53	$	695	$	109
Level 2	—		9		—		20
Total	$	907	$	61	$	695	$	129

Offsetting Assets

The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.

	July 29, 2022
			Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recognized Assets (Liabilities)		Financial Instruments		Cash Collateral (Received) Posted		Net Amount
Derivative assets:
Currency exchange rate contracts	$	907	$	(42)	$	(531)	$	335
Derivative liabilities:
Currency exchange rate contracts	(53)		42		—		(11)
Total return swaps	(9)		—		—		(9)
	(61)		42		—		(20)
Total	$	845	$	—	$	(531)	$	315

	April 29, 2022
			Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recognized Assets (Liabilities)		Financial Instruments		Cash Collateral (Received) Posted		Net Amount
Derivative assets:
Currency exchange rate contracts	$	695	$	(109)	$	(254)	$	332
Derivative liabilities:
Currency exchange rate contracts	(109)		109		—		—
Total return swaps	(20)		—		—		(20)
	(129)		109		—		(20)
Total	$	566	$	—	$	(254)	$	312

Offsetting Liabilities

The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.

	July 29, 2022
			Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recognized Assets (Liabilities)		Financial Instruments		Cash Collateral (Received) Posted		Net Amount
Derivative assets:
Currency exchange rate contracts	$	907	$	(42)	$	(531)	$	335
Derivative liabilities:
Currency exchange rate contracts	(53)		42		—		(11)
Total return swaps	(9)		—		—		(9)
	(61)		42		—		(20)
Total	$	845	$	—	$	(531)	$	315

	April 29, 2022
			Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recognized Assets (Liabilities)		Financial Instruments		Cash Collateral (Received) Posted		Net Amount
Derivative assets:
Currency exchange rate contracts	$	695	$	(109)	$	(254)	$	332
Derivative liabilities:
Currency exchange rate contracts	(109)		109		—		—
Total return swaps	(20)		—		—		(20)
	(129)		109		—		(20)
Total	$	566	$	—	$	(254)	$	312

XML

Inventories (Tables)

3 Months Ended

Jul. 29, 2022

Inventory Disclosure [Abstract]

Inventory Balances

Inventory balances, net of reserves, were as follows:

(in millions)	July 29, 2022		April 29, 2022
Finished goods	$	3,145	$	3,070
Work in-process	739		682
Raw materials	926		864
Total	$	4,809	$	4,616

XML

Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Jul. 29, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in the Carrying Amount of Goodwill

The following table presents the changes in the carrying amount of goodwill by segment:

(in millions)	Cardiovascular		Medical Surgical		Neuroscience		Diabetes		Total
April 29, 2022	$	7,160	$	19,957	$	11,132	$	2,254	$	40,502
Goodwill as a result of acquisitions	66		—		615		—		680
Purchase accounting adjustments	(10)		—		—		—		(10)
Transfer to held for sale	—		(208)		—		—		(208)
Currency translation and other	(49)		(507)		(83)		(1)		(640)
July 29, 2022	$	7,166	$	19,242	$	11,664	$	2,253	$	40,324

Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets

The following table presents the gross carrying amount and accumulated amortization of intangible assets:

	July 29, 2022				April 29, 2022
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	16,927	$	(7,238)	$	16,953	$	(7,005)
Purchased technology and patents	11,311		(5,758)		10,802		(5,667)
Trademarks and tradenames	485		(268)		473		(266)
Other	97		(65)		80		(69)
Total	$	28,820	$	(13,328)	$	28,308	$	(13,006)
Indefinite-lived:
IPR&D	$	283	$	—	$	293	$	—

Gross Carrying Amount of Indefinite-Lived Intangible Assets

The following table presents the gross carrying amount and accumulated amortization of intangible assets:

	July 29, 2022				April 29, 2022
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	16,927	$	(7,238)	$	16,953	$	(7,005)
Purchased technology and patents	11,311		(5,758)		10,802		(5,667)
Trademarks and tradenames	485		(268)		473		(266)
Other	97		(65)		80		(69)
Total	$	28,820	$	(13,328)	$	28,308	$	(13,006)
Indefinite-lived:
IPR&D	$	283	$	—	$	293	$	—

Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets

Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at July 29, 2022, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:

(in millions)	Amortization Expense
Remaining 2023	$	1,261
2024	1,649
2025	1,627
2026	1,613
2027	1,589
2028	1,539

XML

Earnings Per Share (Tables)

3 Months Ended

Jul. 29, 2022

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The table below sets forth the computation of basic and diluted earnings per share:

	Three months ended
(in millions, except per share data)	July 29, 2022		July 30, 2021
Numerator:
Net income attributable to ordinary shareholders	$	929	$	763
Denominator:
Basic – weighted average shares outstanding	1,329.4		1,344.5
Effect of dilutive securities:
Employee stock options	2.7		8.5
Employee restricted stock units	1.3		2.3
Employee performance share units	1.1		1.0
Diluted – weighted average shares outstanding	1,334.5		1,356.4
Basic earnings per share	$	0.70	$	0.57
Diluted earnings per share	$	0.70	$	0.56

XML

Stock-Based Compensation (Tables)

3 Months Ended

Jul. 29, 2022

Share-Based Payment Arrangement [Abstract]

Components and Classification of Stock-based Compensation Expense

The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, performance share units, and employee stock purchase plan shares recognized for the three months ended July 29, 2022 and July 30, 2021:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Stock options	$	12	$	10
Restricted stock	27		41
Performance share units	12		6
Employee stock purchase plan	11		11
Total stock-based compensation expense	$	62	$	69
Cost of products sold	$	6	$	7
Research and development expense	7		8
Selling, general, and administrative expense	49		55
Total stock-based compensation expense	62		69
Income tax benefits	(11)		(11)
Total stock-based compensation expense, net of tax	$	51	$	58

XML

Retirement Benefit Plans (Tables)

3 Months Ended

Jul. 29, 2022

Retirement Benefits [Abstract]

Components of Net Periodic Benefit Cost

The net periodic benefit cost of the defined benefit pension plans included the following components for the three months ended July 29, 2022 and July 30, 2021:

	U.S.				Non-U.S.
	Three months ended				Three months ended
(in millions)	July 29, 2022		July 30, 2021		July 29, 2022		July 30, 2021
Service cost	$	19	$	25	$	12	$	16
Interest cost	36		26		10		7
Expected return on plan assets	(56)		(57)		(16)		(16)
Amortization of net actuarial loss	5		16		1		5
Net periodic benefit cost	$	4	$	10	$	7	$	12

XML

Accumulated Other Comprehensive Loss (Tables)

3 Months Ended

Jul. 29, 2022

Equity [Abstract]

Changes in AOCI by Component

The following table provides changes in AOCI, net of tax, and by component:

(in millions)	Unrealized Gain (Loss) on Investment Securities		Cumulative Translation Adjustments		Net Investment Hedges		Net Change in Retirement Obligations		Unrealized Gain (Loss) on Cash Flow Hedges		Total Accumulated Other Comprehensive (Loss) Income
April 29, 2022	$	(209)	$	(2,599)	$	841	$	(773)	$	474	$	(2,265)
Other comprehensive income (loss) before reclassifications	(22)		(881)		1,002		3		312		414
Reclassifications	6		—		—		(2)		(91)		(87)
Other comprehensive income (loss)	(16)		(881)		1,002		1		220		326
July 29, 2022	$	(225)	$	(3,480)	$	1,843	$	(772)	$	694	$	(1,939)
(in millions)	Unrealized Gain (Loss) on Investment Securities		Cumulative Translation Adjustment		Net Investment Hedges		Net Change in Retirement Obligations		Unrealized Gain (Loss) on Cash Flow Hedges		Total Accumulated Other Comprehensive (Loss) Income
April 30, 2021	$	92	$	(519)	$	(1,458)	$	(1,347)	$	(253)	$	(3,485)
Other comprehensive income (loss) before reclassifications	14		(353)		424		1		144		230
Reclassifications	(2)		—		—		18		30		46
Other comprehensive income (loss)	12		(353)		424		19		174		276
July 30, 2021	$	104	$	(872)	$	(1,034)	$	(1,328)	$	(79)	$	(3,209)

XML

Segment and Geographic Information (Tables)

3 Months Ended

Jul. 29, 2022

Segment Reporting [Abstract]

Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated

The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements:

Segment Operating Profit

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Cardiovascular	$	956	$	1,161
Medical Surgical	642		914
Neuroscience	815		962
Diabetes	77		133
Segment operating profit	2,490		3,170
Interest expense	(164)		(137)
Other non-operating income, net	83		111
Amortization of intangible assets	(423)		(436)
Corporate	(414)		(449)
Centralized distribution costs	(311)		(464)
Restructuring and associated costs	(76)		(81)
Acquisition-related items	(35)		(19)
Certain litigation charges, net	—		(26)
RCS impairments / costs	(74)		—
MCS impairments / costs	—		(726)
IPR&D charges	—		(90)
Medical device regulations	(32)		(21)
Income before income taxes	$	1,044	$	833

Net Sales to External Customers by Geography

The following table presents net sales for the three months ended July 29, 2022 and July 30, 2021 for the Company's country of domicile, countries with significant concentrations, and all other countries:

	Three months ended
(in millions)	July 29, 2022		July 30, 2021
Ireland	$	23	$	26
United States	3,766		4,101
Rest of world	3,582		3,860
Total other countries, excluding Ireland	7,348		7,961
Total	$	7,371	$	7,987

XML

Revenue - Disaggregation of Net Sales by Segment and Division (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 7,371	$ 7,987
Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	2,713	2,890
Cardiovascular | Cardiac Rhythm & Heart Failure
Disaggregation of Revenue [Line Items]
Net sales	1,393	1,483
Cardiovascular | Structural Heart & Aortic
Disaggregation of Revenue [Line Items]
Net sales	741	787
Cardiovascular | Coronary & Peripheral Vascular
Disaggregation of Revenue [Line Items]
Net sales	579	620
Medical Surgical
Disaggregation of Revenue [Line Items]
Net sales	2,001	2,322
Medical Surgical | Surgical Innovations
Disaggregation of Revenue [Line Items]
Net sales	1,338	1,554
Medical Surgical | Respiratory, Gastrointestinal, & Renal
Disaggregation of Revenue [Line Items]
Net sales	664	768
Neuroscience
Disaggregation of Revenue [Line Items]
Net sales	2,115	2,204
Neuroscience | Cranial & Spinal Technologies
Disaggregation of Revenue [Line Items]
Net sales	1,043	1,123
Neuroscience | Specialty Therapies
Disaggregation of Revenue [Line Items]
Net sales	667	641
Neuroscience | Neuromodulation
Disaggregation of Revenue [Line Items]
Net sales	405	440
Diabetes
Disaggregation of Revenue [Line Items]
Net sales	$ 541	$ 572

XML

Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 7,371	$ 7,987
U.S.
Disaggregation of Revenue [Line Items]
Net sales	3,766	4,101
Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	2,328	2,601
Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	1,276	1,286
Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	2,713	2,890
Cardiovascular | U.S.
Disaggregation of Revenue [Line Items]
Net sales	1,298	1,420
Cardiovascular | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	892	1,003
Cardiovascular | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	523	467
Medical Surgical
Disaggregation of Revenue [Line Items]
Net sales	2,001	2,322
Medical Surgical | U.S.
Disaggregation of Revenue [Line Items]
Net sales	843	990
Medical Surgical | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	767	869
Medical Surgical | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	392	463
Neuroscience
Disaggregation of Revenue [Line Items]
Net sales	2,115	2,204
Neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Net sales	1,419	1,446
Neuroscience | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	407	465
Neuroscience | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	290	293
Diabetes
Disaggregation of Revenue [Line Items]
Net sales	541	572
Diabetes | U.S.
Disaggregation of Revenue [Line Items]
Net sales	206	245
Diabetes | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	264	263
Diabetes | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	$ 72	$ 63

XML

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Apr. 29, 2022
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 391	$ 399
Revenue recognized that was previously included in deferred revenue	87
Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations	$ 801
Period over which remaining performance obligations are expected to be recognized as revenue	three years
Other accrued expenses
Disaggregation of Revenue [Line Items]
Rebate obligations	$ 955	981
Deferred revenue	302	305
Reduction of accounts receivable
Disaggregation of Revenue [Line Items]
Rebate obligations	576	548
Other liabilities
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 90	$ 94

XML

Acquisitions and Assets and Liabilities Held for Sale - Narrative (Details) - USD ($)			3 Months Ended
	Aug. 30, 2022	May 13, 2022	Jul. 29, 2022	Jul. 30, 2021	Apr. 29, 2022	Apr. 30, 2021
Business Acquisition [Line Items]
Goodwill			$ 40,324,000,000		$ 40,502,000,000
Purchase price contingent consideration			73,000,000	$ 0
Contingent consideration, fair value			193,000,000	294,000,000	119,000,000	$ 270,000,000
Goodwill impairment				0
Other operating expense, net
Business Acquisition [Line Items]
Goodwill impairment			67,000,000
IPR&D
Business Acquisition [Line Items]
Asset acquisition				$ 90,000,000
Other accrued expenses
Business Acquisition [Line Items]
Contingent consideration, fair value			64,000,000		35,000,000
Other liabilities
Business Acquisition [Line Items]
Contingent consideration, fair value			129,000,000		$ 84,000,000
Intersect ENT
Business Acquisition [Line Items]
Shares price (in dollars per share)		$ 28.25
Total consideration for the transaction, net of cash acquired		$ 1,200,000,000
Cash consideration		1,100,000,000
Previously held investments in Intersect ENT		98,000,000
Goodwill		615,000,000
Net assets acquired		$ 1,277,000,000
Estimated useful life (in years)		20 years
Intersect ENT | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired		$ 635,000,000
Intersect ENT | Customer-related
Business Acquisition [Line Items]
Intangible assets acquired		35,000,000
Intersect ENT | Tradenames
Business Acquisition [Line Items]
Intangible assets acquired		$ 13,000,000
Other acquisitions
Business Acquisition [Line Items]
Goodwill			66,000,000
Net assets acquired			123,000,000
Purchase price contingent consideration			73,000,000
Other acquisitions | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired			$ 57,000,000
Estimated useful life (in years)			16 years
Affera Inc | Subsequent event
Business Acquisition [Line Items]
Total consideration for the transaction, net of cash acquired	$ 1,000,000,000
Contingent consideration, fair value	$ 250,000,000

XML

Acquisitions and Assets and Liabilities Held for Sale - Schedule of Fair Value of the Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Jul. 29, 2022	May 13, 2022	Apr. 29, 2022
Business Acquisition [Line Items]
Goodwill	$ 40,324		$ 40,502
Intersect ENT
Business Acquisition [Line Items]
Cash and cash equivalents		$ 39
Inventory		32
Goodwill		615
Other intangible assets		683
Other assets		40
Total assets acquired		1,408
Current liabilities		63
Deferred tax liabilities		51
Other liabilities		18
Total liabilities assumed		131
Net assets acquired		$ 1,277

XML

Acquisitions and Assets and Liabilities Held for Sale - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments [Roll Forward]
Beginning balance	$ 119	$ 270
Purchase price contingent consideration	73	0
Purchase price allocation adjustments	0	25
Payments	0	(11)
Change in fair value	2	10
Ending balance	$ 193	$ 294

XML

Acquisitions and Assets and Liabilities Held for Sale - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details) $ in Millions	Jul. 29, 2022 USD ($)	Apr. 29, 2022 USD ($)	Jul. 30, 2021 USD ($)	Apr. 30, 2021 USD ($)
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 193	$ 119	$ 294	$ 270
Revenue and other performance-based payments | Recurring | Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 143
Revenue and other performance-based payments | Minimum | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.112
Revenue and other performance-based payments | Maximum | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.272
Revenue and other performance-based payments | Weighted Average | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.150
Product development and other milestone-based payments | Recurring | Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 50
Product development and other milestone-based payments | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.055
Product development and other milestone-based payments | Weighted Average | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.055

XML

Acquisitions and Assets and Liabilities Held for Sale- Assets And Liabilities Classified As Held For Sale (Details) - Held For Sale - Disposal group, held-for-sale, not discontinued operations $ in Millions	Jul. 29, 2022 USD ($)
Business Acquisition [Line Items]
Inventory	$ 119
Property, plant, and equipment, net	141
Goodwill	147
Other intangible assets	114
Other assets	48
Total assets acquired	568
Total liabilities assumed	$ 38

XML

Restructuring and Other Costs - Narrative (Details)	3 Months Ended
	Jul. 29, 2022 USD ($)	Jul. 30, 2021 USD ($)	Jun. 03, 2021 patient
Restructuring Cost and Reserve [Line Items]
Restructuring charges, net	$ 14,000,000	$ 11,000,000
Restructuring charges	85,000,000
MCS asset impairment and inventory write-down	0	515,000,000
Definite-lived intangible asset charges	0	409,000,000
Enterprise Excellence
Restructuring Cost and Reserve [Line Items]
Restructuring charges, net	40,000,000	74,000,000
Enterprise Excellence | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	19,000,000	33,000,000
Enterprise Excellence | Selling, general, and administrative expense
Restructuring Cost and Reserve [Line Items]
Restructuring charges	28,000,000	30,000,000
Enterprise Excellence | Pre-tax exit and disposal costs and other
Restructuring Cost and Reserve [Line Items]
Cost incurred to date	1,600,000,000
Expected cost	1,800,000,000
Simplification
Restructuring Cost and Reserve [Line Items]
Restructuring charges, net	36,000,000	7,000,000
Simplification | Selling, general, and administrative expense
Restructuring Cost and Reserve [Line Items]
Restructuring charges, net	13,000,000
Simplification | Pre-tax exit and disposal costs and other
Restructuring Cost and Reserve [Line Items]
Cost incurred to date	385,000,000
Expected cost	450,000,000
Mechanical Circulatory Support | Cardiovascular
Restructuring Cost and Reserve [Line Items]
Restructuring write down and impairment provisions		726,000,000
MCS asset impairment and inventory write-down		515,000,000
Definite-lived intangible asset charges		409,000,000
Inventory write-down		58,000,000
Other restructuring costs		211,000,000
Restructuring reserve, current	81,000,000
Restructuring reserve, noncurrent	136,000,000
Number of mechanical circulatory support patients (in patients) | patient			3,200
Mechanical Circulatory Support | Cost of products sold | Cardiovascular
Restructuring Cost and Reserve [Line Items]
Restructuring write down and impairment provisions		58,000,000
Mechanical Circulatory Support | Other operating expense, net | Cardiovascular
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 155,000,000
Restructuring write down and impairment provisions		$ 668,000,000

XML

Restructuring and Other Costs - Activity Related to Restructuring Programs (Details) $ in Millions	3 Months Ended
	Jul. 29, 2022 USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 110
Restructuring charges	85
Payments for Restructuring	(103)
Accrual adjustments	(9)
Ending balance	83
Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Beginning balance	81
Restructuring charges	23
Payments for Restructuring	(26)
Accrual adjustments	(9)
Ending balance	69
Associated Costs
Restructuring Reserve [Roll Forward]
Beginning balance	27
Restructuring charges	61
Payments for Restructuring	(75)
Accrual adjustments	0
Ending balance	13
Other Costs
Restructuring Reserve [Roll Forward]
Beginning balance	1
Restructuring charges	1
Payments for Restructuring	(1)
Accrual adjustments	0
Ending balance	$ 1

XML

Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details) - USD ($) $ in Millions	Jul. 29, 2022	Apr. 29, 2022
Schedule of Investments [Line Items]
Cost	$ 7,030	$ 7,131
Unrealized Gains	5	5
Unrealized Losses	(269)	(245)
Fair Value	6,767	6,893
Investments
Schedule of Investments [Line Items]
Fair Value	6,733	6,859
Other Assets
Schedule of Investments [Line Items]
Fair Value	33	33
Level 2
Schedule of Investments [Line Items]
Cost	6,462	6,563
Unrealized Gains	4	4
Unrealized Losses	(253)	(227)
Fair Value	6,213	6,341
Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	6,213	6,341
Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
U.S. government and agency securities | Level 1
Schedule of Investments [Line Items]
Cost	532	533
Unrealized Gains	1	1
Unrealized Losses	(13)	(15)
Fair Value	520	518
U.S. government and agency securities | Level 1 | Investments
Schedule of Investments [Line Items]
Fair Value	520	518
U.S. government and agency securities | Level 1 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
U.S. government and agency securities | Level 2
Schedule of Investments [Line Items]
Cost	928	910
Unrealized Gains	0	0
Unrealized Losses	(37)	(41)
Fair Value	891	869
U.S. government and agency securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	891	869
U.S. government and agency securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Corporate debt securities | Level 2
Schedule of Investments [Line Items]
Cost	4,339	4,457
Unrealized Gains	4	4
Unrealized Losses	(156)	(140)
Fair Value	4,186	4,321
Corporate debt securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	4,186	4,321
Corporate debt securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Mortgage-backed securities | Level 2
Schedule of Investments [Line Items]
Cost	573	592
Unrealized Gains	0	0
Unrealized Losses	(38)	(35)
Fair Value	535	558
Mortgage-backed securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	535	558
Mortgage-backed securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Non-U.S. government and agency securities | Level 2
Schedule of Investments [Line Items]
Cost	17	17
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	17	17
Non-U.S. government and agency securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	17	17
Non-U.S. government and agency securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Certificates of deposit | Level 2
Schedule of Investments [Line Items]
Cost	10	20
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	10	20
Certificates of deposit | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	10	20
Certificates of deposit | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Other asset-backed securities | Level 2
Schedule of Investments [Line Items]
Cost	595	567
Unrealized Gains	0	0
Unrealized Losses	(22)	(11)
Fair Value	574	556
Other asset-backed securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	574	556
Other asset-backed securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Auction rate securities | Level 3
Schedule of Investments [Line Items]
Cost	36	36
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	33	33
Auction rate securities | Level 3 | Investments
Schedule of Investments [Line Items]
Fair Value	0	0
Auction rate securities | Level 3 | Other Assets
Schedule of Investments [Line Items]
Fair Value	$ 33	$ 33

XML

Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details) - USD ($) $ in Millions	Jul. 29, 2022	Apr. 29, 2022
Fair Value
Less than 12 months	$ 243	$ 222
More than 12 months	5,072	5,004
Unrealized Losses
Less than 12 months	(2)	(1)
More than 12 months	(267)	(244)
Corporate debt securities
Fair Value
Less than 12 months	243	222
More than 12 months	3,044	2,993
Unrealized Losses
Less than 12 months	(2)	(1)
More than 12 months	(155)	(139)
U.S. government and agency securities
Fair Value
Less than 12 months	0	0
More than 12 months	942	945
Unrealized Losses
Less than 12 months	0	0
More than 12 months	(50)	(56)
Mortgage-backed securities
Fair Value
Less than 12 months	0	0
More than 12 months	521	507
Unrealized Losses
Less than 12 months	0	0
More than 12 months	(38)	(35)
Other asset-backed securities
Fair Value
Less than 12 months	0	0
More than 12 months	532	526
Unrealized Losses
Less than 12 months	0	0
More than 12 months	(22)	(11)
Auction rate securities
Fair Value
Less than 12 months	0	0
More than 12 months	33	33
Unrealized Losses
Less than 12 months	0	0
More than 12 months	$ (3)	$ (3)

XML

Financial Instruments - Activity Related to the Company's Investment Portfolio and Debt Securities Contractual Maturities (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021	Apr. 29, 2022
Activities Related to Debt Securities Portfolio
Proceeds from sales	$ 1,864	$ 2,272
Gross realized gains	1	4
Gross realized losses	(9)	$ (2)
Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]
Due in one year or less	1,378
Due after one year through five years	3,597
Due after five years through ten years	1,102
Due after ten years	690
Total	$ 6,767		$ 6,893

XML

Financial Instruments - Summary of Equity and Other Investments (Details) - Other Assets - USD ($) $ in Millions	Jul. 29, 2022	Apr. 29, 2022
Schedule of Equity Method Investments [Line Items]
Investments with readily determinable fair value (marketable equity securities)	$ 26	$ 64
Investments without readily determinable fair values	770	732
Equity method and other investments	84	85
Total equity and other investments	$ 880	$ 881

XML

Financial Instruments - Activity Related to the Company's Investment Portfolio, Equity and Other Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Marketable Securities [Line Items]
Proceeds from sales	$ 1,886	$ 2,324
Equity and Other Investments
Marketable Securities [Line Items]
Proceeds from sales	21	52
Gross gains	15	58
Gross losses	(4)	(5)
Impairment losses recognized	$ (7)	$ (10)

XML

Financial Instruments - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Equity Securities and Other Investments
Gain (Loss) on Securities [Line Items]
Net unrealized gains (losses) on equity and other investments still held	$ 8	$ 15

XML

Financing Arrangements - Narrative (Details) ¥ in Billions			3 Months Ended
	May 02, 2022 USD ($)	May 02, 2022 JPY (¥)	Jul. 29, 2022 USD ($)	Jul. 30, 2021 USD ($)	May 02, 2022 JPY (¥)	Apr. 29, 2022 USD ($)
Debt Instrument [Line Items]
Amount of current debt obligations outstanding			$ 5,729,000,000			$ 3,742,000,000
Principal value			21,100,000,000			24,200,000,000
Proceeds from short-term debt			2,284,000,000	$ 0
Loss on debt extinguishment			53,000,000	$ 0
Total debt, fair value			20,100,000,000			22,900,000,000
Commercial Paper
Debt Instrument [Line Items]
Amount of current debt obligations outstanding			0			0
Term loan agreement | Medtronic Luxco
Debt Instrument [Line Items]
Term of debt instrument	364 days	364 days
Principal value | ¥					¥ 300
Proceeds from short-term debt	$ 2,300,000,000	¥ 297
Repayments of debt	$ 376,000,000
Loss on debt extinguishment			53,000,000
Term loan agreement | Medtronic Luxco | TIBOR Rate
Debt Instrument [Line Items]
Margin added to variable rate	0.40%	0.40%
Commercial Paper Program | Commercial Paper
Debt Instrument [Line Items]
Commercial paper, maximum borrowing amount			3,500,000,000
Credit Facility | Line of Credit
Debt Instrument [Line Items]
Line of credit, maximum capacity			$ 3,500,000,000
Term of debt instrument			5 years
Line of credit, amount outstanding			$ 0			0
3.500 percent ten-year 2015 senior notes
Debt Instrument [Line Items]
Term of debt instrument			10 years
Stated interest rate	3.50%		3.50%		3.50%
3.500 percent ten-year 2015 senior notes | Senior notes
Debt Instrument [Line Items]
Repurchased face amount	$ 1,900,000,000
Repayments of debt	$ 1,900,000,000
Long-term debt, gross			$ 0			1,890,000,000
3.350 percent ten-year 2019 senior notes
Debt Instrument [Line Items]
Term of debt instrument			10 years
Stated interest rate	3.35%		3.35%		3.35%
3.350 percent ten-year 2019 senior notes | Senior notes
Debt Instrument [Line Items]
Repurchased face amount	$ 368,000,000
Long-term debt, gross			$ 0			$ 368,000,000

XML

Financing Arrangements - Long-Term Debt (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	May 02, 2022	Apr. 29, 2022	Jul. 30, 2021
Debt Instrument [Line Items]
Current debt obligations	$ 5,729		$ 3,742
Long-term debt
Finance lease obligations	58			$ 56
Deferred financing costs	(101)		(109)
Debt discount, net	(40)		(52)
Long-term debt	$ 17,481		20,372
3.500 percent ten-year 2015 senior notes
Long-term debt
Stated interest rate	3.50%	3.50%
Term of debt instrument	10 years
0.250 percent six-year 2019 senior notes
Long-term debt
Stated interest rate	0.25%
Term of debt instrument	6 years
0.000 percent five-year 2020 senior notes
Long-term debt
Stated interest rate	0.00%
Term of debt instrument	5 years
1.125 percent eight-year 2019 senior notes
Long-term debt
Stated interest rate	1.125%
Term of debt instrument	8 years
3.350 percent ten-year 2019 senior notes
Long-term debt
Stated interest rate	3.35%	3.35%
Term of debt instrument	10 years
0.375 percent eight-year 2020 senior notes
Long-term debt
Stated interest rate	0.375%
Term of debt instrument	8 years
0.375 percent eight-year 2020 senior notes
Long-term debt
Stated interest rate	1.625%
Term of debt instrument	12 years
1.000 percent twelve-year 2019 senior notes
Long-term debt
Stated interest rate	1.00%
Term of debt instrument	12 years
0.750 percent twelve-year 2020 senior notes
Long-term debt
Stated interest rate	0.75%
Term of debt instrument	12 years
4.375 percent twenty-year 2015 senior notes
Long-term debt
Stated interest rate	4.375%
Term of debt instrument	20 years
6.550 percent thirty-year 2007 CIFSA senior notes
Long-term debt
Stated interest rate	6.55%
Term of debt instrument	30 years
2.250 percent twenty-year 2019 senior notes
Long-term debt
Stated interest rate	2.25%
Term of debt instrument	20 years
6.500 percent thirty-year 2009 senior notes
Long-term debt
Stated interest rate	6.50%
Term of debt instrument	30 years
1.500 percent twenty-year 2019 senior notes
Long-term debt
Stated interest rate	1.50%
Term of debt instrument	20 years
5.550 percent thirty-year 2010 senior notes
Long-term debt
Stated interest rate	5.55%
Term of debt instrument	30 years
1.375 percent twenty-year 2020 senior notes
Long-term debt
Stated interest rate	1.375%
Term of debt instrument	20 years
4.500 percent thirty-year 2012 senior notes
Long-term debt
Stated interest rate	4.50%
Term of debt instrument	30 years
4.000 percent thirty-year 2013 senior notes
Long-term debt
Stated interest rate	4.00%
Term of debt instrument	30 years
4.625 percent thirty-year 2014 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
4.625 percent thirty-year 2015 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
1.750 percent thirty-year 2019 senior notes
Long-term debt
Stated interest rate	1.75%
Term of debt instrument	30 years
1.625 percent thirty-year 2020 senior notes
Long-term debt
Stated interest rate	1.625%
Term of debt instrument	30 years
Senior notes | 3.500 percent ten-year 2015 senior notes
Long-term debt
Long-term debt, gross	$ 0		1,890
Senior notes | 0.250 percent six-year 2019 senior notes
Long-term debt
Long-term debt, gross	1,012		1,064
Senior notes | 0.000 percent five-year 2020 senior notes
Long-term debt
Long-term debt, gross	1,012		1,064
Senior notes | 1.125 percent eight-year 2019 senior notes
Long-term debt
Long-term debt, gross	1,518		1,596
Senior notes | 3.350 percent ten-year 2019 senior notes
Long-term debt
Long-term debt, gross	0		368
Senior notes | 0.375 percent eight-year 2020 senior notes
Long-term debt
Long-term debt, gross	1,012		1,064
Senior notes | 0.375 percent eight-year 2020 senior notes
Long-term debt
Long-term debt, gross	1,012		1,064
Senior notes | 1.000 percent twelve-year 2019 senior notes
Long-term debt
Long-term debt, gross	1,012		1,064
Senior notes | 0.750 percent twelve-year 2020 senior notes
Long-term debt
Long-term debt, gross	1,012		1,064
Senior notes | 4.375 percent twenty-year 2015 senior notes
Long-term debt
Long-term debt, gross	1,932		1,932
Senior notes | 6.550 percent thirty-year 2007 CIFSA senior notes
Long-term debt
Long-term debt, gross	253		253
Senior notes | 2.250 percent twenty-year 2019 senior notes
Long-term debt
Long-term debt, gross	1,012		1,064
Senior notes | 6.500 percent thirty-year 2009 senior notes
Long-term debt
Long-term debt, gross	158		158
Senior notes | 1.500 percent twenty-year 2019 senior notes
Long-term debt
Long-term debt, gross	1,012		1,064
Senior notes | 5.550 percent thirty-year 2010 senior notes
Long-term debt
Long-term debt, gross	224		224
Senior notes | 1.375 percent twenty-year 2020 senior notes
Long-term debt
Long-term debt, gross	1,012		1,064
Senior notes | 4.500 percent thirty-year 2012 senior notes
Long-term debt
Long-term debt, gross	105		105
Senior notes | 4.000 percent thirty-year 2013 senior notes
Long-term debt
Long-term debt, gross	305		305
Senior notes | 4.625 percent thirty-year 2014 senior notes
Long-term debt
Long-term debt, gross	127		127
Senior notes | 4.625 percent thirty-year 2015 senior notes
Long-term debt
Long-term debt, gross	1,813		1,813
Senior notes | 1.750 percent thirty-year 2019 senior notes
Long-term debt
Long-term debt, gross	1,012		1,064
Senior notes | 1.625 percent thirty-year 2020 senior notes
Long-term debt
Long-term debt, gross	$ 1,012		$ 1,064

XML

Derivatives and Currency Exchange Risk Management - Narrative (Details) $ in Millions, € in Billions, ¥ in Billions	3 Months Ended
	Jul. 29, 2022 USD ($)	Jul. 29, 2022 EUR (€)	Jul. 29, 2022 JPY (¥)	Apr. 29, 2022 USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI	$ 694			$ 474
Cash flow hedge unrealized gains to be reclassified over the next 12 months	510
Derivative, excluded component, gain (loss), recognized in earnings	21
Currency exchange rate contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	17,700			13,800
Currency exchange rate contracts | Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	5,100			4,900
Currency exchange rate contracts | Derivatives designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount | €		€ 4.5
Currency exchange rate contracts | Derivatives designated as hedging instruments | Euro-denominated Debt
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	4,600
Currency exchange rate contracts | Derivatives designated as hedging instruments | Cash flow hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	$ 8,100			8,800
Maximum remaining maturity of foreign currency derivatives	3 years
Currency exchange rate contracts | Derivatives designated as hedging instruments | Net investment hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount		€ 16.0	¥ 297
Currency exchange rate contracts | Derivatives designated as hedging instruments | Net investment hedging | Euro-denominated Debt
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	$ 16,200
Currency exchange rate contracts | Derivatives designated as hedging instruments | Net investment hedging | Japanese Yen-denominated Debt
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	2,200
Total return swaps | Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	$ 212			$ 226

XML

Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Derivative Instruments, (Gain) Loss [Line Items]
(Gain) Loss Recognized in Accumulated Other Comprehensive Loss	$ (1,378)	$ (584)
(Gain) Loss Reclassified into Income	(120)	30
Currency exchange rate contracts
Derivative Instruments, (Gain) Loss [Line Items]
Recognized in AOCI, net investment hedges	(57)	0
Reclassified into Income, net investment hedges	0	0
Currency exchange rate contracts | Other operating expense, net
Derivative Instruments, (Gain) Loss [Line Items]
Recognized in AOCI, Cash flow hedges	(342)	(164)
Recognized in income, cash flow hedges	(137)	19
Currency exchange rate contracts | Cost of products sold
Derivative Instruments, (Gain) Loss [Line Items]
Recognized in AOCI, Cash flow hedges	(34)	4
Recognized in income, cash flow hedges	18	11
Non-derivative instruments
Derivative Instruments, (Gain) Loss [Line Items]
Recognized in AOCI, net investment hedges	(945)	(424)
Reclassified into Income, net investment hedges	$ 0	$ 0

XML

Derivatives and Currency Exchange Risk Management - Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Derivative Instruments, (Gain) Loss [Line Items]
Derivatives not designated as hedging instruments	$ 25	$ (30)
Other operating expense, net | Currency exchange rate contracts
Derivative Instruments, (Gain) Loss [Line Items]
Derivatives not designated as hedging instruments	26	(17)
Other operating expense, net | Total return swaps
Derivative Instruments, (Gain) Loss [Line Items]
Derivatives not designated as hedging instruments	$ (1)	$ (13)

XML

Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($) $ in Millions	Jul. 29, 2022	Apr. 29, 2022
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	$ 907	$ 695
Derivative Liabilities, Fair Value	61	129
Currency exchange rate contracts
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	907	695
Derivative Liabilities, Fair Value	53	109
Total return swaps
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	9	20
Derivatives designated as hedging instruments
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	889	649
Derivative Liabilities, Fair Value	33	60
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	621	481
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other Assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	268	168
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	24	43
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	8	16
Derivatives not designated as hedging instruments
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	18	46
Derivative Liabilities, Fair Value	29	69
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	18	46
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	20	49
Derivatives not designated as hedging instruments | Total return swaps | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	0	0
Derivatives not designated as hedging instruments | Total return swaps | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	$ 9	$ 20

XML

Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	Jul. 29, 2022	Apr. 29, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	$ 907	$ 695
Derivative Liabilities	61	129
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	907	695
Derivative Liabilities	53	109
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	0	0
Derivative Liabilities	$ 9	$ 20

XML

Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($) $ in Millions	Jul. 29, 2022	Apr. 29, 2022
Derivative assets:
Gross Amount of Recognized Assets (Liabilities)	$ 907	$ 695
Derivative liabilities:
Gross Amount of Recognized Assets (Liabilities)	(61)	(129)
Financial Instruments	42	109
Cash Collateral (Received) Posted	0	0
Net Amount	(20)	(20)
Total
Gross Amount of Recognized Assets (Liabilities)	845	566
Financial Instruments	0	0
Cash Collateral (Received) Posted	(531)	(254)
Net Amount	315	312
Currency exchange rate contracts
Derivative assets:
Gross Amount of Recognized Assets (Liabilities)	907	695
Financial Instruments	(42)	(109)
Cash Collateral (Received) Posted	(531)	(254)
Net Amount	335	332
Derivative liabilities:
Gross Amount of Recognized Assets (Liabilities)	(53)	(109)
Financial Instruments	42	109
Cash Collateral (Received) Posted	0	0
Net Amount	(11)	0
Total return swaps
Derivative liabilities:
Gross Amount of Recognized Assets (Liabilities)	(9)	(20)
Financial Instruments	0	0
Cash Collateral (Received) Posted	0	0
Net Amount	$ (9)	$ (20)

XML

Inventories (Details) - USD ($) $ in Millions	Jul. 29, 2022	Apr. 29, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 3,145	$ 3,070
Work in-process	739	682
Raw materials	926	864
Total	$ 4,809	$ 4,616

XML

Goodwill and Other Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	3 Months Ended
	Jul. 29, 2022 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 40,502
Goodwill as a result of acquisitions	680
Purchase accounting adjustments	(10)
Transfer to held for sale	(208)
Currency translation and other	(640)
Ending balance	40,324
Cardiovascular
Goodwill [Roll Forward]
Beginning balance	7,160
Goodwill as a result of acquisitions	66
Purchase accounting adjustments	(10)
Transfer to held for sale	0
Currency translation and other	(49)
Ending balance	7,166
Medical Surgical
Goodwill [Roll Forward]
Beginning balance	19,957
Goodwill as a result of acquisitions	0
Purchase accounting adjustments	0
Transfer to held for sale	(208)
Currency translation and other	(507)
Ending balance	19,242
Neuroscience
Goodwill [Roll Forward]
Beginning balance	11,132
Goodwill as a result of acquisitions	615
Purchase accounting adjustments	0
Transfer to held for sale	0
Currency translation and other	(83)
Ending balance	11,664
Diabetes
Goodwill [Roll Forward]
Beginning balance	2,254
Goodwill as a result of acquisitions	0
Purchase accounting adjustments	0
Transfer to held for sale	0
Currency translation and other	(1)
Ending balance	$ 2,253

XML

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021	May 25, 2022
Goodwill [Line Items]
Goodwill impairment		$ 0
Definite-lived intangible asset charges	$ 0	409,000,000
Impairment of indefinite-lived intangible assets	0	0
Amortization expense	423,000,000	$ 436,000,000
Medical Surgical | Renal Care Business (RCS)
Goodwill [Line Items]
Goodwill			$ 208,000,000
Goodwill impairment	$ 61,000,000

XML

Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Millions	Jul. 29, 2022	Apr. 29, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 28,820	$ 28,308
Accumulated Amortization	(13,328)	(13,006)
IPR&D
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Indefinite-lived	283	293
Customer-related
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	16,927	16,953
Accumulated Amortization	(7,238)	(7,005)
Purchased technology and patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	11,311	10,802
Accumulated Amortization	(5,758)	(5,667)
Trademarks and tradenames
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	485	473
Accumulated Amortization	(268)	(266)
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	97	80
Accumulated Amortization	$ (65)	$ (69)

XML

Goodwill and Other Intangible Assets - Estimated Future Aggregate Amortization Expense of Amortizable Intangible Assets (Details) $ in Millions	Jul. 29, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining 2023	$ 1,261
2024	1,649
2025	1,627
2026	1,613
2027	1,589
2028	$ 1,539

XML

Income Taxes (Details) - USD ($) $ in Millions		3 Months Ended
	Aug. 18, 2022	Jul. 29, 2022	Jul. 30, 2021	Apr. 29, 2022
Income Tax Contingency [Line Items]
Effective tax rate		10.70%	7.70%
Permanent reinvestment assertion on historical earnings, nondeductible expense			$ 39
Benefit related to release of valuation allowance		$ 25
Gross unrecognized tax benefits		1,700		$ 1,700
Accrued gross interest and penalties		123
Unrecognized tax benefits that would impact effective tax rate		1,600
Gross unrecognized tax benefits, net of cash advance, recorded as noncurrent liability		$ 889		$ 802
Subsequent event | Domestic
Income Tax Contingency [Line Items]
Potential income tax charge	$ 2,000

XML

Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Numerator:
Net income attributable to ordinary shareholders	$ 929	$ 763
Denominator:
Basic - weighted average shares outstanding (shares)	1,329.4	1,344.5
Effect of dilutive securities:
Diluted - weighted average shares outstanding (shares)	1,334.5	1,356.4
Basic earnings per share (usd per share)	$ 0.70	$ 0.57
Diluted earnings per share (usd per share)	$ 0.70	$ 0.56
Stock options
Effect of dilutive securities:
Share based payments	2.7	8.5
RSUs
Effect of dilutive securities:
Employee restricted stock units (shares)	1.3	2.3
Performance share units
Effect of dilutive securities:
Share based payments	1.1	1.0

XML

Earnings Per Share - Narrative (Details) - shares shares in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	14	1

XML

Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 62	$ 69
Income tax benefits	(11)	(11)
Total stock-based compensation expense, net of tax	51	58
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	6	7
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	7	8
Selling, general, and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	49	55
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	12	10
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	27	41
Performance share units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	12	6
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 11	$ 11

XML

Retirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) - Pension plans - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
U.S.
Net Periodic Benefit Cost
Service cost	$ 19	$ 25
Interest cost	36	26
Expected return on plan assets	(56)	(57)
Amortization of net actuarial loss	5	16
Net periodic benefit cost	4	10
Non-U.S.
Net Periodic Benefit Cost
Service cost	12	16
Interest cost	10	7
Expected return on plan assets	(16)	(16)
Amortization of net actuarial loss	1	5
Net periodic benefit cost	$ 7	$ 12

XML

Accumulated Other Comprehensive Loss - Changes in AOCI (Details) - USD ($)	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 52,722,000,000	$ 51,602,000,000
Other comprehensive income	324,000,000	274,000,000
Ending balance	52,843,000,000	51,664,000,000
Total Accumulated Other Comprehensive (Loss) Income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(2,265,000,000)	(3,485,000,000)
Other comprehensive income (loss) before reclassifications	414,000,000	230,000,000
Reclassifications	(87,000,000)	46,000,000
Other comprehensive income	326,000,000	276,000,000
Ending balance	(1,939,000,000)	(3,209,000,000)
Unrealized Gain (Loss) on Investment Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(209,000,000)	92,000,000
Other comprehensive income (loss) before reclassifications	(22,000,000)	14,000,000
Reclassifications	6,000,000	(2,000,000)
Other comprehensive income	(16,000,000)	12,000,000
Ending balance	(225,000,000)	104,000,000
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)	(9,000,000)	2,000,000
Reclassifications, tax expense (benefit)	2,000,000	0
Cumulative Translation Adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(2,599,000,000)	(519,000,000)
Other comprehensive income (loss) before reclassifications	(881,000,000)	(353,000,000)
Reclassifications	0	0
Other comprehensive income	(881,000,000)	(353,000,000)
Ending balance	(3,480,000,000)	(872,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)	(3,000,000)	0
Net Investment Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	841,000,000	(1,458,000,000)
Other comprehensive income (loss) before reclassifications	1,002,000,000	424,000,000
Reclassifications	0	0
Other comprehensive income	1,002,000,000	424,000,000
Ending balance	1,843,000,000	(1,034,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)	0	0
Net Change in Retirement Obligations
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(773,000,000)	(1,347,000,000)
Other comprehensive income (loss) before reclassifications	3,000,000	1,000,000
Reclassifications	(2,000,000)	18,000,000
Other comprehensive income	1,000,000	19,000,000
Ending balance	(772,000,000)	(1,328,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)	1,000,000	1,000,000
Reclassifications, tax expense (benefit)	6,000,000	2,000,000
Unrealized Gain (Loss) on Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	474,000,000	(253,000,000)
Other comprehensive income (loss) before reclassifications	312,000,000	144,000,000
Reclassifications	(91,000,000)	30,000,000
Other comprehensive income	220,000,000	174,000,000
Ending balance	694,000,000	(79,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)	64,000,000	16,000,000
Reclassifications, tax expense (benefit)	$ (22,000,000)	$ 1,000,000

XML

Commitments and Contingencies (Details)			1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 10, 2022 plantiff claim	Aug. 03, 2022 claim	May 31, 2017 claim	Jul. 29, 2022 USD ($) landfill subsidiary manufacturer claimant	Jul. 30, 2021 USD ($)	Apr. 29, 2016 USD ($) claim	Apr. 29, 2022 USD ($)
Loss Contingencies [Line Items]
Certain litigation charges, net | $				$ 0	$ 26,000,000
Accrued litigation charges | $				$ 300,000,000			$ 300,000,000
Orrington, Maine chemical manufacturing facility
Loss Contingencies [Line Items]
Number of landfills requiring removal (in landfills) | landfill				2
Number of landfills requiring capping (in landfills) | landfill				3
Pelvic mesh | Product liability litigation
Loss Contingencies [Line Items]
Number of subsidiaries (in subsidiaries) | subsidiary				2
Number of manufacturers (in manufacturers) | manufacturer				1
Amount of settlement received | $						$ 121,000,000
Number of claims settled (in claims) | claim			5,000			11,000
Number of claimants (in claimants) | claimant				16,200
Pelvic mesh | Product liability litigation | Subsequent event
Loss Contingencies [Line Items]
Number of claims settled (in claims) | claim		15,900
Hernia Mesh Litigation | Pending Litigation | Subsequent event
Loss Contingencies [Line Items]
Number of claimants (in claimants) | claim	90
Number of plaintiffs (in plaintiffs) | plantiff	6,050
Hernia Mesh Litigation | Pending Litigation | Subsequent event | Massachusetts
Loss Contingencies [Line Items]
Number of plaintiffs (in plaintiffs) | plantiff	5,600
Hernia Mesh Litigation | Pending Litigation | Subsequent event | Minnesota
Loss Contingencies [Line Items]
Number of plaintiffs (in plaintiffs) | plantiff	350

XML

Segment and Geographic Information - Narrative (Details)	3 Months Ended
	Jul. 29, 2022 portfolio
Segment Reporting [Abstract]
Number of operating segments (in segments)	4
Number of reportable segments (in segments)	4

XML

Segment and Geographic Information - Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated (Details) - USD ($)	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Segment Reporting Information [Line Items]
Segment operating profit	$ 1,125,000,000	$ 859,000,000
Other non-operating income, net	83,000,000	111,000,000
Amortization of intangible assets	(423,000,000)	(436,000,000)
Restructuring and associated costs and RCS/MCS impairment / costs	(85,000,000)
Certain litigation charges, net	0	(26,000,000)
Income before income taxes	1,044,000,000	833,000,000
Renal Care Business (RCS)
Segment Reporting Information [Line Items]
Restructuring and associated costs and RCS/MCS impairment / costs		0
Mechanical Circulatory Support Operating Unit (MCS)
Segment Reporting Information [Line Items]
Restructuring and associated costs and RCS/MCS impairment / costs	0	(726,000,000)
Operating Segments
Segment Reporting Information [Line Items]
Segment operating profit	2,490,000,000	3,170,000,000
Operating Segments | Cardiovascular
Segment Reporting Information [Line Items]
Segment operating profit	956,000,000	1,161,000,000
Operating Segments | Medical Surgical
Segment Reporting Information [Line Items]
Segment operating profit	642,000,000	914,000,000
Operating Segments | Neuroscience
Segment Reporting Information [Line Items]
Segment operating profit	815,000,000	962,000,000
Operating Segments | Diabetes
Segment Reporting Information [Line Items]
Segment operating profit	77,000,000	133,000,000
Segment Reconciling Items
Segment Reporting Information [Line Items]
Interest expense	(164,000,000)	(137,000,000)
Other non-operating income, net	83,000,000	111,000,000
Amortization of intangible assets	(423,000,000)	(436,000,000)
Corporate	(414,000,000)	(449,000,000)
Centralized distribution costs	(311,000,000)	(464,000,000)
Acquisition-related items	(35,000,000)	(19,000,000)
Certain litigation charges, net	0	(26,000,000)
IPR&D charges	0	(90,000,000)
Medical device regulations	(32,000,000)	(21,000,000)
Segment Reconciling Items | Renal Care Business (RCS)
Segment Reporting Information [Line Items]
Restructuring and associated costs and RCS/MCS impairment / costs	(74,000,000)
Segment Reconciling Items | Restructurings Excluding RCS and MCS
Segment Reporting Information [Line Items]
Restructuring and associated costs and RCS/MCS impairment / costs	$ (76,000,000)	$ (81,000,000)

XML

Segment and Geographic Information - Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographic Region (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2022	Jul. 30, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 7,371	$ 7,987
Ireland
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	23	26
Total other countries, excluding Ireland
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	7,348	7,961
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	3,766	4,101
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 3,582	$ 3,860